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Summary 
 
The aim of the project was to identify and functionally characterize novel human 
proteins that dominantly induce apoptosis upon overexpression. To achieve this, a cell-based 
high throughput assay was developed. The assay is based on the detection of activated 
caspase-3 in cells overexpressing proteins tagged C- and N-terminally with YFP. Apoptotic 
cells were detected by staining with a specific antibody directed against the activated form of 
caspase-3. The assay was automated and data acquisition was done using a flow cytometer 
with an integrated 96-well plate reader. A total of 200 proteins have been screened in the 
assay, out of which five were identified to be significant activators of apoptosis.  
One of the candidates, Vacuole Membrane Protein 1 (Vmp1), which forms vacuoles in 
cells and subsequently induces apoptosis when overexpressed, has been functionally 
characterized in detail. It has been reported that VMP1 mRNA is differentially expressed in 
cancer, acute pancreatitis and kidney ischemia and that the overexpressed protein is localized 
to the Endoplasmic reticulum. But the function of this protein and its role in cancer and other 
diseases was previously unknown. In this study I show that the vacuoles are formed by the 
Endoplasmic reticulum due to accumulation of overexpressed Vmp1, and that Vmp1 is 
actually a plasma membrane protein involved in the formation of initial cell-cell contacts. Its 
function as a cell-cell adhesion protein was confirmed by identifying that Vmp1 interacts with 
the tight junction protein ZO-1, and that down regulation of Vmp1 induces cell detachment. 
Further, down regulation of Vmp1 resulted in a massive increase in the invasion potential of 
kidney cancer cells, which is consistent with the findings that VMP1 mRNA level is 
significantly lower in kidney metastases compared to primary tumours. Thus, these results are 
the first to show that Vmp1 is a cell adhesion protein, and that its expression level is a critical 
determinant of cancer cell invasiveness, metastasis formation and induction of apoptosis.  
 In summary, I have established and applied a high throughput cell-based assay to 
screen for inducers of apoptosis. Functional characterization of one of the candidates from 
this screen revealed it to be a disease relevant regulator of cell-cell adhesion. This 
demonstrates the strength of this high throughput approach in the identification of proteins 
involved in diseases.  
 Zusammenfassung 
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Zusammenfassung 
 
Das Ziel dieses Projektes war die Identifizierung und funktionelle Charakterisierung 
unbekannter Proteine, die nach Überexpression Apoptose induzieren. Dazu wurde ein 
zellbasierter Hochdurch-Assay entwickelt, welcher auf der Detektion aktivierter Caspase-3 
basiert, nachdem die Zellen Fusionsproteine mit YFP am C- und N-Terminus 
überexprimierten. Apoptotische Zellen wurden mittels eines spezifischen Antikörpers gegen 
die aktivierte Form der Caspase-3 detektiert. Der Assay wurde automatisiert und die 
Datenaufnahme wurde mit einem Durchflußzytometer mit integriertem 96-Well-Platten 
Lesegerät durchgeführt. Insgesamt wurden 200 Proteine in diesem Assay untersucht, fünf 
wurden als signifikante Apoptose-Aktivatoren identifiziert. 
 Eines der Kandidaten-Proteine, das Vacuole Membrane Protein 1 (Vmp1), welches 
nach Überexpression die Bildung von Vakuolen und Apoptose induziert, wurde in Detail 
untersucht. In vorherigen Untersuchungen war gezeigt worden, dass die VMP1 mRNA in 
Krebserkrankungen, akuter Pankreatitis und Nieren-Ischämie differentiell exprimiert wird. 
Das überexprimierte Vmp1-Protein ist im Endoplasmatischen Retikulum lokalisiert, die 
Funktion des Proteins und seine Rolle bei der Entstehung von Krankheiten wurde bis jetzt 
jedoch nicht untersucht. In der vorliegenden Studie zeigte ich, dass die Bildung der Vakuolen 
durch die Akkumulation des überexprimierten Vmp1 verursacht wird. Das Protein ist in der 
Plasmamembran lokalisiert, wo es in die Bildung von initialen Zell-Zell Kontakten involviert 
ist. Seine Funktion als Zell-Zell-Adhäsions Protein habe ich durch den Nachweis einer 
direkten Interaktion mit dem Tight Junction-Protein ZO-1 bestätigt. Wird die Expression von 
Vmp1 mittels spezifischer siRNAs reduziert, verlieren die Zellen ihre Adhäsion und in 
Nierenkarzinomzellen resultiert die Reduktion in einem deutlichen Ansteigen der Invasivität. 
Diese Ergebnisse sind im Einklang mit Ergebnissen der mRNA-Messungen für VMP1, die 
eine signifikant niedrigere Expression in Nierenkrebs-Metastasen als in primären 
Nierenkarzinomen zeigen. Diese Resultate zeigen zum ersten Mal, das Vmp1 ein 
Zelladhäsions-Protein ist, und dass das Maß der Expression ein kritischer Indikator für die 
Invasivität von Krebszellen, die Bildung von Metastasen und die Auslösung von Apoptose ist.  
 Zusammengefaßt habe ich 200 Proteine auf die Induktion von Apoptose in einem 
zellbasierten Hochdurchsatz-Assay untersucht. Durch die funktionelle Charakterisierung eines 
der Kandidaten-Proteine habe ich die Verwendbarkeit des Assays zur Identifizierung 
krankheitsrelevanter Gene nachgewiesen.  
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1 Introduction 
 
Sequencing of the human genome has revealed the presence of 20,000 to 25,000 
protein coding genes [1]. Since the classical concept of ´one gene-one protein` does not 
always hold true, the number of proteins resulting from these genes would be enormous. The 
function and biological role of many of these proteins and their variants is yet unknown. So 
the challenge ahead is to identify the function of these proteins, which will allow us to gain a 
molecular understanding of the causes and cures of diseases. Therefore, it is necessary to 
develop and apply parallel high throughput approaches for an efficient functional 
characterization of the human proteome. 
In order to systematically characterize proteins with unknown functions, we have 
adopted the idea of functional profiling, in which the same set of proteins would be screened 
in different functional assays [2] [3]. A single high throughput assay by itself does not always 
provide clear information regarding the function of a protein. However, integration of data 
from a set of well defined assays that probe various biological processes would help in 
drawing valid conclusions. To this end, a range of assays that investigate the activity of 
proteins in cancer related processes have been established in our department (Figure 1.1).  
 
 
 
 
Figure 1.1. Assays to screen for novel cancer relevant proteins.  
Several assays have been established to screen for novel proteins involved in disease relevant processes. The data generated 
from these assays and the subcellular localization of the proteins would be integrated into a database (LIFEdb). 
 
 
Proliferation  Cell  signaling 
Anchorage 
independent growth Invasion 
Apoptosis  
Caspase-3 activation
LIFEdb
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The assays are based on the effect of protein overexpression in well characterized 
mammalian cell systems. The proliferation assay measures effect of the overexpressed 
proteins on BrdU incorporation during DNA synthesis (S) phase [3], while the MAP kinase 
assay detects changes in phosphorylation of p42/p44 (ERK1/2) in the first growth phase (G1). 
Apart from this, other assays which probe the function of the proteins in processes like 
invasion and anchorage independent growth of cells were also established in the department. 
In this line, I have established a high throughput apoptosis assay to identify proteins whose 
overexpression leads to the activation of caspase-3. The data generated from all the assays as 
well as the subcellular localization of the proteins [4] would be integrated into a database, 
LIFEdb [5]. Such a comprehensive approach would allow us to identify proteins involved in 
diseases like cancer. 
Dysregulation of normal programmed cell death mechanisms play an important role in 
the pathogenesis of cancer and several other diseases. Though apoptosis research is 
progressing at a rapid pace, only the death receptor and the mitochondrial apoptotic pathways 
seem to be the most widely studied and understood. However, recent evidences showed that 
other organelles of the cell also initiate apoptotic pathways [6] [7] [8], and the key players 
regulating such pathways largely remain unidentified. The availability of cDNA resources 
provides an opportunity to identify proteins that have previously not been associated with any 
apoptotic pathway. This would ultimately lead to a better understanding of the cell death 
program.  
 
1.1 Types of cell death 
Cell death is a part of normal development of an organism and is essential in the 
maintenance of tissue homeostasis. Several mechanisms of cell death have been identified and 
can be broadly classified into ´non-apoptotic` and ´apoptotic` cell death. The non-apoptotic 
cell death mechanisms include Autophagy [9] [10], Necrosis [11] and Senescence [12], while 
the apoptotic mechanism includes a form of Programmed cell death, termed ´apoptosis` [13]. 
Many diseases are associated with the deregulation of one or more of these cell death 
mechanisms, out of which apoptosis and necrosis are two major processes by which the cells 
die. 
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1.1.1 Necrosis  
Necrosis, also called ´accidental cell death`, is an unregulated and passive form of cell 
death caused by forced destruction of vital cellular machinery, and does not encompass 
activation of any specific cellular pathway. Necrosis is characterized by rapid swelling of the 
cell that is caused by the accumulation of water and electrolytes. The plasma membrane of the 
cell finally ruptures, releasing the cell contents into the surroundings, and thus causing 
damage and inflammation to the tissue concerned. Necrosis only occurs as a consequence of 
pathophysiological conditions such as infection, inflammation or ischemia. The molecular 
mechanisms that regulate necrosis are less clearly understood than that of apoptosis, though 
increasing evidence shows that these two forms are much closer to each other than previously 
thought [14]. 
 
1.1.2 Apoptosis 
Apoptosis, also called ´programmed cell death`, is a genetically programmed process 
of selectively eliminating unwanted or abnormal cells in the body. The term ´apoptosis` was 
first introduced by John Kerr in 1972, referring to the morphological features of apoptotic 
cells forming ´membrane blebs` [13]. The main criterion that distinguishes apoptosis from 
other forms of cell death is that it is an active and physiological mode of cell death, in which 
the cell itself activates and executes the genetic program of its own death. Apoptosis is 
associated with a distinct set of physical and biochemical changes of the cytoplasm, nucleus 
and the plasma membrane. Unlike necrosis, cells undergoing apoptosis exhibit a reduction in 
size and become granular (Figure 1.2). Changes to the plasma membrane and cytoskeleton 
lead to the formation of apoptotic bodies that enclose fragments of nucleus and cytoplasm. 
The apoptotic bodies displaying phagocytic signals on the outer membrane are engulfed and 
digested by phagocytes and neighbouring endothelial cells, thus clearing the cell corpses from 
the tissue. No inflammatory response is triggered during this process, which is considered as 
the most characteristic feature of apoptosis [15]. 
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Figure.1.2. Morphological differences between necrosis and apoptosis.   
Necrotic cells swell and finally the plasma membrane ruptures, releasing the cell contents into surrounding tissue. Apoptotic 
cells shrink and the plasma membrane invaginates forming apoptotic bodies, which are engulfed by the phagocytes. The late 
stage apoptotic cells undergo secondary necrosis, where the membrane of the apoptotic bodies rupture.    
 
Apoptosis serves many important functions in the normal development of an 
organism, such as cell deletion during embryonic development, balancing cell numbers in 
continuously renewing tissues, immune system development, selective immune cell deletion 
and many other physiological processes. Dysregulation of apoptosis have implications in the 
development of several diseases like Alzheimers, cancer, autoimmune disorders, AIDS etc. 
Apoptosis is regulated by a complex set of pathways, originating from different cellular 
organelles, the understanding of which is necessary for therapeutic manipulation.  
 
1.2 Organelle specific initiation of apoptosis pathways 
Previous studies have demonstrated that there are two major pathways for inducing 
apoptosis, one that is mediated by the death receptors on the plasma membrane (Extrinsic 
pathway) and another that involves mitochondria (Intrinsic pathway). However, it is now well 
established that most organelles of the cells can act as sensors for stress and other 
perturbations and initiate organelle specific cell death pathways. Whereas mild perturbation of 
different organelles triggers apoptosis, a sudden and massive destruction leads to unregulated 
necrotic cell death. 
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1.2.1 Death Receptor pathway from the plasma membrane (Extrinsic pathway) 
The receptors triggering this pathway are present in the plasma membrane of the cell 
and are activated by extracellular ligands (Figure 1.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.1.3. The extrinsic (death receptor) and intrinsic (mitochondrial) pathways of apoptotsis.   
The death receptor pathway is initiated by the binding of death ligands to their receptors, leading to the activation of the 
caspase cascade. Mitochondrial stress leads to the activation of pro-apoptotic Bcl-2 family proteins which causes the release 
of cytochrome c and Smac/DIABLO into the cytoplasm and subsequent activation of caspases.  
 
Death receptors of the tumour necrosis factor receptor (TNFR) superfamily, including 
TNF receptor 1 (TNFR1), Fas (also known as APO-1 or CD95), Death receptor 4 (DR4, also 
known as TRAIL receptor 1) or Death receptor 5 (DR5, also known as TRAIL receptor 2) 
interact with their respective ligands Tumour necrosis factor (TNF), Fas ligand (also known 
as CD95L or APO1L), Tumour necrosis factor apoptosis inducing ligand (TRAIL, also 
known as APO2L) and TNF ligand superfamily member 10 (TNFSF10) respectively [16] [17] 
[18] [19]. Upon interaction with the respective ligands, the intracellular death domains of the 
receptors trimerize [20] and bind to the adaptor proteins via their death domains (DD) [21] 
[22]. FADD is the adaptor protein for all the death receptors except for TNF-R1, while 
TRADD (TNFR1-associated death domain protein) is the adaptor protein for TNF-R1 [23]. 
The death effector domain (DED) of the adaptor protein then binds to the DED of procaspase-
EXTRINSIC
INTRINSIC
Mitochondrial stress
Ligation
CD95L, TRAIL
 Introduction 
 
 8
8, leading to the formation of DISC (Death inducing signalling complex) [24]. The complex 
of ligand, receptor, adaptor and procaspase-8 is called DISC. The procaspase-8 molecules are 
brought into close proximity in the DISC, which facilitates the transactivation of one another 
[25] [26]. The active caspase-8 then directly cleaves procaspase-3 and other executioner 
caspases. Caspase-8 also cleaves Bid which then moves to the mitochondria and activates the 
mitochondrial pathway of apoptosis. 
 
1.2.2 Mitochondrial pathway of apoptosis (Intrinsic pathway) 
The first report indicating that mitochondria are essential for apoptosis was shown in a 
cell free model using apoptotic Xenopus egg extracts [27]. The generation of reactive oxygen 
species (ROS), a by-product of the mitochondrial respiratory chain, was initially considered 
as a common mediator of apoptosis [28]. However, the observation that several cell lines 
undergoing apoptosis showed a reduction in the mitochondrial membrane potential indicated 
that alterations of mitochondrial function is an important feature in apoptosis [29] [30]. This 
reduction in the mitochondrial membrane potential was later shown to be due to opening of 
the Permeability Transition (PT) pore complex [31] [32], which led to further investigations 
regarding the involvement of mitochondria in apoptosis.  
Bax and Bak are the crucial pore forming proteins that induce mitochondrial 
membrane permeabilization and release the death inducing molecules from the mitochondrial 
intermembrane space (Figure 1.3). The proapoptotic protein Bax exists in normal conditions 
as monomer in the cytoplasm [33] [34]. Upon receiving the apoptosis stimulus, Bax 
undergoes conformational change due to interaction with Bid [35] [36], resulting in the 
translocation and insertion of Bax into the outer mitochondrial membrane as large oligomers 
[37] [38]. In contrast to Bax, its homologue Bak constantly resides on the outer mitochondrial 
membrane [39] and following stimulation by Bid, undergoes conformational change and 
oligomerization, thus releasing cytochrome c [40] [41] and Smac/DIABLO [42] from the 
mitochondria. The anti apoptotic Bcl-2 family members (Bcl-2 and Bcl-xl) inhibit cytochrome 
c release by blocking the activation of Bax and Bak [39]. Once released from the 
mitochondria, Cytochrome c binds to Apoptotic Protease Activating Factor-1 (Apaf-1) 
triggering the formation of apoptosome, an oligomeric complex that catalyzes activation of 
caspase-9 [43] (Figure 1.3). The activated caspase-9 in turn activates the effector caspases like 
caspase-3. The effector caspases then cleave essential cellular substrates, leading to cell death.  
In normal conditions, members of the protein family of Inhibitor of apoptosis (IAP), 
bind to and inhibit caspases and block apoptosis signalling [44]. SMAC (Second 
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mitochondria-derived activator of caspase, also known as DIABLO), once released from the 
mitochondria following the apoptosis signal, binds to IAPs and antagonizes their anti-
apoptotic activity [45].  
  
1.2.3 The nuclear death pathway 
 
 
 
Figure.1.4. The p53 pathway of apoptosis.  
DNA damage is detected by the enzymes ATM and ATR, which activate p53 by inhibiting its interaction with MDM2. The 
activated p53 acts as transcription factor for genes regulating apoptosis and growth arrest. 
 
Activation of p53 is the best defined nuclear death pathway leading to apoptosis [6]. 
DNA damage caused by exposure to various agents like ultraviolet or ionizing radiations, 
chemicals etc., is detected by ATM (ataxia teleangiectasia mutated) and ATR (ataxia 
teleangiectasia Rad3 related) [46] [47], enzymes of the PtdIns-3-OH kinase family (Figure 
1.4). These enzymes together with other protein kinases phosphorylate p53 [48] [49], a 
modification resulting in inhibiting the interaction of p53 with MDM2 (Mouse double minute-
2), a ubiquitin E3 ligase. Under normal conditions, MDM2 protein binds to the p53 
transactivation domain causing ubiquitylation and degradation of p53 [50] [51] [52]. 
Inhibition of the interaction with MDM2 prevents destruction of the p53 protein, which 
accumulates rapidly [53] and acts as a transcription factor for genes favouring growth arrest 
and apoptosis [54]. 
p53 inhibits the expression of anti-apoptotic protein Bcl-2 and induces the expression 
of pro-apoptotic proteins like Fas, Bax, Noxa, PUMA, p53AIP1, Apaf-1 [55] [56] [57] [58] 
[59]. In addition, p53 may also serve as a direct link to the activation of caspase-2. p53 
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induced death domain protein (PIDD), RIP-associated ICE-like death domain protein 
(RAIDD) and caspase-2 form an apoptosome-like complex, which activates caspase-2 [60]. 
The activated caspase-2 acts as an initiator caspase and triggers the membrane permeability of 
mitochondria, which further amplifies the caspase cascade [61]. 
 
1.2.4 Endoplasmic reticulum (ER) mediated apoptosis   
Role of ER in the initiation of apoptosis is recently gaining attention. ER is an 
important sensor of cellular stress, and it may initiate apoptosis, by at least two mechanisms- 
the unfolded protein response (UPR) and release of Ca2+.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 1.5. Mechanism of Endoplasmic reticulum mediated apoptosis.  
Accumulation of unfolded proteins in the ER triggers apoptosis by the activation of caspase-12, the JNK pathway and 
induction of the transcription factor CHOP which regulates the expression of pro-apoptotic proteins. Release of calcium from 
the ER activates calpains which in turn activate the caspases. (Figure taken from Kadowaki,H et al. [62] ) 
 
1.2.4.1 Unfolded protein response and apoptosis 
When the capacity of ER to fold proteins properly is compromised, unfolded proteins 
accumulate in the ER leading to the onset of UPR. The UPR stops further protein synthesis 
and upregulates ER resident chaperones and other regulatory components of the secretory 
pathway [63] that aid in protein folding. However, if the damage is too strong, the UPR 
ultimately initiates apoptosis [7]. The ER stress response is initiated by three ER membrane 
receptors, Activating transcription factor 6 (ATF6), Inositol-requiring gene 1 (Ire1), and PKR-
like endoplasmic reticulum kinase (PERK) [64] [65] (Figure 1.5). In normal conditions, Ire1 
and PERK are kept inactive by the binding of chaperone BiP (Binding protein) to their 
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lumenal domains. Under conditions of ER stress, BiP dissociates from them to bind to the 
unfolded proteins, causing the activation of Ire1 and PERK. Activated Ire1 stimulates the 
transcription of ER chaperone and CHOP encoding genes [66], while PERK, via 
phosphorylation of eIF2α, stops further protein translation to prevent accumulation of proteins 
in the ER [67]. Activation of ATF6 also results in the upregulation of ER chaperone genes 
[68] [69]. When the survival signals mediated by these proteins are not sufficient, the cells 
undergo apoptosis.  
Ire1 signalling plays an important role in coupling UPR with the apoptosis cascade. 
Activated Ire1 interacts with TNF receptor associated factor 2 (TRAF2), which further 
interacts with procaspase-12, activating it [70]. Murine caspase-12 localizes at the cytosolic 
face of the ER, but once activated due to ER stress, it translocates to the cytoplasm [71], and 
activates other executioner caspases. The human orthologue of caspase-12 is non-functional 
due to inactivating mutations [72] and its involvement in ER mediated apoptosis is not yet 
known. Interaction of TRAF2 with Ire1 also activates the c-Jun amino-terminal kinase 
pathway (JNK pathway) [73] via association with Apoptosis signal-regulating kinase 1 
(ASK1) [74]. The ASK1-JNK pathway activates the pro-apoptotic Bcl-2 family members like 
Bim [75], while it inactivates anti-apoptotic Bcl-2 [76]. Expression of CHOP during ER stress 
conditions regulates the expression of many apoptosis inducing genes, including that of Bcl-2 
family [77]. Overexpression of CHOP in cells was also reported to induce cell cycle arrest 
and apoptosis [78] [79]. 
 
1.2.4.2 Role of Ca2+ in ER stress-induced apoptosis 
Endoplasmic reticulum serves as the principle storage site for calcium in the cell.  
Calcium in the ER is regulated by the uptake through Sarcoplasmic/ER Ca2+ ATPase 
(SERCA) and release via inositol 1,4,5-triphosphate receptor (IP3R) or ryanodine (RyR)-
mediated Ca2+ channels [80] [81]. Conditions resulting in the depletion of Ca2+ from the ER 
or increase in the cytoplasmic Ca2+ levels result in cytotoxicity and apoptosis. Increase of 
cytoplasmic Ca2+ leads to the activation of cytoplasmic cysteine proteases called calpains 
[82](Figure 1.5). Activated calpains in turn activate procaspase-12 and also cleave Bcl-XL, 
converting it into a proapoptotic protein [83]. The proapoptotic Bcl-2 family members Bax 
and Bak have also been reported to localize to the ER in some cell types [84], where they 
might regulate Ca2+ dependent cross link between ER and mitochondria. Another 
proapoptotic protein Bim translocates to the ER during ER stress [85] where it probably acts 
as a trigger for caspase-12 activation. Caspase-7 was shown to activate caspase-12 [86], 
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which in turn activates caspase-9 [87] and caspase-3 [88]. This shows that the ER stress 
response is directly connected to the caspase activation cascade. Although many studies 
implicate a regulatory role for ER in apoptosis, the exact mechanism how it is regulated 
remains largely unclear.  
 
1.2.5 Golgi apparatus and apoptosis 
Golgi apparatus is enriched with several apoptosis signalling proteins like Caspase-2 
[89], and other death receptors of the plasma membrane such as Fas, TNF-R1, TRAIL-R1, 
TRAIL-R2 etc. Reports showing that p53 mediated apoptosis induced transient translocation 
of golgi-located Fas to the cell surface [90], indicate that Golgi might act as a temporary 
storage organelle for the cell surface death receptors. At present it is not known whether the 
Golgi apparatus functions as a stress sensor in the regulation of apoptosis. However, 
inhibition of protein glycosylation by an alkaloid, swainsonine, resulted in the induction of 
apoptosis [91], which suggests that Golgi apparatus might also initiate apoptosis signalling, 
by an yet unknown mechanism.  
 
1.2.6 Lysosome-mediated apoptosis 
The lysosomal cysteine proteases, also called Cathepsins, are the largest group of 
proteolytic enzymes in the lysosomes. The type of cell death mediated by lysosomes depends 
on the extent of lysosomal membrane permeabilization, and consequently the amount of 
proteolytic enzymes released into the cytoplasm. A complete release of the lysosomal 
enzymes into the cytosol causes necrosis, while a partial permeabilization triggers apoptosis 
[92] [93]. The precise mechanism by which lysosomes are involved in apoptosis and the 
possible functional relationships or cross-talks with other known apoptotic pathways is still 
unknown. Possible mechanisms by which the lysosomal proteases trigger apoptosis would be 
either by direct cleavage and activation of caspases or by inducing mitochondrial dysfunction. 
Cathepsin B has been shown to activate procaspase- 1 and -11 in vitro [94] [95], though both 
these caspases have very limited role in apoptosis. Cathepsin L has also been proposed to 
trigger activation of caspase-3 indirectly [96]. The proapoptotic Bcl-2 family protein Bid is 
shown to be cleaved and translocated to the mitochondria following disruption of the 
lysosomes [97]. Cathepsin D triggers activation of Bax and translocation to the mitochondria, 
resulting in mitochondrial membrane permeabilization and the release of Apoptosis inducing 
factor (AIF) [98].  
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1.2.7 Role of cytoskeleton and cell adhesion in apoptosis 
The cytoskeleton controls the induction of apoptosis by binding to the Bcl-2 family 
proteins like Bim and Bmf, thus keeping them inactive [99]. These two proteins act as sensors 
for changes in the actin cytoskeleton. Cytoskeletal changes caused due to loss of cell adhesion 
or by chemicals damaging the cytoskeleton causes the release of these proteins, which then 
translocate to the mitochondria and activate the mitochondrial apoptotic pathway. 
An intact cytoskeleton is required for the cell-matrix and cell-cell adherence based 
signalling pathways. Cells interact with the components of the extracellular matrix through 
integrins [100], while the interactions with the neighbouring cells are mediated by proteins of 
the cell junctions (Cadherins, Catenins, Zonula Occludens etc) [101]. 
 
 
 
Figure.1.6. Cell adhesion mediated signalling.  
Proteins involved in cell-cell and cell-matrix adhesion (cadherins and integrins respectively) mediate several pathways 
leading to cell proliferation, growth and survival. Loss of cell adhesion abrogates these pathways and triggers apoptosis. 
(Figure taken from Grossmann,J et al.[8] ) 
 
Integrins and the Cadherins mediate several pathways including Erk/MAPK, JNK, and 
AKT pathways which result in proliferation, growth and cell survival (Figure 1.6). Activated 
AKT inhibits the proapoptotic proteins like caspase-9 and Bad [8]. Activation of the 
Erk/MAPK leads to the inhibition of Bim [102] and the Fas associated death pathway [8]. 
However, loss of cell adhesion leads to abrogation of these survival pathways, resulting in 
apoptosis (Reviewed by Grossmann et al, 2002) [8]. Upon cessation of these pathways, Bad 
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and Bim translocate to the mitochondria and induce the mitochondrial membrane 
permeability, release of cytochrome c and finally activate the caspase cascade. Loss of cell 
adhesion also leads to activation of p53 and an increase in expression levels of Fas and Fas 
ligand. Loss of cell anchorage seem to trigger apoptosis not via a single specific pathway, but 
through multiple molecular pathways, which often integrate with the traditional mediators of 
apoptosis, like caspases and Bcl-2 family proteins. 
 
1.2.8 Integration of different apoptosis pathways 
 All the cellular compartments are equipped with sensors that can detect different stress 
signals and relay them to the rest of the cell. Though the apoptotic pathways originate in an 
organelle-specific manner, they converge on the central executioner, which is the activation of 
the caspase cascade. Caspases are cysteine proteases that cleave their substrate proteins 
behind an aspartate residue. There are 14 caspases indentified to date [15]. Functionally 
caspases can be divided into 3 subclasses: (i) the initiator caspases (Caspase-2,-8,-9 and-10) 
start the caspase cascade in the specific pathway and activate the effector caspases (ii) the 
effector or executioner caspases (Caspase-3,-6 and -7) execute the actual cleavage of the 
cellular substrates and lead to the apoptotic morphology (iii) the remaining caspases whose 
main role is cytokine maturation rather than apoptosis [103]. Under normal conditions, 
caspases are present as inactive proenzymes. Upon receiving the apoptosis signal, they get 
activated either by dimerization (initiator caspases) [104] [105] or by cleavage at specific 
internal aspartate residues (executioner caspases) [106].  
Caspase-3 is a major effector caspase that cleaves many important cellular substrates. 
Activation of caspase-3 is the point of no return and results in the activation of many down 
stream effector functions  including ICAD (inhibitor of caspase activated DNase), ROCK1 
(Rho-associated coiled-coil forming kinase 1), PARP (poly(ADP-ribose)polymerase) a DNA 
repair enzyme etc. Active caspase-3 causes membrane blebbing (via ROCK 1 cleavage) [107] 
and DNA fragmentation (via ICAD cleavage) [108] which eventually lead to cell death.  
 
1.3 Apoptosis dysregulation and its clinical implications 
Regulation of homeostatic balance between cell proliferation and cell death is essential 
for development and maintenance of multicellular organisms. Dysregulation of apoptosis is 
associated with many pathological conditions. Too little apoptosis result in cancer, 
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autoimmune or other chronic inflammatory diseases, and too much apoptosis result in AIDS 
and neurodegenerative/neurodevelopmental diseases.  
 
1.3.1 Apoptosis and cancer 
Cancer is a condition which is characterized by abnormal and uncontrolled cell 
division. Normal cells become cancerous as a consequence of several genetic alterations that 
allow the cell to disable apoptotic signalling. Human tumours harbour several inactivating 
mutations in pro-apoptotic genes and show increase in expression or activity of anti-apoptotic 
proteins. Mutations in pro-apoptotic p53 tumour suppressor gene or the regulators of its 
activity are the most common genetic abnormalities in cancer [6]. Other alterations that confer 
resistance to apoptosis are increased expression of anti-apoptotic Bcl-2 family proteins, 
survivin or other inhibitor of apoptosis (IAP) family members, anti-apoptotic heat shock 
proteins, cathepsin inhibitors; activating mutations of protein kinase B (PKB, also called Akt) 
and inactivation or loss of pro-apoptotic protein Apaf-1 [109] [110] [111] [112] [99] [113] 
[114] [115]. 
 
1.3.2 Apoptosis and autoimmunity 
Autoimmune diseases are characterized by production of antibodies against cellular 
constituents which are not recognized as antigens in healthy people. Defects in apoptosis 
pathways were identified in the autoimmune diseases like Rheumatoid arthritis, Type I 
diabetes, Autoimmune lymphoproliferative syndrome (ALPS) etc. Among several 
mechanisms responsible for causing these diseases, one possibility is the failure of the 
immune system to remove by apoptosis those lymphocytes which develop reactivity against 
self antigens. An alternative mechanism of how dysregulation of apoptosis may contribute to 
autoimmunity is that if rates of apoptosis are abnormally high in certain tissues, this may 
result in the presentation of increased levels of autoantigens to the immune system [116]. 
Mutations of Fas receptor and/or its ligand (FasL) resulting in decreased apoptosis of 
lymphocytes [117] [118] [119], and defects in the NF-κB related pathways resulting in 
increased apoptosis [120] have been observed in many autoimmune diseases.  
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1.3.3 Apoptosis and AIDS 
This disease is caused by the infection of CD4+ T lymphocytes with Human 
immunodeficiency virus (HIV), resulting in the death of infected as well as the uninfected 
bystander T lymphocytes. The major mechanism by which the T cells die is by apoptosis, 
primarily Fas mediated apoptosis [121]. HIV infected patients show increased levels of Fas 
receptor, Fas ligand, caspase-8, pro-apoptotic Bax and Bim. The NF-κB survival pathway was 
found to be suppressed leading to reduced expression of anti-apoptotic Bcl-2 family proteins 
like Bcl-2 and Bcl-XL [122]. 
 
1.3.4 Apoptosis and Neurodegeneration 
Many neurodegenerative diseases like Alzheimers, Parkinsons, amyotrophic lateral 
sclerosis, retinitis pigmentosa, Friedreich´s ataxia etc. are associated with increased apoptosis 
of the neurons. Mitochondrial dysfunction, disruption of Ca2+ homeostasis, expression of 
mutant proteins and other cellular stresses causing accumulation of misfolded proteins have 
been implicated in the development of these diseases [123]. Diseases like Alzheimers and 
Parkinsons are characterized by accumulation of abnormal protein aggregates in the nucleus 
or cytoplasm of the neurons. Mutations in Presenilins and Parkin have been implicated in the 
pathogenesis of Alzheimers and Parkinsons diseases respectively.  Mutations in these proteins 
result in protein misfolding and formation of aggregates, leading to the onset of Unfolded 
protein response (UPR) and finally apoptosis of the neurons through the endoplasmic 
reticulum stress pathway [124] [125]. 
 
Apart from the above described diseases, hereditary deficiencies in lysosomal enzymes 
cause Farbers disease, Niemann-pick disease, Batten´s disease, infantile neuronal ceroid 
lipofuscinosis (NCL) etc, which are characterized by an increase in apoptosis [126]. It has 
been classically considered that tissue damage leading to ischemia occurs due to necrosis. 
However, in myocardial infarction, ischaemic renal damage or cerebrovascular accidents, the 
cells surrounding the ischaemic zone die through apoptosis [127] [128]. 
1.4 Detection of apoptosis 
Because (dys)regulation of apoptosis is associated with such a wide range of diseases, 
it has become increasingly necessary to precisely identify and quantify cells which died by 
apoptosis. Apoptotic cells exhibit certain morphological and biochemical features which serve 
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as markers to differentiate apoptosis from other forms of cell death. Numerous methods have 
been developed which recognize apoptotic cells based on their characteristic features.  
 
1.4.1 Analysis of cell morphology 
One of the early events of apoptosis is cell dehydration that is caused due to inhibition 
of Na+/K+/Cl- cotransporter system [129]. This leads to condensation of the cytoplasm 
followed by an increase in cytoplasmic granularity and reduction in cell size. The cells round 
up and detach from the neighbours. Convolutions of the plasma membrane occur 
progressively, leading to the formation of ´membrane blebs` and ´apoptotic bodies`, which 
subsequently detach from the surface of the dying cell.  
1. The typical morphology of apoptotic cells i.e. the membrane blebbing and the 
apoptotic bodies can be detected by light microscopy.  
2. The reduction in size and increase in the granularity of apoptotic cells can be detected 
by flow cytometry based on the light scatter property of the cells. Light scattered by 
cells in the forward direction (forward scatter) is dependent on cell size; while light 
scattered at wide angles (Side scatter) is dependent on the granularity of cells [130]. 
Apoptotic cells exhibit an increased side scatter and decreased forward scatter 
compared to the normal cells. In contrast to apoptosis, necrosis is associated with 
transient increase in forward scatter, reflecting cell swelling.  
 
1.4.2 Plasma membrane changes 
The key feature distinguishing dead from live cells is the loss of integrity and transport 
function of the plasma membrane. Early apoptotic cells maintain the plasma membrane 
integrity, while late apoptotic and necrotic cells lose their membrane integrity. The most 
characteristic change in the plasma membrane is the loss of asymmetry of the phospholipids. 
Phosphatidylserine (PS), a phospholipid which in viable cells is present on the cytoplasmic 
side of the plasma membrane, externalizes upon induction of apoptosis [131]. PS 
translocation occurs early in apoptosis when the cell membrane integrity appears to be still 
intact. 
1. Charged cationic dyes such as trypan blue, propidium iodide (PI) or 7- amino 
actinomycin-D (7-AAD) are excluded from live cells with intact plasma membranes. 
When unfixed and unpermeabilized cells are incubated for a short time with such 
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dyes, only the late apoptotic or necrotic cells are stained positive, while early apoptotic 
and healthy cells exclude the dye [132]. This is a suitable assay for flow cytometry.  
2. The externalization of PS can be detected using Annexin V, which binds preferentially 
to negatively charged phospholipids such as PS. By conjugating a fluorophore of 
interest to Annexin V, early apoptotic cells can be identified either by microscopy or 
flow cytometry [133].  
 
1.4.3 Mitochondrial changes 
Apoptotic cells exhibit loss of mitochondrial membrane potential, which can be used as a 
marker for detecting apoptosis. 
1. A drop in the mitochondrial membrane potential can be monitored by the uptake of 
fluorescent probes such as JC-1 by the mitochondria [134]. Uptake of JC-1 by 
mitochondria of healthy cells results in a change of fluorescence emission from green 
to orange due to formation of dye aggregates upon mitochondrial membrane 
polarization. Apoptotic cells that exhibit loss of membrane potential fluoresce green. 
These changes can be detected by flow cytometry.  
 
1.4.4 DNA and nuclear changes  
Apoptotic cells undergo a massive DNA fragmentation due to the activation of 
endonucleases. The DNA is initially cleaved into fragments of 300-50 kbp, followed by 
cleavage of the DNA between nucleosomes thus producing fragments of 180 bp and its 
multiples [135]. Many methods have been developed to detect the DNA fragmentation and 
are described by Allen et al [136].  
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Figure 1.7 Detection of DNA changes associated with apoptosis.  
(A) Fragmented DNA can be seen as a ´ladder` by agarose gel electrophoresis. (B) Apoptotic cells containing less intact 
DNA can be visualized as a sub-G1 peak after staining with DNA staining dyes. (C) In the TUNEL assay, cells with DNA 
strand breaks incorporate labelled nucleotides and can be distinguished by flow cytometry. (D) In a comet assay, the 
fragmented DNA of apoptotic cells is pulled out by electric field into the agarose layer. The apoptotic cells appear as comets 
containing characteristic ´heads` and ´tails`. 
 
 
1. The DNA of the cells can be extracted by standard procedures and assayed on agarose 
gels. Fragmented DNA form a characteristic ´ladder` pattern [136] (Figure 1.7.A). 
2. After selective extraction of low molecular weight DNA (fragmented DNA) from 
cells, the cells containing the remaining DNA can be stained with DNA staining dyes 
like PI, and cell cycle can be analyzed by flow cytometry. The apoptotic cells form a 
sub-G1 peak [137] (Figure 1.7.B). 
3. The 3´OH ends at DNA strand breaks can be detected by attaching them with biotin or 
digoxygenin conjugated nucleotides in a reaction catalyzed by exogenous TdT 
(TUNEL assay) [137] (Figure 1.7.C). A new development of this method is the 
incorporation of BrdUTP into the DNA strand breaks, which can then be detected by 
using antibodies directed against BrdU. This method can be used to identify apoptotic 
cells by microscopy or by flow cytometry. 
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4. When individual cells embedded in a thin layer of agarose gel are subjected to 
electrophoresis, the fragmented DNA is pulled out from the cells by electric field 
(Comet assay). After staining the gel with DNA staining dyes, the apoptotic cells 
appear as ´comets`, with characteristic ´heads` representing cells with high molecular 
weight DNA, and ´tails` representing degraded DNA [138, 139] (Figure 1.7.D). 
5. DNA fragmentation can be detected immunochemically using antibodies against DNA 
and histones which react with nucleosomes. This is an ELISA based method. 
 
Nuclear changes of apoptotic cells include condensation of the chromatin, disintegration 
of the nuclear envelope and subsequent break down or segmentation of the nucleus. 
Fragmentation of the nucleus can be detected by staining cells with DNA staining dyes such 
as DAPI. This method is suitable for microscopy.  
 
1.4.5 Biochemical changes 
Activation of caspases is now well known as a key event in apoptosis. In particular, 
caspase-3 activity is a common effector of most of the apoptotic pathways. Several assays 
have been developed which use caspase-3 or its activity as an indicator for apoptosis. 
1. Incorporation of caspase-3 substrate into living cells and detection of the cleavage 
product using Fluorescence Resonance Energy Transfer (FRET) is one of the recently 
developed methods [140]. Changes in the FRET signal can be detected by 
fluorescence microscopy, flow cytometry or a fluorescence plate reader.  
2. Caspase-3 activity can also be measured in vitro in a colorimetric or a fluorometric 
assay. This assay involves the cleavage of a chromogenic/fluorogenic caspase-3 
substrate by activated caspase-3 present in cell lysates of apoptotic cells. The resulting 
change in colour/fluorescence can be detected using a plate reader. 
3. Apoptotic cells can be detected by staining activated caspase-3 with a specific 
antibody [141]. This method is suitable for flow cytometry or fluorescence 
microscopy. 
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1.5 cDNA resources for identification of novel apoptosis activators  
The cDNA resources required for the apoptosis screen were provided by the German 
cDNA consortium. The German cDNA consortium is a large scale cDNA project which was 
established in 1997 as part of the German genome project. The aim of the consortium is to 
systematically identify and clone novel human genes by means of cDNA library production, 
EST Sequencing, and subsequent full-length sequencing of candidate cDNAs [142]. To date, 
more than 13,000 novel ORFs have been identified and full-length sequenced, out of which 
more than 1000 full length ORFs have been cloned into expression vectors. Cloning was done 
using the GatewayTM cloning system (Invitrogen), which allows the cloning of PCR-amplified 
ORFs by site-specific recombination [4]. To circumvent the possibility of protein localization 
to a wrong cellular compartment as a result of masking of signal peptide by the tag, two 
expression clones were generated for each ORF, allowing the expression of ORF as C- and N- 
terminal fusions with yellow fluorescent protein (YFP). These clones serve as starting 
material for the subsequent screening of proteins in cell based functional assays.  
 
1.5.1 Selection of novel full-length cDNAs for screening 
Our department has identified genes differentially expressed in tumours of the brain, 
breast, kidney and gastrointestinal stroma using a 31,500-element whole transcriptome cDNA 
array [143] [144]. Genes with differential expression between normal and tumour samples or 
between different tumour types were selected by a two-sample t test. From these differentially 
expressed genes, we have initially selected 100 proteins for screening in the apoptosis assay 
based on the availability of full–length cDNAs. Such a pilot screen with these 100 proteins 
enabled us to test the functionality and reliability of the assay. Later, 100 previously 
uncharacterized proteins were randomly selected from the cDNA collection and screened in 
the apoptosis assay. Thus, a total of 200 proteins were selected for screening in the functional 
assays. Extending our approach to large sets of proteins in the future will contribute to better 
understanding of the regulation of apoptosis.  
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1.6 Aim of the project  
The objective of the present study was to establish a high throughput apoptosis assay 
and to identify and functionally characterize novel human proteins that induce apoptosis upon 
overexpression. Thus, the aims of this project were to: 
1. Establish a suitable apoptosis assay and adapt it for high throughput applications 
2. Select, clone and test positive controls for the assay 
3. Automate the assay 
4. Screen novel proteins to identify apoptosis inducers 
5. Validate the candidates with a conventional apoptosis assay 
6. Functionally characterize one of the cancer relevant candidates from the assay 
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2 Materials and Methods 
 
2.1 Materials  
2.1.1 Equipment 
Autoradiography cassettes     IEC 60406, Rego 
Centrifuge        RC5B PLUS, Sorvall 
Cytospin 3       Shandon 
DNA Gel electophoresis chamber    Renner GmbH 
Electronic expandable pipettor    Impact2, Matrix 
Electroporator       Gene Pulser II, Bio-Rad 
Film developer    Hyper processor,  
Amersham pharmacia 
Flow Cytometer      FACSCalibur, Becton-Dickenson 
Fluorescence Microscope     Axiovert 25, Zeiss 
Freezer (-20°C)      Liebherr Premium 
Freezer (-80°C)      Sanyo, München 
Fridge (4°C)       Liebherr Premium 
FusionTM α       PerkinElmer 
Haemocytometer      Neubauer, Brand 
Incubator (cell culture)     Binder GmbH  
Laser scanning microscope     Axiovert 200M, Zeiss  
Light microscope      Hund Wetzler 
Magnetic Stirrers      Neolab 
Multi-channel pipettes     Brand   
PCR Machine   GeneAmp, Applied Biosystems 
pH-meter       Hanna Instruments 
Pipetteboy       Integra Biosciences 
Pipetteman       Gilson 
Pipetting Robot      MultiProbe IIEX, PerkinElmer 
Precision weigher      Neolab 
Protein Gel Apparatus     MiniProtean II, Biorad 
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Real time PCR machine (Taqman) ABI Prism 7900HT sequence 
detection system,  
Applied Biosystems 
Rocker Platform      PolyMax 1040, NeoLab 
Semi-dry protein transfer apparatus     Trans-blot SD, Bio-Rad 
Spectrophotometer       SmartSpec3000, BioRad 
Spectrophotometer   SpectraMax190,Molecular Devices 
Stepper       Neolab 
Sterile Workbench       HeraSafe, Heraeus  
Table top centrifuge    Biofuge Fresco, Heraeus 
Thermomixer       Eppendorf 
UV transilluminator      Herolab 
Vortex Mixer    NeoLab 
Waterbath       Julabo, Seelbach 
 
2.1.2 Chemicals 
0.01% Poly L-Lysine      Sigma 
0.4% Trypan blue solution     Sigma 
Agarose   Gibco BRL 
Albumin Standard      Pierce 
Ampicillin   Sigma 
APS    Roth 
Bacto-Agar   Difco 
Bacto-Tryptone      BD Bioscience 
Blocker TM BSA (10X)     Pierce 
Bromophenolblue   Sigma 
DAPI        Sigma 
DMEM, high glucose    Gibco BRL 
DMSO    Sigma  
DNA Ladder   Invitrogen 
EDC        Sigma 
EDTA   Roth 
Effectene transfection reagent    Qiagen 
Ethanol absolute      Sigma 
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Ethidium bromide   Merck 
FBS        Gibco BRL 
Gateway BP-Clonase Enzyme Mix    Invitrogen 
Gateway LR-Clonase Enzyme Mix    Invitrogen 
Geneticin (G 418)      Roche 
Gentamycin   Sigma 
Glycerol       Roth 
Glycin        AppliChem 
Isopropanol   Sigma-Aldrich 
Kanamycin   Sigma 
L-Glutamine       Sigma 
LipofectamineTM 2000     Invitrogen 
Magnesium Chloride (MgCl2)    New England BioLabs 
Methanol   Riedel-de Haen 
Milk-Powder   Roth 
n-Butanol   Sigma 
Non essential amino acids (100 x)    Invitrogen 
PBS        Gibco 
Pellet Paint       Novagen 
Penicillin / Streptomycin      Invitrogen 
PFA        Applichem 
Ponceau-S Solution   Serva 
Potassium Chloride (KCl)     Sigma 
Potassium hydrogen phosphate (KH2PO4)   Merck 
ProLong Gold anti fade reagent    Molecular Probes 
Protease inhibitor cocktail, EDTA-free   Pierce 
Rainbow protein molecular weight marker  Amersham Pharmacia  
RestoreTM Western blot stripping buffer   Pierce 
Roti-Load 1 (4X)  Roth 
Rotiphorese Gel 30   Roth 
RPMI 1640 Medium      Gibco BRL 
SDS   Gerbu 
SOC Medium       Invitrogen 
Sodium acetate (NaAc)     Novagen, Wisconsin 
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Sodium Chloride (NaCl)     J.T.Baker, Griesheim 
Sodium Hydroxide (NaOH)     Gerbu 
Staurosporine       Roche 
TEMED     Roth 
Topoisomerase       Invitrogen 
Tris-Base       Sigma 
Tris-Sodiumcitrate      Fluka,  
Triton X-100       Sigma 
Trypsin-EDTA solution 0.25%    Sigma 
Tween 20       Gerbu 
X-ray film       Amersham Bioscience 
 
2.1.3 Kits 
BioCoatTM Tumor Invasion system    BD Biosciences 
Cell death detection ELISAPLUS kit    Roche 
ECL Western Blotting detection kit    Amersham 
Expand high fidelity PCR system    Roche 
Gateway BP-Clonase Enzyme Mix    Invitrogen 
Gateway LR-Clonase Enzyme Mix    Invitrogen 
Invisorb Spin Cell RNA mini kit    Invitek 
Micro BCA Protein Assay Reagent Kit   Pierce 
ProFoundTM Mammalian co-immunoprecipitation kit Pierce 
QIAprep Plasmid Maxi Kit     Qiagen 
QIAprep Spin Miniprep Kit     Qiagen 
QIAquick Gel extraction kit     Qiagen 
QIAquick PCR purification kit    Qiagen 
Rapid DNA ligation kit     Roche 
RevertAidTM minus first strand cDNA synthesis Kit  Fermentas 
 
2.1.4 Plastic and glassware 
5ml Polystyrene round-bottom tubes    BD Falcon 
96-well U-bottom storage plate    BD Falcon 
Adhesive plate seals      ABgene 
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Blotting Paper       Sartorius 
Cell culture flasks       Greiner Labortechnik 
Chamber slides      Labtek 
Cover slips       Roth 
Filter tubes, Ultra Free-MC with 0.45µm Filter Unit  Millipore  
Filtertips       Star lab 
Microcentrifuge tubes      Eppendorf 
Multiwell plates (96, 24 and 6-well plates)   Nunc 
Petri dishes        Greiner Labortechnik 
Pipettes        Greiner Labortechnik 
Polypropylene tubes (15ml and 50ml)   Greiner Labortechnik 
PVDF-membrane       Millipore 
Serological pipettes ( 2ml, 5ml, 10ml, 25ml)   BD Falcon 
Slides         Roth 
Sterile filters        Millipore 
 
2.1.5 Oligonucleotides 
For construction of FRET vector 
mbYFPE1B1_fw 5`-AT CTG AAT TCT GTG AGC AAG GGC GAG GAG CTG-3´ 
mbYFPE1B1_rv 5´-G ATC GGA TTC TTA CTT GTA CAG CTC GTC CAT GCC-3´ 
 
mbFRETspacer_up 5´-CC GGA CTC AGA TCT GGA GGC GAC GAG GTG GAC 
GGC GGA TCG-3´ 
mbFRETspacer_down 5´-AAT TCG ATC CGC CGT CCA CCT CGT CGC CTC CAG 
ATC TGA GT-3´ 
 
mbCFPDEVDYFP_seqfw  5´-CGA CAA CCA CTA CCT GAG C-3´ 
mbCFPDEVDYFP_seqrv  5´-CAA GTT AAC AAC AAC AAT-3´ 
 
For cloning of controls 
mbCIDEC_fw 5´-GCT GGC ACC ATG GAA TAC GCC ATG AAG TCC-3´ 
mbCIDEC_rw 5´-GCT GGG TCG CCC TGC AGT ATC TTC AGA CAG-3´ 
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mbcytochr_fw 5´-GCT GGC ACC ATG GGT GAT GTT GAG AAA GGC-3´ 
mbcytochr_rv 5´-GCT GGG TCG CCC TCA TTA GTA GCT TTT TTG AG-3´ 
 
mbAIF_fw 5´-GCT GGC ACC ATG GGG TCC CAG GTC TCG GTG G-3´ 
mbAIF_rv 5´-GCT GGG TCG CCA GGT GGA GAC TGC CTC ATG G-3´ 
 
stattB1_PAGE_R 5´-GGG GAC AAG TTT GTA CAA AAA AGC TGG CAC CAT G-3´ 
stattB2_PAGE_S 5´- GGG GAC CAC TTT GTA CAA GAA AGC TGG GTC GCC-3´ 
 
The primers were obtained from MWG Biotech. 
 
2.1.6 siRNAs 
The siRNAs were designed by Dharmacon using the SMARTselection technology. 
siRNAs with the following sense and antisense sequences were used:  
 
VMP1 
duplex 1:  5´- GAACAGGGCUGCACACCUUUU-3´ (sense),  
5´- PAAGGUGUGCAGCCCUGUUCUU-3´ (antisense);  
duplex-2:  5´- CCACAUAUAGCCUCAGUUAUU-3´(sense),  
5´- PUAACUGAGGCUAUAUGUGGUU-3´(antisense);  
duplex-3: 5´- GGAAUGGACCUCAAAAUUAUU-3´(sense),  
5´- PUAAUUUUGAGGUCCAUUCCUU-3´(antisense);  
duplex-4:  5´- CGUAUUAUGUUGAAGGAGUUU-3´(sense),  
5´- PACUCCUUCAACAUAAUACGUU-3´(antisense);   
 
GFP 
5´- PGGCUACGUCCAGGAGCGCACC-3´(sense),  
5´- PUGCGCUCCUGGACGUAGCCUU-3´(antisense).  
The complementary sense and antisense siRNA strands were annealed according to the 
manufacturer´s instructions. The four duplex siRNAs targeting VMP1 were mixed in 
equimolar ratios and the aliquots were stored at –20°C. 
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2.1.7 Peptides 
 The following peptides of Vmp1 were designed using PeptideSelectTM tool 
(Invitrogen) and selected for generation of rabbit polyclonal antibodies (Inno-Train 
Diagnostik). 
Peptide 1: SSVNEKKRREREERQN 
Peptide 2: ARLSGAEPDDEEYQEFE 
Peptide 3: EAQRQKLHHKSEMGTP 
Antibody against peptide 2 was used for further experiments with endogenous Vmp1.  
 
2.1.8 Antibiotics 
Antibiotic Source Stock solution End concentration Plasmid used 
Ampicillin Sigma   50mg/ml in 50% ethanol 50µg/ml  pdEYFP-amp 
Gentamycin Sigma  10mg/ml in ddH2O 10µg/ml   pdEYFP-gen 
Kanamycin Sigma  50mg/ml in ddH2O 50µg/ml   
pDONR 221 
pCaspase-3 Sensor 
pECFP-C1 
Geneticin Roche 25mg/ml in ddH2O 1.1mg/ml pECFP-C1 
 
 
2.1.9 Restriction enzymes and buffers 
Restriction enzyme Buffer 
BsrG I NEB 2 
BamH I NEB U 
BspE I NEB 3 
EcoR I NEB U 
 
All enzymes were obtained from New England BioLabs (NEB) 
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2.1.10 Bacterial Strains 
DH10B 
DH10B™ (Invitrogen) cells are a strain of Escherichia coli. They have a high 
transformation efficiency, which makes them ideal for generating cDNA or genomic libraries. 
The mcrA, mcrBC, mrr, and hsdRMS restriction systems were eliminated to allow 
construction of more representative genomic libraries 
 
DB3.1 
DB3.1™ (Invitrogen) is a genetically modified bacterial strain and contains plasmid-
derived DNA sequences. This strain contains the gyrA462 allele which renders cells resistant 
to the toxic effects of the ccdB gene [145]. So these cells were used to propagate the vectors 
of the GatewayTM System (Invitrogen) that are toxic to other bacterial strains, because of the 
presence of the ccdB gene in the death cassette of these vectors. 
 
2.1.11 Cell Lines 
Cell line Description Source Growth Medium 
HEK293T 
Human embryonic Renal 
Cells, Virus-transformed 
ATCC (CRL-11268) 
DMEM low Glucose 
+10% FBS 
Caki-1 Human kidney cancer ATCC (HTB-46) RPMI 1640 + 10%FBS 
Caki-2 Human kidney cancer ATCC (HTB-47) RPMI 1640 +10%FBS 
NIH3T3 Mouse fibroblast cells ATCC (CRL-1658) 
DMEM high 
glucose+10% FBS 
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2.1.12 Antibodies 
Primary Antibodies 
Antibody Company Origin Dilution  
Calnexin BD Biosciences Mouse Monoclonal 1:1000 for WB 
Caspase-3 
Cell Signaling 
Technology 
Rabbit Polyclonal 1:1000 for WB 
Cleaved Caspase-3 
Cell Signaling 
Technology 
Rabbit Polyclonal 1:50 for FC 
Cleaved Caspase-3 BD Biosciences Rabbit Monoclonal 
2µg/ml lysatefor IP 
1:1000 for WB 
Connexin-43 BD Biosciences Mouse Monoclonal 1:50 for IF 
Desmoglein-2 Santa Cruz Mouse Monoclonal 1:50 for IF 
GFP Roche Mouse Monoclonal 1:1000 for WB 
Golgin-97 Molecular Probes Mouse Monoclonal 1µg/ml for IF 
N-cadherin Santa Cruz Mouse Monoclonal 1:50 for IF 
VMP1 
Inno-Train 
Diagnostik 
Rabbit Polyclonal 
1:25 for IF 
1:500 for WB 
Zonula occludens-1 Zymed Mouse Monoclonal 
20µg/ml for IF  
1:350 for WB 
 
 
Secondary Antibodies 
Antibody Company Dilution 
anti rabbit IgG HRP conjugated Sigma 1:10,000 for WB 
anti mouse IgG HRP conjugated Sigma 1:10,000 for WB 
Goat anti-rabbit IgG, APC crosslinked  Molecular Probes 1:350 for FC 
Goat anti-rabbit IgG, Alexa Fluor 488 conjugated Molecular Probes 1:500 for IF 
Goat anti-mouse IgG, Alexa Fluor 488 conjugated Molecular Probes 1:500 for IF 
Donkey anti-rabbit IgG, Alexa Fluor 647 conjugated Molecular Probes 1:500 for IF 
Donkey anti-mouse IgG, Alexa Fluor 647 conjugated Molecular Probes 1:500 for IF 
 
WB: Western blotting ; IP: Immuno precipitation ; IF: Immunofluorescence ;  
FC: Flow cytometry  
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2.1.13 Plasmids 
GatewayTM vectors: 
 
Entry vector: 
 
  
 
 
 
 
 
 
 
 
 
Figure 2.1. pDONRTM 221 
This vector was used to generate the entry clones required to shuffle the cDNA into destination vectors. 
 
 This is a GatewayTM system compatible donor vector, obtained from Invitrogen. This 
plasmid was used to generate entry vectors, which were further used to shuffle the cDNA into 
destination vectors. The ORF is cloned by BP reaction between the two recombination sites 
attP1 and attP2. The ccdB gene present in the death cassette inhibits the growth of this 
plasmid in many bacterial strains. The plasmid encodes resistance for kanamycin, which is 
used for the selection of positive clones, while the chloramphenicol resistance gene is 
replaced by the ORF during BP reaction.    
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Destination vectors:  
 
 
 
 
 
 
 
 
 
The ORF from the entry vectors was cloned into the destination vector. The original vector  
 
Figure 2.2. pdEYFP-gen and pdEYFP-amp 
These destination vectors were used to express YFP tagged proteins in mammalian cells. 
 
 Expression vector encoding YFP was obtained from BD Clontech and modified by 
Wiemann et al to generate pdEYFP-gen and pdEYFP-amp. The pdEYFP-gen (encoding 
gentamycin resistance) generates a fusion protein with YFP at the C-teminal of the protein, 
while the pdEYFP-amp (encoding ampicillin resistance) generates a N-terminally tagged 
protein. The ORF is cloned by LR reaction between the two recombination sites attR1 and 
attR2. Both vectors contain the death cassette with ccdB gene, which facilitates the selection 
of positive clones. The transcription is driven by CMV promoter. 
 
Plasmids used for the construction of FRET vector: 
pCaspase-3 Sensor 
 
 
Figure 2.3. pCaspase-3 Sensor 
This vector was used to amplify YFP for the construction of FRET vector 
pdEYFP-gen
5878 bp
EYFP
GentamycinR
CmR
ccdB
CMV immediate early promoter
attR1
attR2
C-terminal YFP
pdEYFP-amp
6157 bp
AmpR
CmR
ccdB
attR2
CMV immediate early promoter
EYFP
attR1
N-terminal YFP
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This plasmid obtained from BD Clontech was used to amplify YFP for the 
construction of FRET vector. It encodes a unique Caspase-3 sensor protein containing a 
nuclear export signal (NES), caspase-3 cleavage site (DEVD) fused C-terminally to EYFP, 
and a nuclear localization signal (NLS). The transcription is driven by CMV promoter.  
 
pECFP-C1: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. pECFP-C1 
YFP was cloned in the multiple cloning site of this plasmid to generate the FRET vector 
 
This plasmid was used for the construction of FRET vector. The multiple cloning site 
(MCS) present at the C-terminus of ECFP allows for the construction of a N-terminally 
tagged fusion protein. The CMV promoter drives transcription of the fusion protein. This 
vector confers kanamycin resistance for selection in bacteria, and Neomycin resistance for 
selection in mammalian cells which facilitates the establishment of stable cell lines. 
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2.2 Methods 
 
2.2.1 Molecular Biology methods 
2.2.1.1 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction is a technique used to amplify the DNA of interest in 
order to produce adequate amount required for down stream applications. This method makes 
use of the ability of thermostable DNA polymerases to synthesize new DNA strand from a 
template at high temperatures.  
 
PCR was used for 2 different purposes. 
1. For the construction of FRET vector – To amplify EYFP from the vector pCaspase-3 
sensor 
2. For the construction of Gateway Vectors – To amplify the cDNA of interest from the 
vector pCMV-SPORT6 and clone it into GatewayTM compatible vectors. 
 
For the construction of FRET vector: 
The following components were mixed together on ice to set up the PCR reaction: 
Template (pCaspase-3 Sensor)  100ng    1µl 
10x Buffer (with 15mM MgCl2)      5µl 
dNTPs      10mM    1µl 
Primer 1 (mbFRETspacer_up)  10pM    1µl 
Primer 2 (mbFRETspacer_down)  10pM    1µl 
Taq Polymerase        1µl 
ddH2O          40µl 
          50µl 
 
The cycling parameters were as follows: 
Initial denaturation   95°C   5 minutes 
Denaturation    95°C   30 seconds 
Annealing    60°C   1 minute  30 cycles 
Extension    72 °C   3 minutes 
Final extension   72°C   10 minutes 
Hold     4°C   α 
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For the construction of Gateway Vectors: 
Expand High Fidelity PCR System (Roche) was used to amplify DNA for the 
Gateway system. This kit uses a mixture of two polymerases, Taq polymerase for high yield 
and Pwo DNA polymerase for high fidelity.  
The PCR was done in 2 separate steps. The primers were designed in such a way that 
the melting temperature was approximately 75°C. The melting temperature (Tm) of the 
primers was calculated according to the following formula: 
 
2 x (A+T) + 4 x (G+C) = Tm °C  
 
Primers for the 1st PCR contain an ORF specific sequence as well as a short overhang 
compatible with the recombination sequence of the Gateway cassette. Primers for the 2nd PCR 
further extend the Gateway cassette overhang of the 1st PCR product. 
Design of primers for the two steps of the PCR is shown in Figure 2.5.   
 
 
Figure 2.5. Principle of the 2 step PCR 
In the first step of PCR, the ORF is amplified using primers that create overhangs compatible with a part of the gateway 
cassette specific primers. In the second PCR, the overhangs of the ORF are further extended using Gateway cassette specific 
primers. The product of PCR 2 is then used in the BP reaction to create an Entry vector.  
 
 
 
 
PCR 1 
PCR 2 
ORF 
specific  
Gateway system compatible 
overhang 
Product of 1st PCR 
Extension of Gateway 
overhang 
Product of 2nd PCR 
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PCR 1: 
The following components were mixed together on ice to set up the PCR reaction: 
Template (Vector containing the ORF) 50ng   1µl 
10x Buffer (with 15mM MgCl2)     5µl 
dNTPs      10mM   1µl 
forward primer (gene specific)  10pM   1µl 
reverse primer (gene specific)  10pM   1µl 
Polymerase mix       1µl 
ddH2O         40µl 
 
         50µl 
 
The cycling parameters were as follows: 
Initial denaturation   95°C   2 minutes 
Denaturation    95°C   15 seconds 
Annealing    58°C   15 seconds  13 cycles 
Extension    68°C   1 minute 
Final extension   68°C   10 minutes 
Hold     4°C   α 
 
PCR 2: 
The following components were mixed together on ice to set up the PCR reaction: 
Template (product of the 1st PCR)    1µl 
10x Buffer (with 15mM MgCl2)    5µl 
dNTPs      10mM  1µl 
forward primer (stattB1_PAGE_R)  10pM  1µl 
reverse primer (stattB2_PAGE_S)  10pM  1µl 
Polymerase mix      1µl 
ddH2O        40µl 
 
        50µl 
 
The cycling conditions were the same as for PCR 1. Both the PCR products, i.e 10µl from 
PCR 1 and 5µl from PCR 2 were loaded on an agarose gel to check if the expected product 
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had been amplified. The product from PCR 2 was slightly bigger than that of PCR 1 due to 
the addition of the Gateway cassette compatible sites.  The product from PCR 2 was directly 
used in the BP reaction (section 2.2.1.4a) to create the entry vector.  
For applications that require purified DNA, the PCR product was either purified using 
QIAquick PCRpurification kit or extracted from a preparative agarose gel.  
 
2.2.1.2 Purification of PCR products 
The PCR products were purified to remove the unincorporated primers, primer dimers 
and other reaction components which might interfere with post-PCR applications. QIAquick 
PCR purification kit was used when there were no unspecific amplification products. The 
required amplification product was purified from a preparative agarose gel when more than 
one product was amplified during the PCR.  
 
PCR purification kit 
The purification was done with QIAquick PCR purification kit, according to the 
manufacturer’s protocol. Five volumes of buffer PB (high-salt buffer) was added to 1 volume 
of PCR reaction and the sample was applied to a column containing a silica gel membrane. 
After a brief centrifugation, the flow-through was discarded, and the column was washed with 
750µl buffer PE. The DNA was eluted by adding 50µl water to the column and centrifuging 
for 1 minute at 13,000 rpm.  
 
Extraction of DNA from agarose gel 
Preparative gel was run at 100V until the desired band was well isolated from the 
others. The desired band was cut out from the gel under UV light and the gel slice transferred 
into a microcentrifuge tube. DNA from the gel was extracted using QIAquick gel extraction 
kit. Briefly, the gel slice was dissolved by adding 3 volumes of buffer QX1 to one volume of 
the gel and heating at 50°C for 10 minutes. The tube was vortexed every 2-3 minutes. After 
the gel has dissolved completely, 1 gel volume of isopropanol was added and the sample was 
applied to the column provided by the manufacturer. The column was then centrifuged for 1 
minute and the flow-through discarded. The column was washed once with buffer PE and the 
DNA was eluted with water. 
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2.2.1.3 Ligation 
Ligation is the process of covalently joining two DNA fragments. T4 DNA ligase 
encoded by the bacteriaophage T4 was used for the ligation reactions. This enzyme catalyzes 
the formation of a phosphodiester bond between a terminal 5´-phosphate group and the 3´- 
hydroxyl group of adjacent nucleotides. The ratio between the vector and insert varies 
depending on the type of ends (staggered or blunt) generated during the restriction digest.  
Two types of ligation were done for the construction of the FRET vector- insertion of 
YFP (~700 base pairs), and ligation of oligonucleotides of 41 base pairs. The two ligation 
procedures differ slightly in the molar ratio of the vector and the insert and the pre-ligation 
treatments. 
 
a. Insertion of YFP  
Since cohesive (staggered) ends were generated by the restriction digest of the vector, 
a molar ratio of 1/1-5 of vector/insert was used for ligation. The following reagents are 
combined in a final volume of 10µl. 
Vector:   50ng 
Insert:    100ng 
10x ligation buffer:  1µl 
T4 DNA Ligase:  1µl 
The reaction mixture was incubated at 12-15°C overnight and later used to transform the 
bacteria. 
 
b. Ligation of oligonucleotides 
Before inserting the two nearly complimentary oligonucleotides (mbFRETspacer_up and 
mbFRETspacer_down) into the vector, they were annealed together to form a short double 
stranded insert. A molar ratio of 1/100 of vector/insert was used for this purpose.  The following 
components were mixed together:  
Vector:    50ng 
Oligo1 (mbFRETspacer_up):  18.98ng 
Oligo1 (mbFRETspacer_up):  18.98ng 
Make up to 8 µl with water. 
This reaction mixure was incubated at 65°C (in waterbath) for 15 minutes, and then slowly 
allowed to cool down to room temperature. This process of slow cooling anneals the two single 
stranded oligonucleotides, thus forming the insert required for the ligation. To this mixture, 1µl 
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of 10x Ligation buffer and 1µl of T4 DNA ligase were added, incubated overnight at 12-15°C for 
the ligation to proceed and was later used to transform the bacteria. The construct was then 
checked by restriction digest and was later sequenced using the primers 
mbCFPDEVDYFP_seqfw and mbCFPDEVDYFP_seqrv.   
 
2.2.1.4 Gateway Reactions 
The reactions of the Gateway cloning technology (BP and the LR reaction) are based on 
the site-specific recombination property of the bacteriophage lambda (Landy A et al., 1989). 
Generation of an expression clone (termed destination clone) through the Gateway system is a 
two step process [4]. The first step is the cloning of the gene of interest into an entry vector 
through the BP reaction. The cDNA present in the entry clone can then easily be shuffled into 
different Gateway compatible expression vectors by recombination. The second step is 
subcloning the gene of interest from the Entry Clone into a Destination Vector through the LR 
Reaction producing the expression Clone. 
 
a. BP reaction 
The BP reaction was used to generate an Entry vector from the gene specific PCR 
product. This reaction is driven by BP ClonaseTM enzyme mix (Invitrogen), a formulation 
containing the bacteriophage lambda recombination protein Integrase (Int) and the E.coli-
encoded protein Integration Host Factor (IHF). The following reagents were mixed together and 
incubated overnight at 25°C.  
5x BP clonase reaction buffer     2µl 
PCR product (obtained from amplification of cDNA) 6µl 
Entry vector (pDONR 221)  (150ng/µl)   1µl 
BP Clonase enzyme mix     1µl 
Make upto 10µl with water 
The following day, 1µl of Proteinase K (2µg/µl) was added to the reaction mix and 
incubated at 37°C for 10 minutes to stop the reaction. The DNA was then precipitated using 
Pellet paint (Novagen). For this, 2µl Pellet paint, 1µl of 3M Sodium acetate, 20µl absolute 
ethanol and 10µl Isopropanol were added to the BP reaction, mixed well and centrifuged at 
13,000 rpm for 15 minutes at room temperature. The supernatant was carefully removed without 
disturbing the pink coloured DNA pellet at the bottom of the tube. The pellet was dried at 37°C, 
resuspended in 5µl ddH2O and 1µl was used to transform the bacteria (DH10B). The mini-prep 
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DNA obtained from the clones was tested by restriction digest and DNA from the positive clone 
was used for the LR reaction.  
  
 b. LR reaction 
LR reaction was used to generate the expression clone, called the Destination vector, 
from the Entry vector. LR ClonaseTM enzyme mix (Invitrogen) was used for this purpose. This is 
a mixture of bacteriophage lambda Integrase (Int) and Excisionase (Xis), and the E.coli-encoded 
protein Integration Host Factor (IHF). Since circular destination vector (and not a linear one) was 
used, Topoisomerase I was included in the reaction to relax the super coiled destination vector.  
The LR reaction was set up by mixing together the following reagents and incubating overnight 
at 25°C.  
5x LR clonase reaction buffer   4µl 
Entry clone (110-150ng/µl)    1µl 
Destination vector (150ng/µl)    3µl 
Topoisomerase I     0.5µl 
LR Clonase enzyme mix    1µl 
Make upto 20µl with water 
The reaction was stopped the next day by adding Proteinase K and the DNA was precipitated as 
described for the BP reaction. 1µl of the DNA was used to transform bacteria (DH10B).  
 
2.2.1.5 Transformation of bacteria 
Transformation is a process by which the genetic material of an organism is modified by 
incorporation of exogenous DNA into its genome.  
 
Preparation of electro-competent cells 
The bacteria were first made competent – that is, capable of taking up exogenous 
DNA molecules. For this, a 1:100 dilution of an overnight culture of DH10B bacterial cells 
was made in LB medium (without antibiotics) and incubated at 37°C in a shaking incubator 
until OD600 of 0.4 to 0.55 has reached. The cells were spun down by centrifuging at 4000 rpm 
for 15 minutes at 4°C and the supernatant was discarded. The bacterial pellet was resuspended 
in 300ml ice cold water and the centrifugation step repeated. The cells were again 
resuspended in 300ml ice cold water, centrifuged and the pellet was resuspended in 10ml ice 
cold 10% glycerine. After another centrifugation, the bacterial pellet was resuspended in 1–
1.5ml ice cold 10% glycerine and the cells were aliquoted into portions of 25–30µl. The 
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microcentrifuge tubes containing the competent cells were snap frozen in liquid nitrogen and 
stored at -80°C until further use.  
 
Electroporation  
This method of transformation is based on the observation that biomembranes can be 
made transiently permeable by the application of short electric pulses [146]. The 
permeabilized membranes of the bacteria are thus able to take up the exogenously applied 
DNA. 
The electrocompetent cells were allowed to thaw on ice. One µl of the precipitated 
DNA was added to the thawed cells just prior to electroporation and mixed well. The cell-
DNA mixture was pipetted into a chilled electroporation cuvette, taking care not to introduce 
any air bubbles. The cuvette was then inserted in the electroporator and the cells were pulsed 
at 1.7kV for approximately 2-3 seconds. The cells were immediately resuspended in 500µl 
SOC medium (without antibiotic), transferred to a microcentrifuge tube and incubated in a 
shaking incubator for 1 hour at 37°C. Different aliquots of the bacterial suspension were 
spread on agar plates and the plates incubated overnight at 37°C. Individual colonies were 
picked and cultured to analyze for the presence of the required insert. 
 
 
   
 
 
     
 
 
 
2.2.1.6 Small – scale preparation of plasmid DNA (mini prep) 
A single isolated bacterial colony from an agar plate (with the appropriate selection 
marker, refer section 2.1.8) was inoculated into 5ml of LB medium containing the same 
selection marker. The culture was incubated overnight at 37°C in a shaking incubator (300 
rpm). The Qiaprep spin miniprep kit was used to extract and purify the plasmid DNA. Two ml 
of the culture was taken into a microcentrifuge tube and centrifuged at 6000 rpm for 2 
minutes at room temperature. The medium was removed by aspiration, taking care not to suck 
off the bacterial pellet. 250µl of buffer P1 was added to resuspend the pellet. Then 250µl of 
LB-Agar plates  
 
Agar  15g 
Dissolve in 1 liter LB Medium 
Autoclave 
LB Medium (Luria Bertani-medium) 
 
Bacto-Tryptone 10g 
Yeast extract   5g 
NaCl   10g 
Make up to 1 liter with water 
Autoclave 
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buffer P2 was added and the tubes were inverted to mix. After 5 minutes, 350µl of buffer N3 
was added and mixed immediately by inverting the tubes 4-6 times followed by centrifugation 
at 13,000 rpm for 10 minutes at room temperature. The supernatant was transferred into the 
column provided by the manufacturer and centrifuged at 13,000 rpm for 1 minute at RT. The 
flowthrough was discarded, the column washed with 750µl of buffer PE and centrifuged at 
13,000 rpm for 1 minute. The flowthrough was discarded and the column centrifuged again at 
13,000 rpm for 1 minute. Finally the DNA was eluted by adding 50µl of water and 
centrifuging at 13,000 rpm for 1 minute at RT. The eluted DNA was then analyzed by a 
restriction digest with the appropriate enzyme. 
 
2.2.1.7 Large – scale preparation of plasmid DNA (maxi prep) 
This was done by using the Qiaspin maxi prep kit (Qiagen). After inoculation with a 
bacterial culture, 100ml of LB medium (with the appropriate antibiotic as indicated in section 
2.1.8), was incubated overnight at 37°C in a shaking incubator (300 rpm). The next day, 
stocks were made by combining 900µl of bacterial culture with 100µl of 10 x HMFM, 
followed by freezing at -80°C. The bacteria were harvested by centrifugation at 6000x g for 
15 minutes at 4°C. After discarding the supernatant, the bacterial pellet was resuspended in 
10ml of buffer P1. To lyse the cells, 10ml of buffer P2 was added to the samples, mixed by 
inverting the tube 4-6 times, and incubated at room temperature for 5 minutes. To stop the 
lysis, 10ml of chilled buffer P3 was added, mixed well, incubated on ice for 20 minutes, and 
then centrifuged at 13.000x g. In the mean time, the QIAGEN-tip 500 columns were 
equilibrated by applying 10ml of buffer QBT, and the column was allowed to drain by 
gravity. The supernatant containing the plasmid was filtered through a filter paper into the 
column and allowed to enter the filter by gravity. The column was washed 2 times with 30ml 
of buffer QC. To elute the plasmid DNA, 15ml of buffer QF was applied to the column and 
the eluate was collected into a fresh tube. The DNA was precipitated by adding 0.7 volumes 
(10.5ml) of isopropanol, followed by centrifugation at 4°C for 30 minutes. The DNA pellet 
was washed with 5 ml of 70% ethanol and centrifuged again at 4°C for 15 minutes. After 
pouring off the ethanol, the pellet was dried at room temperature and then resuspended in 
required amount of sterile water. 
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2.2.1.8 Measurement of DNA concentration  
The concentration of DNA was determined by measuring the absorbance at 260nm 
using a spectrophotometer (SmartSpec3000, BioRad). The purity of plasmid DNA can be 
determined by calculating the ratio of A260 to A280. A ratio of 2:1 indicates high purity. For 
measuring the absorbance, the spectrophotometer was first calibrated with 100µl of water. 
Five µl of DNA was mixed with 95µl of water, transferred to a quartz cuvette, and the 
absorbance was recorded at 260 and 280 nm. The concentration of double stranded DNA was 
calculated by using the following formula: 
 
Absorbance at 260nm (A260) x dilution factor x 50µg/ml = Xµg/ml 
 
2.2.1.9 Restriction digest 
This method makes use of the property of restriction endonucleases to recognize a 
specific and short sequence of the DNA and cut it at that point. The required amount of DNA 
(150ng in case of maxi-prep and 3µl in case of mini prep), one-tenth the final volume of the 
appropriate 10× restriction buffer (refer section 2.1.9), and the enzyme were mixed together. 
The reaction thus prepared was incubated at the temperature specified for the enzyme for a 
minimum of 1 hour to overnight. Loading dye was added to the digested DNA to a final 
concentration of 1x, and the DNA was then analyzed by agarose gel electrophoresis. 
 
10x Hogness Modified Freezing Medium (HMFM)  
 
Solution 1   
MgSO4.7H2O    5mM 
Tri-Sodium citrate 2 H2O  20mM 
 (NH4)2SO4    85mM 
Glycerol    45% 
       
Solution 2       
KH2PO4    0.66M 
K2HPO4    1.3M  
 
Autoclave both the solutions separately.  
Before use, mix Solution 1 and Solution 2 in a ratio of 1:4 
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2.2.1.10 Gel electrophoresis 
Many biological molecules are charged species that can move in an electric field. 
Electrophoresis techniques are based on this property. Under neutral or alkaline pH 
conditions, the phosphate groups of DNA chains become ionized into polyanions. As a 
consequence, DNA fragments placed within a porous matrix and subjected to an electric field 
travel towards the anode. Under these conditions, smaller DNA molecules migrate faster 
through the pores of the gel relative to their larger counterparts. By using this technique 
known as gel electrophoresis, it becomes possible to separate molecules of different size. 
 
Agarose gel electrophoresis 
Here, agarose gel is used to separate DNA fragments of different sizes. Agarose is a 
neutral polysaccharide polymer generally extracted from the cellular walls of Rhodophyceae 
algae, a sea weed. A 1% agarose gel was used for the separation of DNA fragments. For this, 
0.3gm agarose was dissolved in 30gm 1x TAE buffer by heating the mixture in a microwave. 
Heating was continued until a clear, transparent solution was obtained. The solution was then 
poured into the electrophoresis chamber and allowed to solidify. Before loading samples onto 
the gel, the gel was covered with the electrophoresis buffer (1x TAE). Electric field was 
applied across the gel at 100-150V. The DNA moves towards the anode due to the negatively 
charged phosphate groups. The gel was then stained in Ethidium bromide solution for 5 to 10 
minutes. Ethidium bromide is a fluorescent dye that can reversibly intercalate between the 
bases of DNA molecules and emits an orange fluorescence upon excitation by UV light. The 
DNA was then visualized using a UV illuminator. The size of the DNA fragments was 
checked by comparing their size with that of the DNA ladder (Invitrogen). 
 
 
 
 
 
 
 
2.2.1.11 Extraction of total RNA from cells 
Total RNA was extracted from mammalian cells using Invisorb spin cell RNA mini kit 
(Invitek) according to the manufacturer’s instructions. Briefly, the adherent cells were 
50× TAE buffer 
 
Tris Base  2M 
EDTA   0.1M 
Adjust the pH to 8.0 with glacial acetic acid. 
6x Loading dye 
 
Bromophenol blue  0.25% 
Xylene cyanol FF  0.25% 
Ficoll (Type 400)  15% 
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detached by trypsinization, and pelletted by centrifugation at 1500 rpm for 5 minutes. The cell 
pellet was resuspended in lysis solution R, and the lysate (including the precipitate) was 
pipetted into the DNA-binding spin filter to bind the DNA. To precipitate the RNA, 1 volume 
of 70% ethanol was added to the RNA-containing lysate, and then pipetted onto the RNA 
binding spin filter. After washing the filter 2 times with wash buffers, the RNA was eluted 
with 50µl of elution buffer R into a fresh RNAse free elution tube. The RNA was quantified 
and used immediately or stored at -80°C until further use.  
 
2.2.1.12 Quantification of the RNA using Ribogreen 
The total amount of RNA present in the elution was quantified by staining with a 
fluorescent dye called Ribogreen. Ribogreen reagent is non-fluorescent when free in solution. 
However, the fluorescence increases more than 1000 fold upon binding to the RNA. For 
quantification, the RNA standard (RNA ladder from Ambion diluted to 2ng/µl) was serially 
diluted in a final volume of 100µl RNAse free TE buffer in a black 96-well plate to get final 
concentrations of 0, 2, 5, 10 and 25ng of RNA. In a similar way, the RNA samples from the 
cells were diluted in TE buffer. To each well, 100µl of Ribogreen (diluted 1:1000 in TE 
buffer) was added, incubated in dark at room temperature for 5 minutes and then the 
fluorescence was measured with the fluorescence plate reader (Fusion TM α). The filter sets 
used were Excitation: 480/20 and Emission: 515/30. The amount of RNA present in the 
samples was then calculated based on the standard curve obtained from the standards.  
 
2.2.1.13 Reverse transcription  
Generation of first strand cDNA from the mRNA was done using RevertAid H minus 
first strand cDNA synthesis kit (Fermentas) according to the manufacturer’s instructions. For 
this, equal amount of RNA from each sample (in a final volume of 3µl) was denatured at 
72°C for 2 minutes. The denatured RNA was immediately placed on ice and the reverse 
transcription reaction was set up by mixing the following reagents: 
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Denatured RNA:   3µl 
5x reaction buffer:   1.2µl 
Oligo(dT)18 (100pmol/µl)  0.25µl 
10mM dNTPs    0.6µl 
Prime RNAse inhibitor (30u/µl) 0.2µl 
RevertAid RTase (200u/µl)  0.2µl 
RNAse free water   0.55µl 
The reagents were mixed thoroughly and then incubated at 37°C for 5 minutes, 42°C for 1 
hour and finally at 70°C for 10 minutes. The cDNA thus generated was used immediately for 
Taqman reaction or frozen at -20°C until further use.  
 
2.2.1.14 Quantitative Real - time PCR (TaqMan) 
This method uses fluorogeneic probes that enable the detection of PCR product as it 
accumulates during the PCR.  
 
a. TaqMan analysis of cell lines 
HEK293T and Caki-2 cell lines were transfected with siRNAs, and 72 hours later the 
total RNA of floating and adherent was extracted, quantified and reverse transcribed (as 
described in sections 2.2.1.11, 2.2.1.12 and 2.2.1.13). The cDNA obtained by reverse 
transcribing 10ng total RNA (in a volume of 5µl) was used for each reaction of the 
quantitative real-time PCR. The cDNA was pipetted into a 384 well plate and 5.5µl of the 
PCR master mix and 0.5µl of the assay (containing gene specific primers and fluorogenic 
probe) was added to each well. Quantitative RT PCR was performed using the ABI Prism 
7900HT Sequence Detection System (Applied Biosystems). Triplicate reactions were 
performed for each gene of interest using the assay on demand Hs00229548_m1 (VMP1) and 
Hs00212817_m1 (COPB) (Applied Biosystems). For each sample, the median Ct values were 
taken, and the standard deviations were calculated from the triplicates. Gene expression levels 
were determined by relative quantification using COPB as internal control gene for 
normalization. 
 
b. TaqMan analysis of patient samples 
Fifty-six clear cell renal cell carcinoma primary tumour (n=37) and metastasis (n=19) 
samples were collected at the University of Göttingen between 1996 and 2002. Viable tissue 
samples were excised by pathologists immediately after surgery. Parts of the tumours were 
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snap frozen in liquid nitrogen and stored at -80°C. Tissue homogenization and RNA isolation 
were performed as described [144]. RNA quality was checked with an Agilent 2100 
bioanalyzer (Agilent Technologies GmbH, Waldbronn, Germany). Only high-quality RNA 
(28S/18S rRNA and E260/E280 ratios close to 2) was selected for the experiments. Single-
stranded cDNA was transcribed from 1.5µg total RNA using 200U of Revert Aid reverse 
transcriptase. Quantitative real-time PCR for VMP1 was performed with the ABI Prism 
7900HT Sequence Detection System using the assay on demand Hs00229548_m1. Triplicate 
reactions using 0.5ng cDNA per IDC sample were performed. Standard curves were prepared 
through a cDNA dilution series for every gene. For each sample, the median CT values were 
taken, and the standard deviations were calculated from the triplicates. Gene expression levels 
were determined by relative quantification using ACTB, COPB, and HPRT as internal control 
genes for normalization. 
 
2.2.2 Cell biology methods 
 
2.2.2.1 Subculturing of cells 
The cells were regularly passaged to prevent the monolayers from getting confluent and 
to maintain them constantly in an exponential growth phase. Confluency of the monolayer was 
especially critical in case of NIH3T3 cells, which exhibit the property of high contact inhibition.  
The cells were cultured in the recommended growth medium in 75cm2 flasks until they 
achieve a confluency of 70-80%. Before passaging the cells, the medium, 1x PBS and 0.25% 
Trypsin-EDTA were pre-warmed to 37°C. The medium from the flask was removed and the cells 
were rinsed once with 7ml PBS to remove all traces of serum. Two ml of trypsin was added to 
the flask and the cells were incubated at 37°C until they detach from the surface. The cells were 
gently resuspended in 8ml of complete growth medium to stop the trypsin activity and counted 
(as described in section 2.2.2.3). Subsequently the cells were transferred into new culture vessels 
and then incubated at 37°C in an atmosphere of 5% CO2. 
 
 
 
 
 
 
Culture medium  
    
Medium    500ml 
FBS     10% 
Penicillin    50U/ml 
Streptomycin    50µg/ml 
Non essential amino acids  1x 
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2.2.2.2 Freezing and thawing the cells 
To make frozen stocks, actively growing cells were trypsinized, centrifuged at 1200 rpm 
for 5 minutes to remove the medium and then resuspended in freezing medium. Vials containing 
the cells were immediately placed on ice, then allowed to freeze at -20°C for 2 hours and then at 
-80°C overnight. The cells were then transferred to liquid nitrogen for long term storage. To get 
cells back into culture, the frozen cells were thawn in a water bath at 37°C (approximately 2-3 
minutes) and immediately resuspended in pre-warmed medium. The cells were centrifuged at 
1200 rpm for 5 minutes to remove the freezing medium containing DMSO. The cell pellet was 
resuspended in complete growth medium, transferred into the culture flask and incubated at 37°C 
and 5% CO2 until the cells were ready to be subcultured.   
 
 
 
 
 
 
 
 
2.2.2.3 Counting of cells 
 The cells were counted using a Neubauer hemocytometer.  Equal volumes of cells 
and 0.4% Trypan blue solution (100µl of cell suspension and 100µl Trypan blue) were mixed 
together in a microcentrifuge tube and left undisturbed for 3 minutes. Trypan blue is a dye 
which stains dead cells blue, while the live cells remain unstained. The chamber of the 
hemocytometer was filled with the stained cell suspension by capillary action. The total 
number of cells in the four marked squares (Figure 2.6) was counted using a microscope. 
Each chamber of the hemacytometer is divided into nine 1.0mm squares. A cover glass is 
supported over these squares so that the total volume over each square is 0.0001ml or 10-4 ml 
(length x width x height; i.e., 0.1cm x 0.1cm x 0.01cm).  Since 1cm3 is equivalent to 1ml, the 
cell concentration per ml will be the average count per square x dilution factor x 104.  
 
 
 
 
Freezing medium 
 
Medium 70% 
FBS  20% 
DMSO  10% 
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Figure 2.6. Counting cells with Neubauer hemocytometer 
Cells stained with trypan blue were loaded onto the hemocytometer and the total number of cells in the four big squares 
(shown with blue numbers) was counted. The number of cells/ml of cell suspension is then calculated as described. 
 
2.2.2.4 Transfection with plasmid DNA and siRNA 
Transfection is a process of integrating new genetic material, DNA or RNA into a 
eukaryotic cell. Two different transfection reagents, LipofectamineTM 2000 and EffecteneTM, 
were used depending on the nucleic acid to be transfected. EffecteneTM was used for 
transfections with plasmid DNA, while LipofectamineTM 2000 was used for transfections with 
siRNA. LipofectamineTM 2000 is a cationic liposomal formulation which interacts with the 
negatively charged nucleic acid to form lipoplexes that are subsequently endocytosed by the cell 
(Felgner et al., 1987).  A new improvement to the liposomal transfection is the use of non-
liposomal lipids. EffecteneTM is a non-liposomal transfection reagent, whose positively charged 
micellar surfaces bind to the DNA for introduction into the cell. 
 
a. Transfection with plasmid DNA 
 One day before transfection, the cells were seeded into the required culture vessel (petri 
dish, 6-, 24-, or 96- well plate) so that they attain a confluency of not more than 60% at the time 
of transfection. The transfection was done according to the following protocol.  
 
Transfection using EffecteneTM 
The required amount of DNA was first diluted in EC-buffer. The DNA-condensing 
reagent, Enhancer, was then added to the diluted DNA and mixed well by vortexing. The DNA-
Enhancer mixture was incubated for 5 minutes at room temperature. Effectene was added to this 
mixture, mixed well by vortexing and incubated for 10 minutes at room temperature. The 
complexes were then directly added to the cells in complete growth medium (containing serum 
1 2
4 3
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and antibiotics). The cells were incubated with the complexes at 37°C until the required time. 
The quantity of the reagents used for transfection in one well is shown in the table 2.1. 
 
Table 2.1 
 Chamber
slides 
96-well
plate 
24-well
plate 
6-well 
plate 
Petri-dish
∅ 100 mm
DNA (ng) 100 100 200 400 2000 
Enhancer (µl) 0.8 0.8 1.6 3.2 16 
EC-buffer (µl) 50 30 60 100 300 
Effectene (µl) 1 0.5 5 10 60 
Final volume of 
medium on cells (ml) 
0.2 0.1 0.75 2.0 10 
 
b. Transfection with siRNA 
One day before transfection, the cells were seeded in either 24-well or 6-well plates in 
medium containing 10% FBS (but without antibiotics) so that they were 50-60% confluent at the 
time of transfection. LipofectamineTM 2000 was used for transfecting with siRNA. 
 
Transfection using Lipofectamine 2000TM 
All reactions during the transfection were done in serum free medium. The required 
amount of siRNA and Lipofectamine were diluted separately in serum free medium. After 
incubation for 5 minutes at room temperature, they were mixed and incubated again for 20 
minutes. In the mean time, the cells were washed once with 1x PBS, and fresh medium (with 
10% FBS, without antibiotics) was added to the wells. The complexes were then given to the 
cells and mixed well by gently rocking the plate. The cells were incubated at the normal culture 
conditions for 24-72 hours to allow for the protein knockdown. The quantity of the reagents used 
for transfection in one well is shown in the table 2.2. 
 
Table 2.2 
 24-well plate 6-well plate 
Lipofectamine (µl) 1 5 
Total volume of complexes added to cells (µl) 100 500 
Final volume of medium on cells (ml) 0.75 2 
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2.2.2.5 Generation of Stable cell line 
Stable cell lines constitutively expressing the FRET vectors CFP-YFP and CFP-DEVD-
YFP were generated using the NIH3T3 cells. The vectors encode Neomycin (G418) resistance 
which allows for selection of stable transfectants in mammalian cells. An antibiotic, Geneticin 
disulphate (G418), was used for the selection of stable clones. Geneticin is lethal to normal cells, 
but the cells expressing the Neomycin resistance gene are resistant to the toxic effects. 
Generation of the stable cell lines was done in the following steps:  
 
Determination of optimum cell density 
Since NIH3T3 cells are very sensitive to cell-cell contact, it was important to determine 
the minimum cell density at which the cells survive. For this purpose, the cells were seeded into 
6-well plates at different densities ranging from 5000 to 3x105 cells/well and incubated overnight 
at 37°C and 5% CO2. The cell density of 1.5x105 cells/well was found to be optimum for 
survival. 
 
Determination of optimum Geneticin concentration 
The minimum concentration of Geneticin required to kill the cells not expressing the 
G418 resistance was determined. This was done by titrating the Geneticin concentration over a 
period of 8 days. 1.5x105 cells/well were split into 6-well plates and incubated overnight. The 
following day, Geneticin was added to each well at different concentrations ranging from 
150µg/ml to 1.1mg/ml of medium. After 4 days, the medium was replaced with fresh medium, 
again containing Geneticin, and the cells incubated for 4 more days. After 8 days the viability of 
cells at different concentrations of Geneticin was checked by microscopy. It was found that 
approximately 30% of the cells survived at 1mg/ml, while all the cells died at a concentration of 
1.1mg/ml. So, a concentration of 1.1mg/ml Genetic was chosen for the generation of stable cell 
line. 
 
Transfection and selection with Geneticin 
1.5x105 cells/well were split into 6-well plates (in medium with out Geneticin) and the 
cells were transfected with the required vectors using Lipofectamine 2000TM. Two days after 
transfection the medium in the wells was replaced with Geneticin containing medium (1.1mg/ml) 
and the cells were allowed to grow for 8 days. Fresh medium was given to the cells every 3 days. 
Appropriate control wells with out antibiotic treatment were included in the experiment.  
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Seeding of cells for isolation of stable clones 
After 8 days, the cells were trypsinized, resuspended in 3ml medium and seeded into 
different plates. Different strategies of seeding the cells were followed to isolate the clones stably 
expressing the FRET probes.  
1. 3µl of cell suspension was diluted in 3ml medium (without Geneticin) and seeded into 
each well of a 6-well plate.  
2. The cells were seeded into a 96-well plate in such a way that each well receives one cell. 
This was done by diluting the cells to a final concentration of 1 cell/100µl medium and 
seeding 100µl/well. 96-well plates with flat as well as round bottom were used. Since 
NIH3T3 cells die at high dilutions, the round bottom plates would facilitate better cell-
cell contact.  
3. A serial 1:1 dilution was done in a 96-well round bottom plate. For this, the plate was 
first prepared by adding 100µl medium/well. 10µl of cell suspension was added to the 
first well (A1) and mixed thoroughly. The dilution scheme is shown in Figure 2.7. 
 
 
 
Figure 2.7. Dilution scheme followed for isolation of stable clones 
The 96-well plate was initially pre-prepared by adding 100µl of medium to each well. 10µl of cell suspension was then added to 
well A1, mixed well and 100µl of this was transferred to the next well in the same column. In this way, the cells were serially 
diluted till well H1. In the second step, 100µl of the cell suspension from each well was serially diluted in the same row. 
 
Picking of clones 
Viable clones were found only in the 96-well plates where serial dilution of cells was 
done. To isolate the clones, the cells were trypsinized by adding 50µl trypsin/well and incubating 
for 2 minutes at 37°C. The viable clones from the 96-well plate were transferred into a 24-well 
plates and cultured until the cells were confluent. The cells were trypsinized, cultured in 6-well 
A 
H 
B 
C 
D 
E 
F 
G 
100µl 
Order of 
dilution 
100µl 
100µl 
100µl 
100µl 
100µl 
100µl 
100µl Order of 
dilution 
10µl cell 
suspension 
Step 1 Step 2 
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plates and then transferred into T25 flasks. When the cells were confluent, an aliquot of cells 
from each clone was taken aside and the constitutive expression of the protein was checked by 
western blotting. The rest of the cells were frozen down to be used at a later time.  
 
2.2.2.6 Immunocytochemistry  
This method makes use of the specificity of the antigen-antibody interactions for the 
detection of specific cellular components. Cells were split into 6 well-plates and allowed to grow 
on cover slips for 12-24 hours prior to the required treatment. Cover slips that had been pre-
coated with 0.1% (w/v) Poly-L-Lysine solution were used in case of cell lines that do not attach 
well to the substrate. The cover slips were treated with Poly-L-Lysine for 5 minutes, air dried 
and used immediately. Poly-L-Lysine has polycationic nature which strongly attracts the 
negatively charged molecules on the cell suface, thus retaining the cells on the cover slip.  
After incubating cells for the required time, the medium from the wells was removed and 
the cells were fixed with 1ml 4% PFA for 15 minutes at room temperature. The cells were 
washed thrice with 1x PBS and then permeabilized with 0.2% Triton X-100/PBS for 5 minutes. 
After washing three times with 1x PBS, 1ml of blocking solution (3% BSA/1x PBS) was added 
to each well and incubated for 30 minutes at room temperature. This is done to block any 
unspecific reactive sites in the cells which might cause high background signal. Subsequently, 
the slides are incubated in a recommended dilution of the primary antibody (refer section 2.1.12) 
for 30 minutes at room temperture. The cells were washed three times, 5 minutes each wash, 
with 1x PBS. The slides were then incubated in the secondary antibody coupled to a fluorophore, 
diluted 1:400 to 1:600 in 1x PBS for 30 minutes in dark. After washing thrice in 1x PBS, slides 
were incubated for 5 minutes in DAPI staining solution (1µg/ml DAPI in 1x PBS), to stain the 
nucleus. DAPI is a fluorescent dye which binds specifically to the minor groove of DNA. The 
cells were washed to remove the excess staining solution and cover slips were mounted on slides 
using ProLong gold anti fade mounting solution. After letting them dry over night in dark, the 
slides were analyzed on the confocal fluorescence microscope. Images were taken using a 63x 
oil immersion objective. 
 
 
 
 
 
 
Blocking solution 
 
BSA  3% 
PBS  1× 
1x PBS  
 
NaCl 140mM 
KCl  2.7mM 
KH2PO4  1.5mM 
Na2 HPO4 8.1mM 
Adjust pH to 7.4 with NaOH 
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2.2.2.7 Cell death detection ELISA 
This is a photometric enzyme-immunoassay for the detection of histone associated 
DNA fragments. During apoptosis, the activated endonucleases cleave the double stranded 
DNA at internucleosomal regions generating mono- and oligonucleosomes. The DNA 
fragments thus formed are multiples of 180bp and are enriched in the cytoplasm of apoptotic 
cells. The Cell death detection ELISAPLUS kit (Roche) detects these fragments of DNA in a 
sandwich ELISA based method. The principle of the assay is shown in Figure 2.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Principle of the Cell death detectection ELISA  
The supernatant containing contents of the necrotic cells was initially removed and the remaining cells were lysed. Cell lysate 
containing the cytoplasmic nuclear fragments of the apoptotic cells was transferred into a streptavidin coated micro titre 
plate. The anti-histone and the anti DNA antibodies capture the DNA fragments, which can be detected in a colourimetric 
reaction. 
 
After inducing apoptosis for the required time, floating and the adherent cells were 
collected and centrifuged at 1200 rpm for 5 minutes. The supernatant was carefully removed, 
the cell pellet resuspended in 200µl of lysis buffer, and incubated for 30 minutes at room 
temperature. The lysate was centrifuged at 200 x g for 10 minutes and then 20µl of the lysate 
was transferred to the streptavidin coated micro titre plate. 80µl of the immunoreagent, 
containing a mixture of biotin labelled anti-histone antibody and peroxidase conjugated anti-
DNA antibody, was added to each well and incubated under gentle shaking (300 rpm) for 2 
hours at room temperature. During the incubation time, the anti-histone antibody binds to the 
histones of the nucleosomes, simultaneously capturing the immunocomplex to the streptavidin 
coated micro titre plate. The solution was removed by suction and the wells were rinsed 3 x 
Normal Apoptotic Necrotic 
Cell lysis 
Remove supernatant 
ELISA 
Streptavidine 
coated MTP 
Anti-histone 
biotin 
Nucleosomes Anti-DNA POD
Substrate 
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with 300µl incuation buffer. 100µl of substrate solution was added to the wells and incubated 
for 15 minutes. The absorbance at 405nm was measured using the spectrophotometer, 
SpectraMax190.  
 
2.2.2.8 Caspase-3 assay 
This method is based on the detection of the activated form of caspase-3 by flow 
cytometry. The cells were transfected with the cDNAs of interest and then stained with an 
antibody specific for activated caspase-3. The principle of the assay is shown in figure 2.9.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. Principle of the caspase-3 assay 
Cells transfected in 24-well plates with YFP tagged cDNAs were allowed to express the protein for 3 days and then 
transferred to 96-well plate for staining with the active caspase-3 antibody. The cells were then measured on the FACS to 
identify proteins that induce apoptosis upon overexpression.  
 
The assay was done in a 24-well format and the detailed protocol is as follows: 
 
Day 1: Seeding the cells 
HEK293T cells were seeded in four 24-well plates (24 x 4= 96) at a density of 32,000 
cells/well in a final volume of 600µl complete growth medium/well. The plates were rocked 
gently to ensure even distribution of cells in the wells.  
 
Day 2: Transfection 
The cells were transfected under the sterile hood of the robot (MultiPROBE IIEX) with 
96 different expression clones. The transfection was carried out according to the protocol 
Transfection in 24-well plates 
Antibody staining
FACS 
Activator
No effect
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described in section 2.2.2.4a for 24-well plates. The plates were labelled carefully according 
to the order of the transfection and put back in the incubator (37°C, 5% CO2). 
 
Day 3: Check for protein expression 
The cells were checked under a fluorescence microscope for the expression of the 
protein and the incubation was continued. 
 
Day 4: Incubation 
Incubation continued 
 
Day 5: Staining and measurement on FACS 
Trypsinization 
The medium from the 24-well plates was collected and saved in a U-bottomed 
polypropylene 96-deep well plate. The saved medium contains the floating apoptotic cells. 
The adherent cells in the 24-well plates were washed once with 1x PBS and then trypsinized 
by incubating with 150µl trypsin/well for 2 minutes at 37°C. After the cells have dislodged 
from the surface, 100µl of medium with 10% FBS was added to the wells to inhibit the 
Trypsin. The cells were resuspended thoroughly to dissociate the cell clumps and then 
transferred to the respective well of the deep well plate containing the floating cells. The cells 
were then stained with the specific antibody.   
 
Staining 
The plate was centrifuged at 1350 rpm for 5 minutes to pellet the cells. The medium 
was aspirated carefully and the cells were fixed by resuspending in 150µl 2% PFA and 
incubating at 37°C for 10 minutes. The cells were placed on ice for 1 minute and then 
centrifuged to remove the PFA. Permeabilization was done by adding 200µl ice cold 90% 
methanol and incubating on ice for 30 minutes. Cells can be stored at this point at –20°C, 
until further use. After removing the methanol, 150µl of wash buffer (0.5% BSA in PBS) was 
added to the cells to block any high affinity binding sites on the cells. Blocking was done by 
incubating in wash buffer for 10 minutes at room temperature. The wash buffer was removed 
and the cells were incubated in 50µl of primary antibody staining solution (Rabbit anti active 
caspase-3, diluted 1:50 in wash buffer) for 45 minutes at room temperature. The cells were 
washed twice with 150µl wash buffer and then incubated in 50µl of secondary antibody 
staining solution (anti-rabbit IgG-APC conjugated, diluted 1:350 in wash buffer) for 30 
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minutes at room temperature in dark. The unbound antibody was removed by washing twice 
with 150µl of wash buffer, and the cells were finally resuspended in 50µl wash buffer.  
 
Measurement with FACS 
The cells from the deep well plate were transferred into a polypropylene 96-well U-
bottom plate which is compatible with the HTS (High throughput sampler) of the 
FACSCalibur.  The settings of the instrument were adjusted to measure the signal from 
20,000 cells. CellQuestPro® was the software used for the measurement. Setup and 
calibration of the instrument were done as described in the FACSCalibur manual.  
Statistical analysis 
The data obtained from the assay was analyzed using the statistical programming 
language R, which is openly available on the net as the software package prada (collaboration 
with Florian Hahne). Effect of a given protein on apoptosis was then quantified based on the 
calculation of odds-ratio. Odds-ratio is defined by 
     
TP+1   UTN+1     
TN+1   UTP+1 
Where,  
TP    = Transfected, active caspase-3 Positive  
TN    = Transfected, active caspase-3 Negative 
UTN = Untransfected, active caspase-3 Negative 
UTP = Untransfected, active caspase-3 Positive 
Fisher t-test was used to test for the significance against the null hypothesis of no effect. The 
results were then visualized as colour coded 96-well plate plots displaying various quantities 
of interest like odds ratio, transfection efficiency, total cell number/well etc.  
 
2.2.2.9 Nuclear fragmentation assay 
HEK293T cells were seeded in 24-well plate (32,000 cells/well) and incubated overnight 
at 37°C. On the following day the cells were transfected with YFP tagged ORFs and allowed to 
express the protein for 3 days. The floating and adherent cells were collected by trypsinization, 
centrifuged and fixed with 500µl of 2% PFA for 10 minutes at room temperature. After 
removing PFA, the cells were permeabilized by incubating with 0.2% Triton X-100/PBS for 5 
minutes. The cells were then resuspended in 500µl of DAPI staining solution (diluted 1:1000 in 
PBS) and incubated for 5 minutes. After washing twice with PBS, the cells were fixed on slides 
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using Cytospin centrifuge and then mounted using Prolong Gold antifade mounting solution. 
Fluorescence images were obtained using a Confocal laser scanning microscope, Axiovert 
200M. Images were taken using a 40x oil immersion objective.  
 
2.2.2.10 Adhesion assay 
HEK293T cells were seeded in 6-well plates (2x105 cells/well) and transfected with 
siRNA. After incubating for 72 hours, the culture medium from the wells was collected, 
centrifuged to remove the medium and the cells were fixed with 4% PFA for 15 minutes at 
room temperature. The pelletted cells were resuspended in PBS and the cell number was 
counted with FACSCalibur. 
 
2.2.2.11 Invasion assay 
BioCoatTM Tumor invasion system from BD Bioscience was used for the Invasion 
assay. This system consists of a 24-well insert plate with a porous membrane (8.0 micron pore 
size) that has been uniformly coated with BD MatrigelTM Matrix. The matrix coating mimics 
in vitro, the basement membrane of the tissue through which the matastatic cells invade. In 
this assay, the cells were induced to invade due to the stimulus provided by a chemoattractant 
(serum). The invading cells produce proteases which degrade the Matrigel coating [147]. The 
number of invaded cells was then measured with FACS. Figure 2.10 shows the principle of 
the assay. 
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Figure 2.10. Principle of the invasion assay 
Cells were transferred into the top chamber of the BioCoatTM Invasion plate containing serum free medium. The bottom 
chamber contains medium with 10% FBS, which acts as chemo-attractant. After incubating for 72 hours, the invaded cells 
were detached by trypsinization and counted on FACS. 
 
 
The assay was done in the following steps: 
 
Transfection and serum starvation 
Caki-2 cells were seeded into 6-well plates (1.2x105 cells/well) and transfected with 
siRNA the following day. After 24 hours, the medium was removed, cells washed with 1x 
PBS and medium with 1% serum was given to the wells. The cells were serum starved in 1% 
FBS medium for 24 hours.  
 
Rehydration of the Invasion plates 
The BioCoatTM Invasion plate was allowed to warm to room temperature and 500µl of 
pre-warmed PBS was added to the wells of the insert. The plate was rehydrated by incubating 
for 2 hours at 37°C and 5% CO2.  
   
Seeding of cells into invasion plates 
The serum starved cells from the 6-well plates were trypsinized, counted and 
resuspended in serum free medium. In the mean while, the PBS from the insert of the invasion 
plate was removed carefully without disturbing the Matrigel matrix, and 750µl of medium 
with 10% FBS (chemoattractant) was added to the bottom wells through the sample prots for 
Serum free medium 
Medium with 10 % FBS 
Serum free medium 
Medium with 10 % FBS 
Incubation for 72 hours 
Trypsinization 
Count cells with FACS 
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access to the bottom chamber.  1 x 105 cells, resuspended in 500µl of serum free medium, 
were seeded into each well of the top chamber and incubated for 72 hours at 37°C and 5% 
CO2 atmosphere.  
 
Harvesting the invaded cells 
During the 72 hours of incubation the invading cells degrade the gel matrix, pass 
through the porous membrane towards the chemoattractant and attach themselves to the 
bottom of the membrane. These cells were detached from the membrane by trypsinization. 
For this, the 24-well insert was placed in a 24-well plate prepared with 300µl trypsin/well and 
incubated at 37°C for 2-4 minutes. The cells were detached from the bottom of the membrane 
by tapping the insert thoroughly. The trypsinization was stopped by adding 1ml of 10% FBS 
medium/well. The cells were centrifuged at 1000 rpm for 5 minutes to remove the medium 
and then resuspended in 300µl of PBS. The number of invaded cells for each condition was 
determined by counting the cells with FACS. 
 
 
2.2.3 Protein Chemistry methods 
 
2.2.3.1 Mammalian cell lysis 
a. Extraction of Soluble and membrane proteins  
48-72 hours after transfection, the medium was either removed from the culture dishes or 
saved to collect the floating apoptotic cells. The cells were washed once with 1x PBS. The 
monolayer was then scraped with 2ml of 1x PBS into a microcentrifuge tube and centrifuged at 
4,000 rpm for 5 minutes at 4°C. After the supernatant was removed, the pellet was resuspended 
in M-Per protein extraction reagent (lysis buffer from Pierce) containing protease inhibitors, left 
at room temperature for 5 minutes and spun at 14,000 rpm for 5 minutes. The supernatant, which 
corresponds to the soluble protein fraction, was saved. The protein concentration was determined 
by the BCA assay. 
 
b. Whole cell lysate 
Whole cell lysates were prepared for applications where it was not necessary to 
determine the protein concentration. After collecting the floating cells (depending on the protein 
to be analyzed), the adherent cells were detached from the culture vessel by trypsinization and 
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were washed once with 1x PBS. The cells were resuspended in 1x SDS loading buffer (double 
the volume of the cell pellet) and boiled immediately at 95°C for 5 minutes. The cell lysate was 
either loaded directly on SDS-PAGE gel or stored at –80°C until further use. 
  
2.2.3.2 Protein quantification 
The protein extracted following the protocols described in section 2.2.3.1.a was 
quantified using the Micro BCATM protein assay reagent kit (Pierce). This method is based on the 
detection of Cu+1 ions by bicinchoninic acid (BCA) [148]. The Cu+1 ions are formed by the 
reduction of Cu+2 by the protein in an alkaline environment. The end product is a purple-colored 
water soluble complex that has an absorbancemax at 562nm.  
One volume of WR reagent (containing reagents MA:MB:MC in the ratio of 25:24:1) 
was mixed with equal volume of the diluted protein and incubated at 37°C for 2 hours. Reagent 
MA provides the alkaline environment required for the reaction, Reagents MB and MC 
contributes the bicinchoninic acid and Cu+2 ions respectively. After the purple color has 
developed, the microtitre plate was allowed to cool down to room temperature and the 
absorbance at 562nm was measured on a plate reader (SpectraMax190, Molecular Devices). The 
protein concentration of the unknown samples was determined from the standard curve plotted 
for the BSA standards.  
 
2.2.3.3 Co-Immunoprecipitation  
Co-Immunoprecipitation is the method of choice to detect Protein-protein interactions. 
This method uses an antibody to immunoprecipitate the antigen (bait protein) and co-
immunoprecipitate any interacting partners (prey proteins). The components of the protein 
complex can be analyzed by SDS-PAGE (gel electrophoresis), often followed by Western blot 
detection to verify the identity of the antigen. Co-Immunoprecipitation was performed using 
the Profound mammalian Co-Immunoprecipitation kit from Pierce Biotechnology according 
to manufacturer’s instructions. In this method, an antibody against a specific target antigen 
was covalently immobilized on amine-reactive gel. Co-IP methods that use Ptotein A or G 
result in detection of antibody along with the proteins of interest. Because the antibody heavy 
and light chains may co-migrate with one of the relevant bands, the important data may be 
masked. This problem is not encountered with this kit because the antibody is retained on the 
gel by covalent binding.   
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Antibody immobilization 
The antibody coupling gel and other reagents provided by the manufacturer was 
equilibrated to room temperature. 100µl of antibody coupling gel was transferred into a spin 
column and was washed 2 times with 0.4ml of coupling buffer (0.1%Triton X-100/PBS) by 
inverting and gently shaking the tube 4-5 times and centrifuging the tubes briefly. 200µg of 
purified antibody against the bait protein diluted in coupling buffer to a final volume of 400µl 
was then added to the coupling gel. The beads were resuspended well by inverting the column 
and shaking gently. 5µl of 5M sodium cyanborohydride was added to every 100µl of diluted 
antibody added to the gel and the tubes were inverted 4-5 times to mix well. The coupling was 
performed by incubating the columns overnight at 4°C on an end to end shaker. The tubes 
were then centrifuged to remove the antibody solution and then washed once by adding 400µl 
of coupling buffer. 400µl of quenching buffer was added to the gel followed by 4µl of 5M 
sodium cyanoborohydride. The slurry was incubated at RT for 30 min on an end to end 
shaker. The tubes were centrifuged and the flow through was discarded. The gel was then 
washed 4 times with 400µl of washing buffer and two times with 400µl of coupling buffer. 
Finally the columns were stored at 4°C with the gel resuspended in 400µl of coupling buffer.  
 
Preparation of cell lysates 
HEK293T cells were seeded in 15cm dishes (3x106 cells/dish) and incubated overnight 
at 37°C. On the following day, cells were lysed with M-Per lysis buffer (Pierce 
Biotechnology) as described in section 2.2.3.1a.  
 
Co-ImmunoPrecipitation 
4mg of total protein was diluted in the coupling buffer to a final volume of 1.4ml and 
then added to the gel with immobilized antibody. The tubes were inverted 4-5 times and 
incubated for 2hrs at RT on an end to end shaker. The tubes were centrifuged and the flow 
through was collected for further analysis and stored at –80°C. The columns were washed 3 
times with 400µl of coupling buffer by inverting the tubes 10 times followed by 
centrifugation. The wash fractions were collected and kept aside for further analysis. The 
protein complexes were eluted from the antibody coupled gel by adding 50µl of elution buffer 
and tapping the tubes gently to allow resuspension of the gel in the elution buffer. The 
columns were then centrifuged and the elution fractions were collected for further analysis. 
The Flow through, wash and elution fractions were resolved by SDS-PAGE and further 
analyzed by western blotting. 
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2.2.3.4 Protein gel electrophoresis (SDS-PAGE) 
Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is a very 
common method used to separate proteins based on their molecular weight. It is based on the 
principle that SDS, an anionic detergent, denatures the proteins by binding to their hydrophobic 
regions, thus rendering them negatively charged. The negatively charged proteins are then 
resolved on a polyacrylamide gel. This method was used in combination with Western blotting to 
detect a protein of interest, or to determine the abundance or distribution of a certain protein in 
different sub-cellular fractions. Western blotting or immuno blotting is a method to detect a 
protein of interest in a sample by using a specific antibody directed against that protein. 
In SDS-PAGE, a stacking gel is combined with a resolving gel. The stacking gel has a 
large pore size and is used to stack to proteins before they reach the resolving gel. Protein 
separation is achieved in the resolving portion. The separating gel (resolving gel) was cast by 
combining the reagents shown in table 2.3 according to the concentration of acrylamide required. 
 
Table 2.3 
 
 
 
 
 
 
 
 
 
 
 
 
The volumes shown in the above table are sufficient to make 4 mini-gels of 8 cm (W) x 
7.3 cm (H). The gel was covered with water saturated n-butanol or water to get a horizontal gel 
surface. Polymerisation was allowed for ~60 minutes or till a clear liquid-gel interface was 
visible. Then the water or butanol was removed and a 4% stacking gel was cast on top of the 
resolving gel by combining the following:  
 
 
Stock            
solutions (ml)   5%  7.5%  10%  12.5%  15% 
 
37.5:1 Acrylamide/  3.30  5.00  6.70  8.30           10.00 
bis-acrylamide 
4x Running buffer  5.00  5.00  5.00  5.00  5.00 
10% SDS   0.20  0.20  0.20  0.20  0.20 
ddH2O    11.40  9.70  8.00  6.40  4.70 
10% APS   0.10  0.10  0.10  0.10  0.10 
TEMED   0.067  0.067  0.067  0.067  0.067 
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The volumes shown above are sufficient for 4 gels. 
When the stacking gel had polymerized for ~60 minutes, the whole assembly was immersed in a 
chamber containing running buffer. Typically 20-40µg of protein was loaded and the gel was run 
at 120V until the required resolution was obtained. 
 
 
 
 
 
 
 
 
 
2.2.3.5 Western blotting  
Protein transfer 
The proteins resolved by SDS-PAGE were transferred onto a PVDF membrane by semi-
dry ectrophoretic transfer. This method uses a three buffer system consisting of Anode I, Anode 
II, and Cathode buffers. The membrane was first wet in 100% methanol for 5 seconds and then 
equilibrated in Anode buffer II. The blot was assembled on a semi-dry blotting apparatus in the 
order shown in Figure 2.11. Transfer of proteins was done for 1 hour at 40V.  
 
 
 
 
 
 
4x Stacking gel 
 
37.5:1 Acrylamide / bis-acrylamide  1.33ml 
4x Stacking gel buffer    2.50ml 
10% SDS     0.10ml 
Water       6.00ml 
10% APS     0.10ml 
TEMED.      5µl 
4x Running gel buffer 
 
Tris pH 8.8 1.5M 
4x Stacking gel buffer 
 
Tris pH 6.8 0.5M 
10x Tank buffer 
 
Tris 0.25M 
Glycine 1.92M 
Adjust pH to 8.3 
PAGE Running buffer 
 
Tank buffer 1 x 
SDS 0.1%
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Figure 2.11. Assembly order of the blot for semi-dry blotting 
From anode to cathode, the blot consists of 6 whatman papers soaked in anode buffer I, 3 in anode buffer II, PVDF membrane, 
gel and finally 9 whatman papers containing cathode buffer.  
 
 
 
 
 
 
 
Protein detection 
The membrane was first stained with Ponceau S, a reversible organic stain, to check if the 
proteins have transferred onto the membrane. The Ponceau S staining solution was washed away 
with water before the membrane was blocked in the blocking solution for 1 hour at room 
temperature. The membrane was then incubated overnight with the primary antibody in blocking 
solution. Following three 10-minute washes with 0.1% Tween 20 in 1x TBS the blot was 
incubated for 1 hour at room temperature with the HRP-conjugated secondary antibody diluted 
in blocking solution. The membrane was then washed 3x 10 minutes each with 0.1% Tween 20 / 
1x TBS. Equal volumes of the chemiluminescence reagents, detection solution 1 (oxidizing 
reagent) and detection solution 2 (enhancer reagent) from the ECL Western Blotting detection kit 
were mixed together and the membrane incubated in this solution for 2 minutes at room 
temperature. For signal detection, the blot was placed in a sheet protector, exposed to XAR film 
and developed at different time points using the film developing machine. The size of the 
proteins was determined by comparing the protein bands with that of the Rainbow protein 
molecular weight marker.  
 
 
 
Anode (+) 
Cathode (-) 
6x Whatman in Anode buffer I 
3x Whatman in Anode buffer II 
9x Whatman in Cathode buffer I
Gel
PVDF membrane 
Cathode solution 
  
6-amino-n-caproic acid  40mM 
Methanol   20% 
Anode solution I 
 
Tris 300mM 
Methanol 20% 
Anode solution II 
 
Tris 25mM 
Methanol 20% 
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Reprobing the immunoblot 
The membrane was reprobed when it was necessary to detect another protein/proteins of 
interest. This was done by first stripping the membrane of the Primary antibody and the HRP 
conjugate. For this, the membrane was incubated at 37°C in sufficient volume of the stripping 
buffer with constant shaking for 20-30 minutes.   
  
2.2.3.6 Purification of peptide antibodies  
Three different antigens (peptides) per protein were designed for the production of anti-
peptide antibodies (section 2.1.7). The PeptideselectTM tool from Invitrogen was used to select 
some regions of the full length protein which are highly antigenic, soluble and easily 
accessible. Polyclonal anti-Peptide antidodies were generated against three of these regions by 
Inno-Train Diagnostik by immunizing rabbits with synthetic peptide antigens (2 rabbits for 
each peptide). To avoid self-recognition of the antigen by the host animal, the rabbits to be 
used for immunization were selected after testing the pre-immune sera by western blotting. 
Three bleeds of antiserum was obtained from each rabbit, 1st bleed 1 week after initial 
immunization, 2nd bleed 1 month after 2nd boost, and final bleed 1 month after the 3rd boost. 
The antipeptide antibody was then immunopurified on an affinity column. The process of 
purification involves three steps: 
1. Coupling of the synthetic peptide to the beads 
2. Extraction / Purification of the antibody from the serum 
3. Testing of the purified antibody  
 
Coupling of peptide to beads 
Affinity purification of the antibody requires the immobilization or coupling of the 
antigen to a matrix or a solid support. Here, the peptide was coupled to ECH Sepharose 4B 
(Amersham Biosciences).  ECH Sepharose 4B beads are formed by covalent linkage of 6-
aminohexanoic acid to Sepharose 4B. The free carboxyl groups of ECH Sepharose 4B bind to 
10x TBS 
 
Tris base 0.2M 
NaCl  8% 
Adjust pH to 7.6 with HCl 
Blocking buffer 
 
Non-fat dry milk  5% 
Tween-20   0.1% 
TBS  1 x 
Wash buffer 
 
Tween 20 0.1% 
TBS 1 x 
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the primary amino groups of the peptide in the presence of a carbodiimide (EDC), thus 
immobilizing the peptide.   
The peptide (20mg) was dissolved in 1ml of distilled water adjusted to pH 4.5. 
Approximately 7ml of sepharose bead suspension (to get 5ml packed column of beads) was 
taken in a 15ml centrifuge tube and centrifuged at 1000 rpm for 5 minutes to remove the 20% 
ethanol in which the beads were supplied. The beads were washed with 20 column volumes of 
water of pH 4.5, and 500µl or 10mg of peptide was added to the beads. The ratio of matrix : 
ligand solution was adjusted with water (pH 4.5) to be 1:0.5 to 1:1 to produce a suspension 
that is suitable for coupling, and then 30mg or 250µl of EDC (in water of pH 4.5) was added 
to the beads. The mixture was rotated end-over-end overnight at 4°C. The pH of the mixture 
was checked after the first hour of incubation, which should be slightly below 7.0. When the 
pH had dropped down, it was adjusted by adding 0.1M sodium hydroxide. The next day, the 
column was washed atleast three times alternatively with high and low pH buffers to remove 
the excess of uncoupled peptide. The beads were washed thrice with distilled water and then 
stored in 0.02% sodium azide / PBS at 4°C until further use. 
 
 
 
 
 
 
 
 
 
Purification of antibody from the serum 
The beads (coupled with the peptide) were washed twice with 1x PBS, mixed with the 
respective serum in a 50ml tube and incubated on an end-to-end rotator overnight at 4°C. This 
leads to the binding of antibody to the peptide. The beads and the serum were poured into a 
5ml polypropylene column provided with a frit (Qiagen). The serum was allowed to flow 
through, and the beads with the peptide and the corresponding antibody were left in the 
column. The beads were washed with 10 column volumes (approximately 80-100ml) of 1x 
PBS, or until the A280 of the washed out PBS was nearly zero. The antibody was eluted with 
atleast 3-4 column volumes of elution buffer. The eluent was collected in microcentrifuge 
tubes on ice and the A280 of each fraction was measured with a spectrophotometer 
Acetate buffer (low pH buffer) or 
Elution buffer  
 
sodium acetate 0.1M 
sodium chloride 0.5M 
Adjust pH to 4.0 
Tris buffer (high pH buffer) 
 
Tris Hcl  0.1M 
sodium chloride 0.5M 
Adjust pH to 8.0 
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(SmartSpec3000, BioRad). The fractions with high OD, which corresponds to high antibody 
concentation, were saved. The beads were washed with 10 column volumes of 1x PBS and 
stored at 4°C to be used again. 
 
Testing of the purified antibody: 
The saved antibody fractions were tested by western blotting to check if the expected 
protein is being recognized. The fractions with similar affinity were pooled, aliquoted and 
stored at –80°C.  
Results 
 70
3 Results 
 
3.1 Establishment of high throughput apoptosis assay 
 The apoptotic pathways originating from different organelles converge on the 
activation of the caspase cascade. Caspase-3 is a major effector caspase that cleaves several 
important cellular substrates, and its activation is considered as the point of no return. So, 
activation of caspase-3 was chosen as the apoptosis marker for establishment of the apoptosis 
assay.  
 
Figure 3.1. Schematic representation of various steps in the establishment of high throughput apoptosis assay 
Activation of caspase-3 was selected as a marker for identification of apoptosis activators. Two assays, one FRET based plate 
reader assay and the other utilizing FACS to identify cells stained positive for active caspase-3 were tried. Establishment of 
these methods involve optimization of various biological and technical parameters, which are listed for each method.      
 
Assaying the activity of caspase-3, and identifying the physical presence of cleaved 
caspase-3 are two different approaches by which activated caspase-3 can be detected. An 
assay to detect the activity of caspase-3 as a function of Fluorescence Resonance Energy 
Transfer (FRET), and another assay to detect the presence of cleaved caspase-3 by flow 
cytometry after staining with a specific antibody were tested for their suitability for high 
High throughput apoptosis assay 
Detection of active caspase-3 or its activity 
Plate reader based assay 
(FRET) 
FACS based assay 
(Stain active caspase-3) 
Establishment of the method Establishment of the method 
Biological Technical Biological Technical 
1. Construction of FRET  
     vector 
2. Confirmation of FRET 
3. Generation of stable  
    cell line 
1. Adaption of the assay 
    to multi-well plate 
    format 
2. Measurement with  
    plate reader 
1. Cloning and testing 
    the effect of control  
    proteins    
2. Optimization of  
    staining conditions  
1. Adaption of assay to 
    multi-well plate format 
2. Automation of  
    transfection and  
    staining 
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throughput screening. A method suitable for high throughput screening should be sensitive 
enough to detect even minute changes in the parameter under question, and be amenable for 
automation. To meet these requirements, various biological and technical parameters of the 
assays need to be optimized. A schematic representation of different steps in the assay 
establishment is shown in Figure 3.1.  
 
3.1.1 Induction of apoptosis with Staurosporine 
NIH3T3, the mouse fibroblast cell line had been previously characterized in our 
department for the cell cycle regulation and activation of MAPK signalling pathway, and 
subsequently used for cell proliferation and signalling assays. Inorder to obtain 
complementary data for a set of proteins from the proliferation, MAPK and the apoptosis 
assays, the same cell line was chosen also for the establishment of the apoptosis assay. To 
determine the optimum conditions for chemically inducing apoptosis and to make sure that 
the apoptotic machinery necessary for programmed cell death is intact in the NIH3T3 cells, 
the cells were treated with staurosporine (0-3µM), and various parameters specific for 
apoptosis (DNA fragmentation, activation of caspase-3 and the development of morphological 
changes) were analyzed (Figure 3.2). Staurosporine is a broad spectrum protein kinase 
inhibitor which induces apoptosis through the mitochondrial pathway [149] via the activation 
of caspase-3 [150].  
Internucleosomal DNA fragmentation was measured using the Cell death detection 
ELISAPLUS kit (Roche) 4 hours after incubation with different concentrations of staurosporine 
(Figure 3.2.A). In this method, after discarding the DNA of necrotic cells, the low molecular 
weight DNA fragments extracted from apoptotic cells are detected using antibodies against 
DNA and histones in a colorimetric reaction. The absorbance measured at 405nm is indicative 
of DNA fragmentation (for protocol, refer section 2.2.2.7). Cells treated with 1µM 
staurosporine showed an absorbance of 2.6, which is >2 times higher than that of the cells 
treated with the vehicle alone, i.e DMSO (0µM staurosporine). However, with an increase in 
the concentration of staurosporine to 2 and 3µM, a corresponding decrease in the absorbance 
was observed. This might be due to the cytotoxic effects of higher concentration of 
staurosporine leading to an increase of necrosis and a decrease in the number of apoptotic 
cells. So, 1µM staurosporine with an incubation time of 4 hours was used for further 
experiments.  
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Figure 3.2. Induction of apoptosis in NIH3T3 cells 
(A) The cells were treated with 0-3µM Staurosporine for 4 hours and internucleosomal DNA fragmentation was detected 
using the Cell death detection ELISA kit (Roche). Absorbance measured at 405nm showed that incubation with 1µM 
staurosporine induced maximum DNA fragmentation (B) Cells were treated either with DMSO (lane 1) or 1µM 
Staurosporine (lane 2) for 4 hours and Caspase-3 from the lysates was immunoprecipitated using an antibody detecting both 
uncleaved and cleaved forms of Caspase-3. The protein was then resolved by SDS-PAGE and the caspase-3 was detected 
using the same antibody. (C) Morphology of cells treated either with DMSO or 1µM Staurosporine for 4 hours. Apoptotic 
bodies in case of Staurosporine treated cells are shown with arrows.  
 
Since activation of caspase-3 was selected as apoptosis marker for the assay, the 
cleavage of caspase-3 after treatment with staurosporine was verified by wester blotting 
(Figure 3.2.B). For this, NIH3T3 cells were either treated with DMSO alone or incubated with 
1µM Staurosporine for 4 hours, and cell lysates made from these samples were 
immunoprecipitated using a caspase-3 antibody which recognizes both cleaved and uncleaved 
forms. The proteins were then resolved by SDS-PAGE and the membrane was probed with 
the same antibody. Cells treated with DMSO alone (lane 1) showed a single band at 32kDa 
corresponding to the size of uncleaved caspase-3. However, cells treated with staurosporine 
(lane 2) showed two bands, one at 32kDa and another at 17kDa corresponding to the size of 
uncleaved and cleaved caspase-3 respectively. This shows that treatment with 1µM 
staurosporine induces cleavage of caspase-3. To check if the observed effects correlate with 
induction of morphological changes, cells treated either with DMSO or 1µM staurosporine for 
4 hours were monitored under a light microscope (Figure 3.2.C). Staurosporine induced 
morphological changes characteristic of apoptosis i.e. rounding off of the cells, membrane 
blebbing, and detachment from the surface while cells treated with DMSO alone did not show 
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any changes in morphology. This shows that treatment with 1µM staurosporine induces 
features characteristic of apoptosis, and that the components necessary for undergoing 
apoptosis are intact in NIH3T3 cells.  
 
3.1.2 Establishment of FRET based assay 
FRET is the radiationless transmission of energy from an excited fluorophore (donor) 
to another fluorophore (acceptor) when both are located within close proximity (1-10nm). 
Based on this principle, an assay was designed which would allow the screening for apoptosis 
activators in a 96-well format using a fluorescence plate reader.  
 
 
 
Figure 3.3. Principle of the FRET based assay 
(A) Fluorescence spectra of CFP and YFP. The shaded area represents the spectral overlap between CFP and YFP which 
makes them an ideal FRET pair.  (B) The top panels show the excitation and emission wavelengths of CFP and YFP. Bottom 
panel shows principle of FRET.  In non apoptotic cells, upon excitation of the donor fluorophore (CFP) at 433nm, the emitted 
energy (475nm) is transferred to the acceptor (YFP) and is re-emitted at 530nm. In apoptotic cells, the linker region is 
cleaved by caspase-3 resulting in the elimination of FRET. 
 
In this assay, a construct encoding CFP (donor) and YFP (acceptor) linked together 
with the substrate for caspase-3 (DEVD) acts as the FRET probe (Figure 3.3). CFP and YFP 
were chosen as the FRET pair because of overlap of the emission spectrum of CFP with the 
absorption spectrum of YFP which results in an efficient transfer of energy from CFP to YFP 
(Figure 3.3.A). In non apoptotic cells, when CFP is excited by light at 433nm, the emitted 
light is taken up by YFP which it in turn emits light at 530nm due to FRET (Figure 3.3.B). In 
apoptotic cells the linker region is cleaved by activated caspase-3, and the FRET is 
eliminated. So, when CFP is excited at 433nm, the detected emission would be at 475nm, and 
 475 nm 
CFP 
433 nm 510 nm 530 nm 
YFP 
FRET
CFP YFP 
530 nm 
SGLRSGGDEVDGGSN
433 nm 
YFP GGSNCFP SGLRSGGDEVD 
433 nm 
475 nm 
Non apoptotic cell 
Apoptotic cell 
A B
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not at 530nm. When a stable cell line constitutively expressing this FRET probe is transiently 
transfected with apoptosis inducers, cleavage of DEVD by activated caspase-3 would cause a 
decrease in FRET between CFP and YFP, which can be measured by a fluorescence plate 
reader. However, this method does not allow the discrimination between transfected and the 
untransfected cells. Therefore, cells would be transfected with ORFs tagged with 6x His, and 
after measuring the FRET, the same wells would be stained with anti-His antibody to 
determine the transfection efficiency in a colourimetric reaction.  
 
3.1.2.1 Generation of FRET constructs 
 A FRET probe (designated as CFP-DEVD-YFP) was constructed with CFP and YFP 
fused together by a special linker containing a caspase-3 cleavage sequence (DEVD).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Generation of FRET vector 
(A) YFP was amplified and cloned at the C-terminus of CFP in pECFP-C1 vector generating the construct CFP-YFP. 
Synthetic oligonucleotides encoding DEVD were inserted between CFP and YFP to generate the FRET construct CFP-
DEVD-YFP. (B) Cells expressing CFP-YFP (lanes 1 and 3) or CFP-DEVD-YFP (lanes 2, 4 and 5) were either left untreated 
(lanes 1 and 2) or treated with 1µM staurosporine for 2 hours (lane 4) or 4 hours (lanes 3 and 5). Treatment with 1µM 
staurosporine resulted in cleavage of the linker region in CFP-DEVD-YFP, but not in CFP-YFP. 
 
To construct the probe, YFP was amplified from pCaspase-3 sensor vector (using the 
primers mbYFPE1B1_fw and mbYFPE1B1_rv), and cloned at the C-terminus of CFP in the 
vector pECFP-C1 (Figure 3.4.A). This construct was termed as CFP-YFP, and was used as a 
pECFP-C1
SGLRSRAQASNS
SGLRSGGDEVDGGSNS
CFP
YFP
PCR amplification of YFP 
Insert YFP into pECFP-C1
Insert synthetic oligonucleotide 
containing DEVD
CFP
CFP
YFP
YFP
CFP-YFP
CFP-DEVD-YFP
1 2 3 4 5
26.5 kDa
55 kDa
A B
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control probe. Two synthetic oligonucleotides (mbFRETspacer_up and 
mbFRETspacer_down) encoding DEVD were then inserted between the CFP and YFP to 
form the linker (for protocol refer to section 2.2.1.3b). This construct was called CFP-DEVD-
YFP and serves as the FRET probe. The 16 amino acid linker used here was shown previously 
by Luo KQ et al., to produce a strong FRET effect, and also to be efficiently cleaved by 
caspase-3 because of the special design of the sequence flanking the DEVD substrate site 
[151].  
To check if the DEVD substrate site present in the linker is accessible for cleavage by 
caspase-3, NIH3T3 cells transiently transfected with CFP-YFP or CFP-DEVD-YFP were 
either treated with 1µM staurosporine for 2 and 4 hours or left untreated. The cell lysates were 
resolved by 12% SDS-PAGE and the membrane was probed with anti-GFP antibody (Figure 
3.4.B). In untreated cell lysates, both CFP-YFP (lane 1) and CFP-DEVD-YFP (lane 2) 
showed a single band near 55kDa which is the expected molecular weight of the FRET probe. 
Treatment with 1µM staurosporine for 2 hours did not yield significant amount of cleavage 
product (lane 4). However, in samples treated with 1µM staurosporine for 4 hours, the control 
probe remained unaffected (lane 3), while the FRET probe showed a second band near 27kDa 
(lane 5) which corresponds to the molecular weight of separated CFP and YFP due to 
cleavage of the linker by caspase-3. This showed that the DEVD substrate site was accessible 
to caspase-3. 
 
3.1.2.2 Determination of FRET 
The occurrence of FRET between CFP and YFP in the FRET probe was then 
determined by confocal microscopy using a technique called acceptor photobleaching [152]. 
When FRET occurs, there is quenching of the donor fluorescence signal since some of the 
donor excitation energy is transferred to the acceptor. Selective photobleaching of the 
acceptor abolishes FRET, and in regions where FRET occurred there will be an increase in 
donor emission because of dequenching.  
To check if there is an energy transfer between CFP and YFP, defined areas on cells 
expressing CFP-DEVD-YFP were subjected to acceptor photo-bleaching. A series of time 
lapse images were made during the process of bleaching the acceptor (YFP). Figure 3.5.A 
shows the pre- bleach (a-c) and post bleach (d-f) images of a cell taken at 0 and 16 seconds 
respectively. The bleached region of the cell is shown with an arrow (Figure 3.5.Ae). For 
analysis, two regions of interest (ROI) were defined on the cell, ROI 1 being the bleached 
region and ROI 2 the unbleached region (Figure 3.5.Af). The fluorescence intensities of CFP 
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and YFP in these ROI were plotted against the time of bleaching (Figure 3.5.B). In ROI 1, 
loss of fluorescence intensity of YFP was observed from 5 seconds after the start of the 
bleaching cycle reaching a maximum at 16 seconds, after which the intensity remained 
constant. The decrease in the intensity of YFP was accompanied by a corresponding increase 
in the fluorescence of CFP, which also remained constant after 16 seconds. However, no 
significant differences in the spectra were noticed in case of ROI 2. These results indicate the 
occurrence of FRET between CFP and YFP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Determination of FRET by acceptor photo-bleaching 
(A) NIH3T3 cells were transfected with CFP-DEVD-YFP and fixed 24 hours later. Images of the donor and the acceptor 
were obtained before (a-c) and after (d-e) photo-bleaching of the acceptor in the center of the cell (indicated with an arrow in 
e). Two Regions of Interest (ROI) were selected (indicated by 1 and 2 in f) to determine the FRET efficiency. (B) Inside the 
bleached region (ROI 1), the donor is unquenched resulting in an increase in intensity indicative of FRET, while in ROI 2 no 
increase in the intensity of donor was detected.  
 
3.1.2.3 Adaption of the assay to 96-well format 
 Since the requirements of a FRET probe i.e., the accessibility of the cleavage site, and 
occurrence of FRET have been fulfilled, the next step was to adapt the assay to 96-well 
fluorescence plate reader. To achieve a uniform fluorescence read out from all the wells, it 
was necessary to generate a stable cell line expressing the control and the FRET probes. 
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a. Generation of stable cell line 
Stable cell lines of NIH3T3 cells constitutively expressing CFP-DEVD-YFP and CFP-
YFP were generated. The protein expression level of the positive clones was tested by 
immunoblotting using anti-GFP antibody (Figure 3.6.A). Two clones from CFP-YFP (lanes 2 
and 3) and seven clones from CFP-DEVD-YFP (lanes 1,4,5,8,9,10 and 14) were found to 
contain the correct insert. Clone 2 from CFP-YFP and clone 4 from CFP-DEVD-YFP (due to 
high expression level) were selected for further experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Generation of stable cell line and measurement with fluorescence plate reader 
(A) Cell lysates of clones stably expressing CFP-YFP and CFP-DEVD-YFP were resolved by SDS-PAGE and the protein 
was detected with anti-GFP antibody. (B) Different cell numbers of clone 4 from CFP-DEVD-YFP were seeded in 96-well 
plate and the fluorescence intensities of CFP and YFP were measured with a fluorescence plate reader. Fluorescence intensity 
more than the back ground signal (empty wells) was observed only in wells with more than 18,000 cells/well. 
 
b. Measurement of fluorescence intensity on a plate reader 
Cells stably expressing the FRET probe (clone 4) were seeded into 96-well black 
culture plates (8,000 cells/well), and the fluorescence of YFP (filters: excitation 510/10nm; 
emission 535/10) and CFP (filters: excitation 440/35; emission 485/20) was measured on a 
fluorescence plate reader FusionTMα. But the signal detected in the wells with cells was equal 
to that of the background signal i.e. wells with out any cells. To check if the signal intensity 
increases with an increase in cell number, the measurement was repeated with different cell 
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numbers ranging from 8,000 to 20,000 cells/well (Figure 3.6.B). The fluorescence intensity 
remained equal to that of the back ground signal till a cell number of 14,000 cells/well. The 
intensity gradually increased with increase in cell number from 16,000 to 20,000 cells/well. 
However, cell numbers of more than 14,000 cells/well in a 96-well plate resulted in a very 
confluent monolayer which is not suitable for transfection. Too many cells result in contact 
inhibition, making cells resistant to uptake of foreign DNA. Moreover, minute changes in the 
signal caused by cleavage of the FRET probe in apoptotic cells might not be detected at all 
when the instrument is not sensitive enough. A more sensitive way to detect changes in FRET 
signal would be by microscopy. But microscopy is not an ideal method for a high throughput 
FRET based assay because photo-bleaching of individual cells in a 96-well plate to analyze 
FRET is a very cumbersome and time consuming process, and difficult to automate.  
So, another assay for the detection of activation of caspase-3 in apoptotic cells was 
developed using Fluorescence activated cell sorter (FACS).  
 
3.1.3 Establishment of flow cytometry based assay to detect active caspase-3 
 Cytometry is a very sensitive method and allows rapid and accurate analysis of large 
populations of individual cells. Moreover, this method offers the advantage that several 
parameters of the same population can be measured simultaneously, and the observed effects 
can be correlated on a cell by cell basis. Due to these advantages, a FACS based apoptosis 
assay was designed to detect the presence of cleaved caspase-3 by staining cells with an active 
caspase-3 specific antibody. The cells would be transfected with YFP tagged ORFs so that it 
is possible to differentiate the transfected from untransfected cells.To speed up the process of 
data acquisition, the stained cells would be measured on a FACSCalibur equipped with a 96-
well plate reader. When transfected cells show a higher amount of active caspase-3 compared 
to the untransfected cells of the same well, the protein is considered as an apoptosis inducer.  
 
3.1.3.1 FACS measurement of active caspase-3 in staurosporine treated cells 
Activation of caspase-3 requires proteolytic processing of its inactive zymogen into 
activated p17 and p12 fragments due to cleavage adjacent to Asp175. A rabbit polyclonal 
antibody (Cell signalling technology) detecting the endogenous levels of the large fragment 
(17kDa) of activated caspase-3 was used for establishment of the assay.  
The functionality of the antibody was tested in NIH3T3 cells which were induced to 
undergo apoptosis by treating with 1µM staurosporine for 4 hours. Cells without any 
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treatment were used as control. The cells were trypsinized and stained in suspension with 
active caspase-3 antibody, followed by a secondary antibody labelled with allophycocyanin 
(APC). Data from at least 10,000 cells was acquired using FACSCalibur, and the data analysis 
was done with CellquestTM Pro software (Figure 3.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Detection of Staurosporine induced apoptosis with active Caspase-3 antibody 
Cells were treated with 1µM Staurosporine for 4 hours or left untreated, stained with cleaved Caspase-3 antibody followed by 
allophycocyanin (APC) coupled secondary antibody and measured with FACS. (A) Scatter plots of untreated cells show that 
0.1% of the cells are apoptotic. (B) Treatment with Staurosporine induced apoptosis in 17.3% of cells (indicated with red 
colour). These cells also displayed a reduction in size as indicated by a reduction in forward scatter (the center of each 
population is marked). Gates R1, R2 and R3 represent the intact, non-apoptotic and apoptotic populations respectively.  
 
The scatter plots with forward scatter vs. side scatter show the morphology of the 
cells, with forward scatter representing the size, and side scatter the granularity of cells 
(Figure.3.7.Aa and Ba). To eliminate the interference of contaminants like cell clumps and 
debris in data processing, the main population of cells from the untreated sample (seen as a 
dense cloud in the centre of the plot) were gated as R1 (Figure.3.7.Aa). Only the cells in gate 
R1 were used for further analysis. The activation of caspase-3 was then analyzed from the 
scatter plot drawn with fluorescence intensity of YFP against APC signal which represents the 
activation of caspase-3 (Figure.3.7.Ab). The cells in this scatter plot are the untreated cells 
which are negative for activated caspase-3, and were gated as R2. Cells that show more APC 
signal than the cells in gate R2 were considered positive for activated caspase-3, and were 
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gated as R3. Therefore, gates R2 and R3 represent non apoptotic and apoptotic populations, 
respectively. To analyze the morphology of cells, another scatter plot was drawn with forward 
scatter plotted against APC signal of activated caspase-3 (Figure 3.7.Ac). The non apoptotic 
cells from gate R2 are shown in green and apoptotic cells from gate R3 are shown in red 
colour. The cells treated with staurosporine were analyzed in the same way using the same 
gates as that of the untreated cells (Figure 3.7.B). 
As is evident from the scatter plots with forward vs. side scatter, cells treated with 
staurosporine showed an elongated distribution pattern compared to the normal cells (Figure 
3.7.Aa and Ba). This indicates a change in the light scatter property of cells due to induction 
of morphological features of apoptosis. Scatter plots with intensity of YFP plotted against 
APC signal (activation of caspase-3) showed that 17.3% of cells from gate R1 in 
staurosporine treated sample were positive for activated caspase-3 compared to 0.1% in the 
untreated sample (Figure 3.7.Ab and Bb).  
It is described that cells undergoing apoptosis show a reduction in size [130]. Since 
forward scatter represents the size of a cell, the reduction in size should result in a reduction 
in the forward scatter. So this parameter was used to verify if the cells recognized by the 
antibody are apoptotic. For this, scatter plots are drawn with fluorescence intensity in the APC 
channel plotted against forward scatter, and shift in the distribution of active caspase-3 
positive cells is indicated by a line connecting the centers of both the populations (Figure 
3.7.Bc). This scatter plot shows that the cells positive for active caspase-3 (shown in red) 
indeed show a reduction in size compared to active caspase-3 negative cells (shown in green). 
This indicates that the antibody can be used for flow cytometric applications and that it 
specifically recognizes apoptotic cells. Since the assay is based on overexpression of proteins, 
it was necessary to check the functionality of the assay by overexpressing some proteins 
which are known inducers of apoptosis. 
 
3.1.3.2 Generation of positive controls for the assay 
In order to examine the effect of protein overexpression on apoptosis, control proteins 
whose function is already known, were selected (table 3.1). The cDNAs were amplified and 
cloned into the GatewayTM destination vectors, resulting in the generation of ORFs tagged C- 
or N-terminally with YFP. Although it is not described for some of these proteins if 
overexpression induces apoptosis or not, they were shown to either directly or indirectly 
activate apoptosis. Along with the positive controls, proteins without any known effect on 
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apoptosis (neutral controls) were also selected. The list of the control proteins along with the 
cell line in which we overexpressed them is shown in table 3.1. 
 
Table 3.1. Control proteins tested in the assay  
Protein Role in 
assay 
Function Cell line  
Cathepsin B Activator Cysteine protease, degrades intra- and extra cellular proteins, can activate 
BID and caspases [97]. 
NIH3T3 
Cathepsin D Activator Aspartic protease, protein degradation, involved in oxidative stress related 
apoptosis pathway, activates Bax by proteolytic cleavage [153]. 
NIH3T3 
Fas receptor Activator Cell surface receptor of the TNFR super family, starts the death receptor 
pathway of apoptosis upon ligation with Fas ligand [18]. 
NIH3T3 and 
HEK293T 
Death 
associated 
protein (DAP3) 
Activator It is a mitochondrial protein and acts down stream of several apoptotic 
stimuli like TNFα, IFNγ and Fas ligand [154]. 
NIH3T3 
Cell death 
inducing DFF-A 
like effector 
(CIDE-C)  
Activator Over expression of CIDE proteins induce DNA fragmentation and 
apoptosis, which can be inhibited by DFF. The C-terminal domain of these 
proteins (CIDE-C) is sufficient for inducing apoptosis, while N-terminal 
(CIDE-N) is required for DFF45 to inhibit CIDE induced apoptosis [155].  
NIH3T3 and 
HEK293T 
 
Cytochrome-c Activator Following apoptotic stimulus, cytochrome c releases from the mitochondria 
and induces the formation of apoptosome [43].  
HEK293T 
 
Apoptosis 
inducing factor 
(AIF) 
Activator It is a mitochondrial protein, which upon receiving the apoptosis stimulus 
translocates to the nucleus and induces chromatin condensation and 
fragmentation of DNA [156]. 
HEK293T 
 
Cyclin 
dependent 
kinase 2 
(CDK2) 
Neutral It is a member of the protein kinase family that in association with cyclins 
initiates the transition of G1 to S- phase of the cell cycle and progression 
through the S-phase [157].   
HEK293T 
 
Yellow 
Fluorescent 
Protein (YFP) 
Neutral Spectral variant of Green fluorescent protein (GFP) [158].  NIH3T3 and 
HEK293T 
 
 
3.1.3.3 Effect of control proteins on induction of apoptosis in NIH3T3 cells 
To check if overexpression of the control proteins induces apoptosis, NIH3T3 cells 
were transfected with plasmid DNA maxi preparations of a subset of clones from table 3.1, 
stained 72 hours later with the active caspase-3 antibody and measured with FACS. The 
scatter plots obtained from N-terminally tagged proteins are shown in Figure 3.8. Based on 
the distribution of cells from mock transfected sample, quadrants were drawn on the scatter 
plot separating the 4 different populations (Figure 3.8a). Untransfected, non apoptotic cells 
are in the lower left quadrant; untransfected, apoptotic in upper left; transfected, non apoptotic 
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in lower right; and transfected, apoptotic cells in the upper right quadrant. The other proteins 
were analyzed using the same quadrants as those of the mock transfected sample. A protein 
was considered as an activator when the percentage of transfected apoptotic cells was 
significantly higher than that of the percentage of untransfected apoptotic cells. The value 
obtained for the neutral control (YFP) was taken as the threshold for deciding if the protein is 
an apoptosis activator. A summary of the effects due to overexpression of the control proteins 
is shown in table 3.2. The Fas protein was identified as a strong inducer of apoptosis 
(highlighted in table 3.2). 
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Figure 3.8. Selection of positive controls for the assay 
NIH3T3 cells transfected with N-terminally tagged control proteins were stained after 72 hours with the active Caspase-3 
antibody and measured with FACS. Shown are the plots with expression level of the protein plotted against the signal 
intensity of activated caspase-3. Quadrants are drawn to separate different populations of cells resulting from expression of 
the protein. 
 
Table 3.2. 
Protein % Transfection % Untransfected 
apoptotic cells 
(A) 
% Transfected 
apoptotic cells 
(B) 
Difference 
(B-A) 
YFP 56.75 1.62 5.31 3.69 
Cathepsin B 64.53 2.49 6.00 3.51 
Cathepsin D 46.31 1.38 7.00 5.62 
DAP 3 35.19 0.93 4.55 3.62 
Fas 16.49 0.98 14.00 13.02 
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 The transfection efficiency of different proteins ranged from 16.49 to 64.53%, with 
Fas receptor showing the least transfection as well as protein expression level (Figure 3.8f). 
The percentage of untransfected apoptotic cells did not vary much between different proteins 
(0.93 to 2.49%) indicating that the transfection procedure itself did not induce significant 
cytotoxicity. However, overexpression of YFP resulted in a slight increase in the apoptotic 
cells compared to the untransfected cells of the same well. The percent of apoptotic cells in 
Cathepsin B and DAP3 transfected wells did not differ significantly from that of YFP 
transfected samples. However, Cathepsin D showed a slight activating effect, with cells 
expressing high amount of protein undergoing apoptosis, but the total effect is not clear. Even 
though the transfection efficiency and protein expression level of Fas is much lower than the 
other proteins, overexpression of Fas induced apoptosis in 14% of the transfected cells, while 
only 0.98% of the untransfected cells were positive for cleaved caspase-3. These results 
suggest that this assay is capable of identifying proteins whose overexpression induce 
apoptosis.  Fas would be used as a positive control and YFP as neutral control for the assay. 
 
3.1.3.4 Automation of the assay 
As the assay was ultimately intended for high throughput screening, it was necessary 
to minimize the number of steps which require manual intervention. So the next step in the 
establishment of the assay was to automate all the liquid handling steps for the process of 
transfection and staining (done in collaboration with Christian Schmidt). For this purpose, a 
pipetting robot (MultiProbe IIEX, Perkin Elmer) was used. 
The process of transfection involves removal of medium from the cells, preparation of 
DNA complexes in 96-well plates and pipetting the complexes into the appropriate wells. 
Since NIH3T3 cells adhere well to the culture plates, the process of aspirating the medium 
from the wells and the washing steps done by the robot during transfection did not result in 
significant cell loss.  
However, staining of the cells by the robot required some optimization steps to 
minimize loss of cells. The cells were stained in suspension in 96-well plates and the process 
of staining involved several washing and centrifugation steps (refer to section 2.2.2.8 for 
protocol). The robot removes buffers from the wells by aspiration which resulted in loss of 
cells in every step. To obtain sufficient cell numbers for statistical analysis, a series of test 
runs were performed on the robot with different conditions (as shown in table 3.3). For this, 
9,000 cells/well were seeded in 96-well plates, allowed to grow overnight and the whole 
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staining protocol was followed (without using antibodies). The cell numbers obtained with 
various conditions is shown in table 3.3. Condition that gave the best result is highlighted.  
 
Table. 3.3. 
Kind of 96-well 
Plate 
Material of plate Method of removing 
buffer 
Centrifugation 
speed (rpm) 
Cell number 
after staining/ 
well 
Flat bottom Polystyrol Aspiration at 70 µl/sec 1200 62 
Flat bottom Polystyrol Tipping the plate 1200 90 
U-bottom Polystyrol Aspiration at 70 µl/sec 1000 495 
U-bottom Polystyrol Aspiration at 30 µl/sec 1200 510 
U-bottom Polypropylene Aspiration at 30 µl/sec 1350 1,270 
 
 
Lowest cell number was obtained with flat bottom plates (< 100 cells/well) and the 
cell number increased to 1,270 cells/well when U-bottom plates were used. Though reduction 
in the speed of aspiration from 70µl/second to 30µl/second and an increase in the 
centrifugation speed from 1,000 to 1,350 rpm had some positive effect, change in the material 
of the plate from polystyrol to polypropylene significantly increased the cell number. Based 
on these experiments, polypropylene U-bottom plates in combination with aspiration speed of 
30µl/second and centrifugation at 1,350 rpm were taken as the optimum conditions for 
staining on the robot. Since cells cultured in polypropylene U-bottom plates can not be easily 
observed under a microscope (due to the material and thickness of the plate), the cells would 
be cultured and transfected in polystyrol flat bottom plates and transferred into a U-bottom 
polypropylene plate for staining on the robot. 
 
3.1.3.5 Effect of mini-prep DNA on the assay result   
Having optimized the transfection and staining on the robot, the next step was to run a 
test screen to verify if the automated transfection and staining conditions on the robot were 
optimal for identifying apoptosis activators. Since mini preparations of DNA would be used 
for the screening, miniprep DNA of 96 different ORFs were distributed in a 96-well plate, and 
the transfection of the cells with this DNA (100 ng/well) as well as the staining were done on 
the robot. The cells were then measured with FACS equipped with an integrated 96-well plate 
reader. An overview of the total cell number/well and the transfection efficiency obtained 
over the whole plate is shown in Figure 3.9.A. 
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Figure 3.9. Assay effects with NIH3T3 cells in a 96-well format 
NIH3T3 cells transfected in 96-well plate with miniprep DNA were stained after 72 hours with active Caspase-3 antibody 
and measured with FACS. Transfection and staining were done on the robot and the data was acquired using the multiwell 
plate reader of FACS. (A) Graphical overview of the cell number/well and the transfection efficiency of the 96 clones (B) 
Scatter plots of controls and 3 randomly selected proteins. 
 
Table.3.4. 
Protein Total 
number 
of cells 
Transfection 
(%) 
Untransfected 
apoptotic cells (%) 
(A) 
Transfected 
apoptotic cells (%) 
(B) 
Difference 
(%) 
(B – A) 
p-value 
of Fisher 
test 
Mock transfected 2,849 0.00 1.82 -- - 1.82 0.672 
YFP 2,479 27.6 1.67 4.08 2.41 5.07 
YFP-Fas 2,296 6.88 1.77 7.59 5.82 3.24 
YFP-htes3_8j21 2,056 8.85 4.59 13.7 9.11 5.34 
YFP-hamy2_24k15 2,491 5.78 1.95 8.33 6.38 6.32 
YFP-hfkd2_46j20 1,947 5.34 1.84 5.76 3.92 2.83 
 
The cell number over the whole plate (after excluding the cell clumps and debris) 
ranged from 500 to 3,000 cells/well, with majority of the wells (92 wells) having cells 
A 
B 
a b 
Results 
 86
between 1,500 and 3,000 (Figure 3.9.Aa). This cell number is enough for analysis provided 
the transfection efficiency is more than 50%. However, the transfection efficiency of most of 
the wells (91 wells) ranged only between 0-20%, with majority of the wells (65 wells) lying 
between 0 and 10% (Figure 3.9.Ab). The maximum transfection efficiency obtained was 40-
45% with only 1 well showing this.  
All the wells in the plate were analyzed to verify the effect of the overexpressed 
proteins on the induction of apoptosis. The scatter plots obtained for wells which are either 
mock transfected or transfected with YFP, Fas receptor and three randomly selected ORFs are 
shown in Figure 3.9.B and the effects are summarized in table 3.4. Though an average cell 
number of more than 2,000 cells/well was obtained, the transfection efficiency of the proteins 
other than YFP was below 10% (Table 3.4). Since transfection with Fas and the other three 
unknown proteins resulted in more percentage of transfected apoptotic cells (5.76 to 13.7%) 
when compared to YFP (4.08%), they could be considered as activators of apoptosis. 
However, the transfection efficiency of these proteins is between 5.34 to 8.85%, and the effect 
is calculated based on only a few cells (6 to 28 cells) which are positive for activated caspase-
3 (cell number shown in the upper right corner of the scatter plots in Figure 3.9.B). This is 
reflected by high p-values (>1) which indicates that the observed effects are statistically 
insignificant (table 3.4). These statistically insignificant effects are because of very low 
number of active caspase-3 positive cells in conjunction with very low transfection efficiency. 
I tried to further optimize the transfection efficiency by increasing the amount of DNA and 
the transfection reagent, but could not succeed in improving it to an extent that the effects in 
the assay were clear. So, HEK293T, a human embryonic kidney cell line that is known to 
have good transfection efficiency, was tested for its suitability in the assay.   
 
3.1.3.6 Effect of control proteins in HEK293T cells 
 HEK293T cells were seeded in 96-well plate (15,000 cells/well, resulting in a 
confluency of 50-60%), transfected with maxi prep DNA of some of the control proteins 
shown in table 3.1, and stained manually with the active caspase-3 antibody after 72 hours. 
The scatter plots obtained for N- and C-terminally tagged proteins are shown in Figure 3.10, 
and the effects are summarized in table 3.5. Proteins which produced significant effects are 
highlighted. 
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Figure 3.10. Effect of control  proteins in HEK293T cells 
HEK293T cells were transfected in 96-well plate with control proteins tagged C- and N-terminally with YFP and stained with 
active caspase-3 antibody after 72 hours. Both the tag orientations of CIDE-C and Fas showed a clear apoptosis activating 
effect, while the other proteins did not induce apoptosis.  
 
Table 3.5. 
Protein Total number of 
cells 
Transfection 
(%) 
Transfected 
apoptotic cells (%) 
p-value 
of Fisher 
test 
YFP 1,676 99.1 1.5 0.02 
CDK2-YFP 2,725 94.2 2.9 0.34 
YFP-CDK2 1,334 99.3 2.3 0.19 
AIF-YFP 1,605 85.7 6.2 0.88 
YFP-AIF 1,080 81.7 7.9 0.47 
CIDE-C-YFP 1,827 86.3 47.3 2.40e-45 
YFP-CIDE-C 1,529 80.0 39.3 9.12e-53 
Cytochrome C-YFP 1,296 94.7 3.9 0.0006 
YFP-Cytochrome C 1,485 94.6 3.5 1.0 
Fas-YFP 2,047 98.7 36.5 0.001 
YFP-Fas 2,439 83.1 40.1 2.59e-72 
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 Transfection efficiency of more than 80% was obtained for all the clones, with some 
clones like YFP, YFP-CDK2 and Fas-YFP showing a transfection efficiency of almost 100% 
(table 3.5). Though the total cell number/well ranged only between 1,080 and 2,725, the final 
effect of the proteins on apoptosis was very clear because of the high transfection efficiency 
(Figure 3.10). Over expression of the neutral controls (YFP and CDK2) induced apoptosis in 
less than 3% of the transfected cells, while AIF and Cytochrome C induced apoptosis in 7 and 
3.7% (average effects of both tag orientations) of transfected cells respectively. However, the 
effect of AIF and Cytochrome C is negligible when compared to that of Fas and CIDE-C 
(Figure 3.10g, h, k and l). Irrespective of the tag orientation, overexpression of Fas and CIDE-
C led to a strong apoptosis induction in 38.3 to 43.3% (average effects of both tag 
orientations) of transfected cells respectively (values high lighted in table 3.5). Moreover, the 
statistical significance of these effects is strengthened by p-values of less than or equal to 
0.001. Based on these data, Fas and CIDE-C were selected as positive controls, while YFP 
and CDK2 would be used as neutral controls for the assay. The HEK293T cell system was 
thus validated to be suitable for a systematic screen and this cell line was determined superior 
to NIH3T3. 
 
3.1.3.7 Transfection of HEK293T cells with mini prep DNA 
In order to test the effect of mini prep DNA on the assay outcome, HEK293T cells 
were transfected with miniprep DNA of 96 clones and stained with active caspase-3 antibody 
after 72 hours. However, since the average cell number obtained from a 96-well plate was 
only 1,500 cells/well (as seen in section 3.1.3.6), to obtain higher cell numbers the 
transfections were done in four 24-well plates (4x24=96 wells) with 200ng DNA/well. After 
72 hours the cells were transferred into a 96 well plate for staining on the robot as well as data 
acquisition with the FACS.  
An overview of the total cell number/well and the transfection efficiency obtained 
over the whole plate is shown in Figure 3.11.A. Cell number ranging from 2,000 to16,000 
cells/well was obtained over the whole plate, with 64 wells having cells between 6,000 and 
12,000 (Figure 3.11.Aa). Moreover, the transfection efficiency of most of the wells (71 wells) 
is above 70%, out of which 37 wells showed transfection in 90-100% of cells (Figure 
3.11.Ab). Scatter plots of the controls and 3 randomly selected proteins are shown in Figure 
3.11.B and the effects are summarized in table 3.6. Proteins which showed a clear activating 
effect are highlighted.  
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Figure 3.11. Assay effects with HEK 293T cells with mini-prep DNA 
HEK 293T cells transfected in four 24 well plates (= 96-wells) with miniprep DNA were stained after 72 hours with active 
Caspase-3 antibody and measured with FACS. Transfection and staining were done on the robot and the data was acquired 
using the multiwell plate reader of FACS. (A) The cell number/well and the transfection efficiency of the 96 clones and (B) 
the scatter plots of controls and 3 randomly selected proteins are shown. 
 
Table.3.6. 
Protein Total 
number of 
cells 
Transfection 
(%) 
Untransfected 
apoptotic cells (%) 
(A) 
Transfected 
apoptotic cells (%) 
(B) 
Difference 
(%) 
(B – A) 
p-value 
of Fisher 
test 
Mock transfected 13,725 0.00 0.37 -- - 0.37 0.5 
YFP 15,160 9.35 0.06 0.00 -0.06 0.6 
YFP-Fas 15,949 10.6 0.19 26.3 26.11 0.00 
YFP-CIDE-C 13,622 34.2 0.23 4.75 4.52 4.22e-50 
YFP-htes3_13c10 14,464 93.4 0.71 0.58 -0.13 2.92e-07 
YFP-hute1_19h9 15,798 61.6 0.04 1.85 1.81 2.96e-259 
YFP-hamy2_2h17 11,706 85.2 1.01 0.82 -0.19 3.39e-14 
 
The percentage of untransfected apoptotic cells is very low (0.06 to 1%) which shows 
that this cell line is not too sensitive to stress conditions like transfection. Transfection with 
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Fas receptor induced apoptosis in 26.3% of transfected cells, while transfection with CIDE-C 
resulted in only 4.75% apoptotic cells. The effects are also visually clear from the scatter plots 
(Figure 3.11.Bc,d). Cells expressing YFP, htes3_13c10 and hamy2_2h17 did not undergo 
apoptosis, but cells expressing high levels of hute1_19h9 showed activation of caspase-3 
resulting in 1.85% of apoptotic cells. The high cell number combined with good transfection 
efficiency resulted in p-values of <0.5 suggesting that the effects observed in the assay are 
statistically significant.  
Compared to NIH3T3 cells, HEK293T cells showed higher transfection efficiency, 
lower percentage of untransfected apoptotic cells, as well as clear and statistically significant 
effects in the assay. Low transfection efficiency of 3T3 cells in conjunction with high amount 
of spontaneous cell death (as indicated by the number of untransfected apoptotic cells) would 
mask the specific signal generated by the overexpressed protein, leading to misinterpretation 
of the final effect. Based on these results, HEK293T cells were chosen for the assay instead of 
NIH3T3 cells.  
  
Taken together, the conditions that were optimized for the screening are as follows:  
• Method: A flow cytometry based assay would be used, in which apoptosis inducers 
can be detected by staining the cells with an antibody recognizing the cleaved form of 
caspase-3. This method offers the advantage that the transfected cells can be 
distinguished from untransfected cells making it possible to detect changes of 
activated caspase-3 levels in individual cells.  
• Cell line: HEK293T cells would be used for the assay because of the high transfection 
efficiency that could be achieved with this cell line. Transfection efficiency of the cell 
line was found to be very important for obtaining statistically significant effects. 
• Controls for the assay: N- and C-terminally tagged Fas receptor and CIDE-C would be 
used as positive controls, while YFP and CDK2 would be used as neutral controls for 
the assay.  
• Automation: Both transfection and staining of the cells with the antibody were 
automated. The automation was aimed at minimizing cell loss during the process of 
staining and to increase the throughput of the screen. Aspiration speed of 30 µl/second 
and centrifugation at 1350 rpm were taken as the optimum conditions for staining on 
the robot.  
• Plate format for screening: In order to obtain more cells for statistical analysis, the 
cells would be seeded and transfected in 24-well plates (32,000 cells/well). After 72 
Results 
 91
hours, both floating and adherent cells from four 24-well plates would be transferred 
into a polypropylene 96-deep well plate for staining on the robot.  
• Data acquisition: Stained cells would then be transferred into 96-U bottom plates 
which are compatible with the plate reader of the FACS, and the data would be 
acquired using an automated fluorescence activated cell sorter.  
 
3.2 Screening 
The conditions mentioned above were used to screen for novel apoptosis inducing 
proteins. All the proteins used for the screen were tagged C- or N-terminally with YFP and 
both the tag orientations for each protein were screened in the assay. As a proof of principle 
of the assay the screen was initially done with a set of 100 open reading frames (ORFs) 
selected from a list of proteins which were differentially expressed in cancer. Later, based on 
the availability of full length cDNAs the screen was extended to other previously 
uncharacterized proteins. So far 266 ORFs (200 proteins) have been screened in the assay 
(table 6.1 in Supplements), which amounts to 532 expression clones (C- and N-terminally 
tagged ORFs). Each gene of interest was screened in 4 independent replicate experiments 
finally resulting in data acquisition for 2,128 wells (4 x 532 wells).  
 
3.2.1 Statistical analysis  
The raw data obtained from the assay was analyzed using specialized software based 
on the statistical programming language R which is openly available through the 
Bioconductor package prada (collaboration with Florian Hahne). The raw data was initially 
pre-processed to remove the contaminants like cell clumps and debris, and the scatter plots for 
all the 96 wells were then generated automatically. A measure for the effect of a protein on 
activation of caspase-3 was then obtained through the log-transformed odds-ratio (refer 
section 2.2.2.8) and a measure of significance was calculated by testing against the null-
hypothesis of an odds-ratio of one, by means of the Fisher's Exact Test. Results from replicate 
measurements for each protein were combined using a generalized Chi2 statistic for stratified 
contingency tables through the Mantel-Haenszel test.  
 
 
 
Results 
 92
3.2.2 Selection of potential candidates from the Caspase-3 assay 
The procedure by which candidates were selected is shown in Figure 3.12, taking one 
96-well screening plate as an example. To facilitate candidate selection and to obtain an 
overview of protein effects in a 96-well plate, the odds ratios were visualized as colour coded 
96-well plate plots (Figure 3.12A). The proteins which showed an activating effect in the 
assay were indicated with red colour, with the intensity of colour being directly proportional 
to strength of the effect in the assay. For example, in the plate shown in figure 3.12.A, some 
of the proteins in the plate induced caspase-3 activation for both the tag orientations (wells C2 
and G2; wells C8 and G8). However, some proteins induced apoptosis only when YFP is 
fused at the N-terminus of the protein (wells G1 and G4). This shows that orientation of the 
tag has an effect on the assay outcome of some ORFs probably due to mislocalization of the 
protein caused by masking of the localization signal by the tag.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Selection of potential candidates of the apoptosis assay  
(A) Visual representation of the odds ratio as colour coded 96-well plate plot. The C-terminally tagged proteins are present in 
the upper half of the plate, while the N-terminally tagged proteins are present in the corresponding lower half of the plate. 
Expression clones which showed an activating effect in the assay are indicated with red colour. (B) Effect of the proteins 
from replicate experiments is shown as an interactive boxplot. Each vertical bar represents one expression clone. The clones 
which show an effect size (or –log odds ratio) of more than 0.65 (shown with arrows) were selected for further analysis. (C) 
The three patterns of scatter plots seen in the assay are shown. The first and the second patterns are recognized as activators 
by the statistical analysis method, while the third one is not. 
 
The results from 4 replicate experiments for this plate were combined and visualized 
as a box plot (Figure 3.12B). The box plot provides an overview of the effect of a protein with 
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respect to replicate measurements of other proteins on the same plate. Each bar in this box 
plot represents one expression clone. Though the effect of some proteins in the assay was 
observed to vary with orientation of the tag, initially all the expression clones with –log odds 
ratio of more than 0.65 were selected (expression clones shown with arrows in Figure 3.12B). 
The subcellular localization of these selected proteins was then examined in LIFEdb [4] [5] 
and only those fusion proteins that showed correct localization were considered as candidates 
for further validation (Table 3.6).  
Upon examining the scatter plots of all the expression clones in the assay, three 
different patterns of scatter plots for activators were observed (Figure 3.12.C). In the first kind 
of scatter plot, a very strong apoptosis induction was observed in the transfected cells, while 
most of the untransfected cells were negative for active caspase-3 (Figure 3.12.Ca). In the 
second type of scatter plot, only the cells with very high protein expression were found to 
undergo apoptosis (Figure 3.12.Cb). Proteins that exhibited these two patterns were identified 
as apoptosis inducers by the automated analysis method, because of the high odds ratio. 
However, proteins that exbited the 2nd type of scatter plots (Figure 3.12.Cb) were not 
considered for further validation because, very high overexpression of a protein induces 
undesirable nonphysiological effects, which in many cases is induction of apoptosis. 
Therefore, 9 proteins that exhibited the first type of scatter plots were selected for validation 
(Table 3.6, 1-9). In the third kind of scatter plot, along with the transfected cells even the 
untransfected cells were found to undergo apoptosis (Figure 3.12.Bc). In this case, the odds 
ratio was small and these clones were not recognized by the automated analysis method as 
activators. However, proteins that show such a pattern might represent death inducing ligands, 
secreted or other proteins which induce apoptosis also in the neighbouring untransfected cells. 
So, three proteins that exhibited such a pattern of scatter plot were also considered for further 
evaluation (Table 3.6, 10-12). Thus, a total of 12 proteins were selected as candidates for a 
second screen, where the apoptosis inducing effect of these proteins was tested in a nuclear 
fragmentation assay (table 3.6).  
 
3.2.3 Confirmation of candidates with nuclear fragmentation assay 
HEK293T cells were transfected with maxi-prep DNA of the 12 candidates, and 
allowed to express the proteins for 3 days. After collecting the floating and adherent cells, the 
cells were stained with DAPI and fixed on slides using Cytospin3. Nuclei of the cells were 
observed under confocal laser scanning microscope, and the proteins were scored according to 
the extent of nuclear fragmentation seen (table 3.6). In table 3.6, proteins which caused no 
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evident nuclear changes were indicated by `NO´; those with only condensed but no 
fragmented nuclei with `+´; proteins with both condensed and fragmented nuclei are indicated 
by `++´; and nuclei with clear fragmentation are scored `+++´. One example for each class of 
nuclear change is shown in Figure 3.13. Only the proteins which are scored ´++` for both tag 
orientations, and those with ´+++` for either of the orientations, were considered as final 
candidates in the apoptosis assay. List of the proteins that were considered for this screen and 
the results of the nuclear fragmentation assay are shown in table 3.6.   
 
NO
DAPI DAPI + YFPA
+
DAPI DAPI + YFPB
++
DAPI DAPI + YFPC
+++
DAPI DAPI + YFPD
 
 
Figure 3.13. Selection of candidates based on nuclear morphology 
HEK293 cells were transfected in 24-well plates with maxi preparations of DNA. After 3 days, the floating and adherent cells 
were pooled, fixed and stained with DAPI. The cells were fixed on slides using Cytospin 3 and images were made on the 
confocal microscope. Shown are the example images where (A) no evident nuclear changes occurred, indicated with ´NO` 
(B) Nucleus is condensed or deformed but no fragmentation, indicated with ´+` (C) Both condensed and fragmented nuclei 
are seen, indicated with ´++` (D) strong fragmentation is observed, indicated with ´+++`.   
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Table. 3.6. Candidates for Nuclear fragmentation assay  
No. ORF p-value Nuclear Fragmentation 
     ORF-YFP YFP-ORF 
1 akxq28i14160 0.000152 +++ +++ 
2 akxq28n1210739 3.3e-06 NO  ++ 
3 hfkd2_46m10 2.5e-05 +  ++ 
4 IRATp970A0419 6.4e-07 +++  ++ 
5 htes3_35n12 0.00195 +++  +++ 
6 hfbr2_7b16 0.00043 NO  +++ 
7 IRATp970E129 0.0085 ++ + 
8 IRAUp969G0861 2.8e-06 NO  NO  
9 hlcc2_1m1 0.0023 +  ++ 
10 hfkd2_3i13 2.39e-52 ++  ++ 
11 htes3_23a19 0.038 +  + 
12 akxq28j1311548 0.14 NO  + 
 
All the 12 candidates were confirmed in the nuclear fragmentation assay. However, 
based on the strength of nuclear fragmentation (i.e, apoptosis induction), 5 proteins were 
selected for more detailed analysis (proteins marked red in table 3.6). The scatter plots of 
these 5 proteins from the Caspase-3 assay, and the corresponding DAPI images are shown in 
Figure 3.14.  
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xq28i14160 
IRATp970A0419 
htes3_35n12 
Results 
 97
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14. Confirmation of the candidates in a nuclear fragmentation assay 
Shown are the scatter plots and images of DAPI stained nuclei of 5 proteins which showed a strong induction of 
apoptosis.  
 
Examination of scatter plots and the images of DAPI stained nuclei show that the 
strength of the signal in the caspase-3 assay strongly correlates with the nuclear fragmentation 
results of the corresponding expression clone i.e., the clones which showed a strong caspase-3 
activation also showed a very clear nuclear fragmentation. This further emphasizes the 
specificity of the caspase-3 assay. A summary of the five candidates of the apoptosis assay is 
shown in table 3.7. One of the candidates that were considered for detailed functional analysis 
is highlighted. 
hfkd2_3i13 
hfbr2_7b16 
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Table 3.7. Summary of the 5 candidate proteins of the apoptosis assay 
 
Clone ID Protein name 
Genbank 
accession 
number 
Localization 
Apoptosis 
p-value 
Annonation (Source, InterPro) 
   YFP-ORF ORF-YFP   
Xq28i14160 
FUN14 domain 
containing 2 
BC000255 Mitochondria Mitochondria 0.000152 
FUN14 domain containing 2 (Hepatitis C virus core-binding 
protein 6) (Cervical cancer oncogene 3) 
IPR007014 FUN14 
IRATp970A0419 
Interferon alpha inducible  
           protein 27 
BC015492 Unknown 
Endoplasmic 
reticulum and 
Golgi apparatus 
6.4e-07 
Interferon alpha inducible protein 27 
IPR002091 Aromatic amino acid permease; IPR009311 
Interferon-induced 6-16 
htes3_35n12 
Solute carrier family 25, 
member 31 
AL136857 
Cytoplasm and 
Mitochondria 
Mitochondria 0.00195 
Solute carrier family 25 (mitochondrial carrier; adenine 
nucleotide translocator), member 31 
IPR001993 Mitochondrial substrate carrier; IPR002113 
Adenine nucleotide translocator 1; IPR002167 Graves disease 
carrier protein 
hfbr2_7b16 Brain protein 44 AL110297 Mitochondria Mitochondria 0.00043 
Brain protein 44 
IPR005336 Protein of unknown function 
hfkd2_3i13 
Vacuole membrane 
protein 1 
AL136711 Plasmamembrane Plasmamembrane 2.39e-52 
Likely homologue of Vacuole Membrane Protein 1 (VMP1); 
No InterPro hits 
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3.3 The Vacuole Membrane Protein (VMP1) 
 The expression level of VMP1 was found to be differentially regulated in various 
disease conditions like cancer, renal failure and acute pancreatitis. Though Vmp1 is 
associated with such diverse disease mechanisms, the function of this protein is not elucidated 
yet. So we selected Vmp1 for detailed functional analysis. The cDNA of VMP1 used in the 
assay was obtained from human kidney library. So, we proceeded to examine the effects of 
Vmp1 in a kidney cell system by both overexpression as well as knock down. 
 
3.3.1 Overexpression of Vmp1 in kidney cells   
HEK293T, a ´normal` kidney cell line was chosen for the over expression experiments 
because of the high transfection efficiency that could be achieved with this cell line. Since 
overexpression of Vmp1 induced apoptosis in HEK293T cells, we started with investigating 
the possible reason for this.  
 
3.3.1.1 Vmp1 induces apoptosis in neighbouring non-transfected cells 
 HEK293T cells were transfected with VMP1 tagged C-terminally with YFP and the 
cells were observed over 3 days for the activation of caspase-3 (Figure 3.15.A). One day after 
transfection, only 2.66% of untransfected cells and 2.56% of transfected cells were positive 
for activated caspase-3. However by 48 hours, 24.3% of untransfected and 15.3% of 
transfected cells showed active caspase-3, indicating that overexpression of Vmp1 induces 
apoptosis in transfected as well as the untransfected cells. The same was observed by 72 hours 
of overexpression, again with a higher number of untransfected cells (22.1%) undergoing 
apoptosis compared to transfected cells (19.4%).   
The Vmp1 transfected cells were then monitored over 3 days to verify if the observed 
changes in the caspase-3 activation with time correlates with the induction of other apoptotic 
features like plasma membrane blebbing and nuclear fragmentation. Plasma membrane 
changes were observed in live cells by confocal microscopy, while the nuclear fragmentation 
was monitored by staining fixed cells with DAPI. One day after transfection, the morphology 
of both the untransfected and transfected cells remained normal and the cells did not lose their 
adherence (Figure 3.15.Ba). However, the nucleus of the transfected cells was condensed, 
where as the untransfected cells did not show any nuclear changes (Figure 3.15.Ca). By 48 
and 72 hours of protein expression, the cells died progressively showing features 
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characteristic of apoptosis i.e. loss of cell adherence, rounding and membrane blebbing 
(Figure 3.15.Bb and c). Untransfected cells adjacent to Vmp1 overexpressing cells also died 
with morphological evidence of apoptosis (cell shown with an arrow in Figure 3.15.Bc). The 
nucleus of the cells exhibited fragmentation starting from 48 hours after transfection (Figure 
3.15.Cb and c), confirming the result of the caspase-3 assay. This shows that the cells can 
tolerate Vmp1 overexpression to a certain extent, but prolonged overexpression is toxic to the 
tranfected as well as the untransfected bystander cells, which subsequently undergo apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15. Overexpression of Vmp1 induces apoptosis in the bystander cells  
(A) HEK293T cells were transfected with the construct VMP1-YFP and the cells were stained with active caspase-3 antibody 
for 3 days. Scatter plots show that the cells were not apoptotic on the 1st day after transfection, but on 2nd and 3rd days, more 
number of apoptotic cells were detected. Note that even the untransfected cells were positive for active caspase-3. (B) Cells 
were transfected with the same construct and morphology of live cells was monitored over 3 days. Shown are the confocal 
images of cells made 1, 2 and 3 days after transfection. On the first day, the cells did not show apoptotic morphology, but the 
cells died progressively after 48 hours of protein expression. Untransfected cells adjacent to Vmp1 overexpressing cells also 
showed apoptotic morphology (cell indicated with an arrow). (C) Images of DAPI stained nuclei show that on 1st day only 
condensed nuclei were seen. The number of fragmented nuclei increased on 2nd and 3rd days.   
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3.3.1.2 Subcellular localization of overexpressed Vmp1   
Determining the subcellular localization of a protein in most cases provides a hint 
towards the function of that protein. To understand the function of Vmp1 and to determine the 
reasons for apoptosis induction, the subcellular localization of YFP tagged Vmp1 was studied 
in HEK293T cells. Dusetti et al. showed that rat Vmp1 is localized in the endoplasmic 
reticulum and Golgi apparatus and that overexpression of Vmp1 leads to the formation of 
intra-cellular vacuoles [159]. To verify this for human Vmp1, HEK293T cells were 
transfected with plasmids encoding Vmp1 fused to YFP at its C- or N- terminus and the 
subcellular localization was observed by confocal microscopy. As described for the rat 
homologue, human Vmp1 was also found in the endoplasmic reticulum and the Golgi 
apparatus (Figure. 3.16.A) and it led to the formation of vacuoles in cells (Figure. 3.16.B). 
However, in cells with low overexpression, Vmp1 was found at the plasma membrane where 
it is distributed in a punctuate pattern (Figure.3.16.C). The protein was not distributed equally 
all over the cell, but it seemed to cluster specifically at some areas of the cell membrane, 
which were represented by intense fluorescence. Vacuole formation was not detected in cells 
where Vmp1 localized to the membrane.  
 
 
 
 
 
 
 
 
 
 
Figure 3.16. Subcellular localization of Vmp1 
(A) HEK293T cells were transfected with VMP1 tagged C-terminally with YFP, allowed to express the protein for 24 hours 
and images were made using the confocal laser scanning microscope. Vmp1 was found in some cells in the endoplasmic 
reticulum and the golgi apparatus (B) Overexpression of Vmp1 induced formation of intra cellular vacuoles. (C) In cells with 
very slight overexpression, Vmp1 localized to the plasmamembrane in a punctate pattern. The protein seemed to cluster at 
certain areas on the membrane as indicated by the bright fluorescence signal.  
 
Vmp1 has been reported to be overexpressed during acute pancreatitis, a condition in 
which pancreatic acinar cells show intracellular vacuole formation followed by cell death 
[159]. Though the mechanism of vacuole formation is not known, it was proposed that Vmp1 
A B C 
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might play an important role in this process. So, we investigated from which structures of 
Vmp1 overexpressing cells the vacuoles originated.  
 
3.3.1.3 Vacuoles are formed from Endoplasmic Reticulum 
Live cell imaging was done to monitor the formation of vacuoles. For this, HEK293T 
cells grown in chamber slides were transfected with VMP1-YFP and a series of time lapse 
images were taken every 30 minutes, using the confocal laser scanning microscope (Figure 
3.17). One cell in which vacuole formation had just started (shown with an arrow in Figure 
3.17a) was observed until the vacuole has completely formed (21/2 hours). By 30 minutes a 
protrusion was seen starting from the brightly stained region of the cell, which over the next 2 
hours further extended into a network and finally resulted in the formation of a vacuole. The 
extensions resembled endoplasmic reticulum or Golgi network, which hints that the vacuoles 
are formed from one or both of these structures (Figure 3.17e).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17. Live cell imaging to detect the origin of vacuoles 
HEK293T cells were transfected in chamber slides with VMP1-YFP and 24 hours later, live cell imaging was done using the 
Confocal laser scanning microscope. Time lapse images were taken every 30 minutes and the cell indicated with arrow in (a) 
was observed for the formation of vacuoles. The protrusion seen at 0 minutes extended into a network resembling 
Endoplasmic reticulum or Golgi apparatus (indicated with an arrow in (e) which finally formed the vacuole.       
 
To identify the exact origin of the vacuoles, HEK293T cells transfected with VMP1-
YFP were stained with antibodies against golgin-97 and calnexin, marker proteins for Golgi 
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and endoplasmic reticulum respectively, and the cells were observed under a confocal 
microscope. Though Vmp1 was found to colocalize also with golgin-97 (Figure 3.18a, b and 
c), the vacuoles in Vmp1 overexpressing cells colocalized only with calnexin, but not with 
golgin-97 (Figure 3.18d, e and f). This shows that the vacuoles are formed by the endoplasmic 
reticulum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18. Vacuoles are formed from Endoplasmic reticulum 
(A)  HEK293T cells were transiently transfected with Gateway expression plasmids encoding the YFP fused VMP1. After 24 
hours they were fixed, permeabilized and stained with primary antibodies against golgin-97 or calnexin followed by a 
secondary antibody labelled with the fluorochrome Alexa-647. The localization of Vmp1-YFP, calnexin and golgin-97 was 
detected with a confocal laser scanning microscope. Though Vmp1 colocalized with golgin-97 (a-c), vacuoles originated 
exclusively from the ER (d-f).  
 
 In summary, the overexpression studies show that Vmp1 induces apoptosis in 
transfected as well as in the neighbouring untransfected cells. Overexpressed YFP tagged 
Vmp1 localized to the Endoplasmic reticulum, Golgi apparatus and the plasma membrane and 
it promoted formation of vacuoles in cells. The vacuoles were formed from the endoplasmic 
reticulum. This suggests that the cells might have undergone apoptosis due to accumulation of 
the protein in the endoplasmic reticulum.  
 
3.3.2 Functional analysis of endogenous Vmp1 
  Overexpression studies showed that plasma membrane is probably the final 
localization of Vmp1 (Figure 3.16). However, overexpressed Vmp1 is mostly retained in the 
ER, which hinders the functional analysis of the protein by overexpression strategies. So, 
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examination of the endogenous Vmp1 would be ideal for further functional analysis. To 
achieve this, rabbit polyclonal antibody specific for Vmp1 was generated and was tested for 
its specificity. 
 
3.3.2.1 Specificity of Vmp1 antibody 
 The specificity of the antibody was tested in HEK293T cells by western blotting and 
immunofluorescence approaches (Figure 3.19). Whole cell lysates of HEK293T cells either 
mock transfected (lane 1), YFP (lane 2) or VMP1-YFP transfected (lane 3) were resolved by 
SDS-PAGE and the membrane probed with anti-Vmp1 antibody (Figure 3.19.A). A band at 
46kDa representing the endogenous Vmp1 was detected in all the three samples, while only 
the cells transfected with VMP1-YFP showed another band at 72kDa corresponding to the 
size of YFP tagged Vmp1. As a control for specificity of the antibody, lysates from HEK293T 
cells transfected with VMP1 siRNA were tested using the same antibody (Figure 3.19.B). A 
band at 46kDa was detected in control siRNA transfected cells (lane 1), whereas a reduction 
in protein level was detected in cells transfected with 10 and 15nM VMP1 siRNA (lanes 2 and 
3 respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19. Expression of endogenous Vmp1 
 (A) Lysates of HEK293T cells, either mock transfected (lane 1), YFP (lane 2) or VMP1-YFP transfected (lane 3) were 
resolved by SDS-PAGE and the membrane probed with anti-VMP1 antibody. The band at 72kDa in lane 3 represents the 
combined size of Vmp1 and GFP, while the 46kDa band in lanes 1, 2 and 3 is the endogenous Vmp1. (B) A reduction in the 
protein level was observed in siRNA transfected samples, which confirms that the antibody specifically recognizes Vmp1 (C) 
(a) Cells cultured on cover slips were transfected with VMP1-YFP (b).fixed, permeabilized and stained with anti-Vmp1 
antibody followed by a secondary antibody labeled with Alexa 647 (c) Confocal microscopy images showed that Vmp1 
antibody specifically recognizes YFP tagged Vmp1.  
 
VMP1-YFP anti-VMP1 Overlay
46 kDa
1 2 3
72 kDa
1 2 3
A B
C a b c
Results 
 105
Suitability and specificity of the antibody for immunofluorescence was tested using 
VMP1-YFP transfected cells (Figure3.19.C). Cells cultured on cover slips were transfected 
with VMP1-YFP, fixed, permeabilized and stained with anti-Vmp1 antibody followed by a 
secondary antibody labeled with Alexa 647. Confocal microscopy images showed that Vmp1 
antibody specifically recognized YFP tagged Vmp1, confirming that the antibody can be used 
for applications based on immunofluorescence.   
 
3.3.2.2 Subcellular localization of endogenous Vmp1  
Vmp1 is predicted by SOSUI [160]to be a seven transmembrane domain protein with 
major parts of the protein located towards the extracellular space (Figure 3.20.A). Since no 
seven transmembrane domain protein known to date is located in the Endoplasmic reticulum, 
and as large predicted extracellular domains of Vmp1 indicate a function that might be 
associated with extracellular processes, we speculated the localization of Vmp1 in the ER to 
be due to the high expression level. Proteins destined for the plasma membrane mostly pass 
through the ER and Golgi network, and it is well possible that an overexpressed protein with 
seven transmembrane helices is not folded correctly leading to its retention in the 
Endoplasmic reticulum. Moreover, under conditions of low overexpression, Vmp1 was found 
on the plasma membrane (Figure 3.16.C). Considering this possibility, we stained cells 
without prior permeabilization, using a specific antibody directed against a predicted 
extracellular domain.  
Confocal microscopy revealed that the endogenous protein is indeed present at the 
plasma membrane and that the expression pattern is similar to that of the lowly overexpressed 
YFP fused protein (Figure 3.20.Ba). Endogenous Vmp1 is distributed all over the membrane 
in a uniform fashion in cells which are not in contact with neighboring cells. However, in 
subconfluent colonies of cultured cells Vmp1 is also seen as brightly stained puncta at sites of 
cell-cell contact (Figure3.20.Bb). These puncta consist of two structures, each contributed by 
one cell, suggesting a role in the formation of initial cell-cell contacts (Figure 3.20.Bc). 
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Figure 3.20. Vmp1 is a plasma membrane protein and is localized to cell-cell contact sites  
(A) Scheme of the predicted Vmp1 protein structure, modified after the visualized prediction of SOUSI. Vmp1 is predicted to 
be a seven transmembrane domain protein, with very short cytoplasmic sequences and large extracellular domains. (B) 
Subcellular localization of endogenous Vmp1 in HEK293T cells. Cells cultured on cover slides for 24 hours were fixed and 
with out permeabilization, stained with Vmp1-antibody directed against a predicted extracellular domain. The secondary 
antibody was labeled with Alexa-488 and detection of Vmp1 was done by confocal laser scanning microscopy. (a) Vmp1 is 
located on the plasma membrane in a punctuate pattern. (b) Vmp1 was also detected at sites of cell-cell contact (indicated 
with arrows) (c) The spots are composed of two Vmp1 cores, each of them provided by one cell. 
 
3.3.2.3 Vmp1 partially colocalizes with the tight junction protein ZO-1 
To investigate if Vmp1 localizes to cell junctions, we used specific antibodies against 
proteins described as markers for different cell junctions and examined their possible co-
localization with Vmp1 in HEK293T cells (Figure 3.21). Desmoglein-2 (Dsg-2), N-Cadherin, 
Zonula occludens-1 (ZO-1) and Connexin-43 were used as marker proteins for desmosomes, 
adherens junctions (AJ), tight junctions (TJ) and gap junctions, respectively. We could not 
detect co-localization of Vmp1 with Dsg-2 or N-cadherin (Figure 3.21.A and B), eliminating 
the possibility of Vmp1 being localized to desmosomes or adherens junctions. However, 
Vmp1 colocalized partially with ZO-1, a plaque protein of tight junctions (Figure 3.21.C). 
The colocalization was restricted to some of the brightly stained structures formed by Vmp1, 
but not all the puncta of Vmp1 colocalized with ZO-1. Vmp1 did not colocalize with ZO-1 
where the tight junctions had already formed, rather colocalizion was restricted to spots where 
ZO-1 had not yet completely incorporated into the tight junctions. These observations 
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demonstrate that Vmp1 itself is not a structural component of tight junctions, but it might 
interact with ZO-1 in the early stages of junction formation.  
To check if Vmp1 colocalizes with gap junction markers, cells were stained with an 
antibody against connexin-43, a transmembrane protein of the gap junctions. No 
colocalization was detected between the two proteins which suggest that Vmp1 is not a 
structural component of gap junctions. However, in some cells a similar staining pattern was 
observed, where Connexin-43 staining was seen along the edges of Vmp1 plaques (Figure 
3.21.D). The similar staining patterns might be because of the formation of gap junctions 
immediately after the initial cell-cell contact had been established by Vmp1.  
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Figure 3.21. Colocalization of Vmp1 with junction markers 
HEK293T cells cultured on cover slides for 24 hours were fixed, and with out prior permeabilization stained with anti-Vmp1 
antibody followed by Alexa 488 labelled secondary antibody. These cells were then permeabilized and stained with 
antibodies against cell junction markers followed by secondary antibody coupled with Alexa 647. Images were made using 
the confocal laser scanning microscope. (A) No colocalization was detected with the desmosomal marker protein 
Desmoglein-2. (B) Vmp1 did not colocalize with adherens junction protein N-Cadherin (C) Vmp1 colocalized partially with 
tight junction marker protein Zonula Occludens-1. (D) Though the staining pattern of gap junction protein Connexin-43 and 
Vmp1 looks similar, the two proteins did not colocalize.  
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3.3.2.4 Vmp1 interacts with ZO-1 
 Colocalization studies with various cell junction markers showed that Vmp1 
colocalizes partially with ZO-1. In order to check if ZO-1 also interacts with Vmp1, 
coimmunoprecipitations were performed using endogenous ZO-1 as the bait protein (Figure. 
3.22). Since the interaction of ZO-1 with Vmp1 was expected at the initial stages of cell 
junction formation, HEK293T cells were seeded at a low density and cultured to a confluency 
that allows the formation of initial cell-cell contacts. Cell lysates made from these cells were 
then used to immunoprecipitate ZO-1 and there by its interacting partners using the 
ProFoundTM Mammalian co-immunoprecipitation kit (Pierce). The proteins were resolved by 
SDS-PAGE and the membrane was probed with Vmp1 and ZO-1 antibodies. The cell lysate, 
flow through (cell lysate after incubating with the beads coupled to ZO-1 antibody) and wash 
before the elution were used as controls. 
 
 
 
Figure 3.22 Vmp1 interacts with ZO-1 
HEK293T cells were cultured to a confluency that allows the formation of cell-cell contacts and the cell lysates were used to 
immunoprecipitate ZO-1 together with its interacting partners. ZO-1 could be detected in the lysate and the eluate but not in 
the flow through and the wash. Vmp1 co-immunoprecipitated along with ZO-1 and was detected as a 47 kDa band in the 
elution. The size of the band is same as that of the Vmp1 detected in the lysate.  
 
A band at 220kDa corresponding to the endogenous ZO-1 was detected in the cell 
lysate and the elution, while no band was seen in the flow through and the wash (Figure 3.22). 
Incubating the same membrane with Vmp1 antibody revealed a band at 46kDa corresponding 
to Vmp1 in the lysate and the elution. This shows that Vmp1 specifically elutes together with 
ZO-1, thus confirming the interaction between ZO-1 and Vmp1.   
 
3.3.2.5 Reduced VMP1 expression results in loss of cell adherence 
Interaction of Vmp1 with ZO-1 confirmed the idea that Vmp1 is a cell-cell contact 
protein and suggests its involvement in the formation of junctions between cells. If this is true, 
down regulation of Vmp1 should inhibit the formation of junctions. To test this, HEK293T 
Lysate Flow through Wash Elution 
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WB: Vmp1 46 kDa Vmp1 
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cells expressing endogenous Vmp1 were cultured in 6-well plates and transfected with 
siRNAs against VMP1. The cells were seeded at low density to ensure that no junction 
formation could occur prior to the transfection. Morphology of the transfected cells was 
observed over a period of 3 days. By 3 days, cells transfected with VMP1 siRNA had rounded 
up and showed loss of adherence, while transfection with control siRNA did not induce 
significant changes in cell morphology (Figure 3.23.A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23. Reduction of VMP1 expression level causes loss of cell adherence  
HEK293T cells cultured in 6-well plates were transfected with control siRNA against GFP, which is not expressed in these 
cells, and siRNAs against VMP1. (A) Three days after transfection, morphology of the cells was observed under a light 
microscope. Cells transfected with VMP1 siRNA showed loss of cell adherence. (B) To quantify cell detachment, the 
detached cells were collected separately, then centrifuged and fixed for measurement on the FACS. Knockdown of Vmp1 
resulted in 2.5 fold more non-adherent cells compared to control. (C) Down regulation of VMP1 due to transfection with 
siRNA was confirmed by quantitative taqman RT-PCR. Transfection with VMP1 siRNA resulted in the reduction of VMP1 
mRNA by more than 80%.   
 
To quantify the loss of cell adherence, detached cells from the wells transfected with 
siRNAs against GFP and VMP1 were collected from the culture medium and counted on 
FACS. After gating the main population for excluding the debris and cell clumps, only the 
intact cells were used for analysis. The number of detached cells was >2.5 fold higher in wells 
transfected with VMP1 siRNA as compared to the control (Figure 3.23.B). This suggests that 
the down regulation of VMP1 and the consequential missing protein at the plasma membrane 
result in loss of adherence. The down regulation of VMP1 mRNA was confirmed by 
quantitative Taqman PCR (Figure 3.23.C). The mRNA level of VMP1 in siRNA transfected 
cells was calculated relative to that of untransfected cells which is considered as 100%. 
Though transfection with GFP siRNA resulted in 10% decrease of VMP1 mRNA, cells 
transfected with VMP1 siRNA showed a decrease in the level of VMP1 mRNA by more than 
80%.  
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3.3.2.6 Decreased VMP1 expression in kidney cancer cells induces invasion 
An increasing body of evidence indicates that reduction in cell adhesion and cell-cell 
communication correlates with tumor invasion and metastasis. To test if knock down of 
VMP1 affects the invasion capacity of cancer cells, an in vitro invasion assay was done using 
Caki-2, a non-invasive kidney cancer cell line. Cells transfected with VMP1 or GFP siRNAs 
were seeded into BioCoatTM Invasion plates (BD Bioscience) and the number of invaded cells 
was counted on FACS. Down regulation of VMP1 resulted in a significant increase in the 
number of invading cells by 3.9 fold, compared to the GFP control (Figure 3.24.A). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24. Effect of VMP1 down regulation on tumour cell invasion  
(A) Caki-2 cells cultured in 6-well plates were transfected with siRNAs against VMP1 or GFP. After 24 hours, the cells were 
serum starved in 1% FCS containing medium for 24 hours. Invasion assay was done using BioCoatTM Invasion plate (BD 
Bioscience). After 72 hours, the invading cells were detached from the membrane by trypsinization and counted on FACS. 
Loss of VMP1 resulted in 3.9 fold increase in the number of invaded cells compared to the control. (B) Down regulation of 
VMP1 mRNA due to transfection with siRNA was confirmed by Taqman RT-PCR. Caki-2 cells were transfected with VMP1 
and GFP siRNAs and the total RNA was extracted after 48 hours. Equal amount of RNA was used to quantify expression 
level of VMP1. Transfection with VMP1 siRNA resulted in the reduction of VMP1 mRNA by more than 85%.   
 
Reduction of the mRNA level due to transfection with VMP1 siRNA was confirmed 
by quantitative TaqMan PCR (Figure 3.24.B). Transfection with VMP1 siRNA resulted in a 
significant decrease in the mRNA level of VMP1 (reduction of more than 85%) compared to 
the untransfected and the GFP siRNA transfected cells. This shows that the loss of VMP1 
increases the invasiveness of kidney tumor cells.  
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3.3.2.7 VMP1 is down regulated in kidney cancer metastasis 
VMP1 had been found to be up regulated in kidney tumors compared to normal tissues 
in two independent studies [143] [161], however, no data was available regarding the 
differences between primary tumors and metastasis. Therefore the expression level of VMP1 
in kidney cancer patient samples was examined for differences between primary tumors and 
metastasis (collaboration with Holger Sültmann). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25. Expression analysis of VMP1 in kidney cancer patient samples 
Total RNA was extracted from fifty six clear cell renal carcinoma primary tumour (n=37) and metastases (n=16) samples, 
and the mRNA expression level of VMP1 was analyzed by quantitative RT-PCR. VMP1 mRNA level was found to be 
significantly less in metastases compared to the primary tumours.  
 
Fifty six clear cell renal cell carcinoma primary tumour (n=37) and metastases (n=16) 
samples were collected at the University of Göttingen between 1996 and 2002 (by Lazlo 
Füzesi). The mRNA level of VMP1 in these patient samples was quantified by quantitative 
Taqman Real Time-PCR (Figure 3.25). VMP1 mRNA was found to be significantly reduced 
in metastasis compared to primary tumors (p=0.0347). This data suggests that Vmp1 plays an 
important role when tumor cells leave the primary tumor and move to distant sites where they 
establish metastases. 
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In conclusion, the overexpression studies revealed that Vmp1 induces apoptosis in 
HEK293T cells and that the subcellular localization of Vmp1 is dependent on the protein 
expression level. Endogenous Vmp1 is a plasma membrane protein, but an increase in the 
expression level results in the accumulation of protein in the ER resulting in the formation of 
vacuoles ultimately leading to cell death. Vmp1 localizes to cell-cell contact sites, and it also 
colocalizes partially and interacts with the tight junction protein ZO-1. Loss of VMP1 induces 
cell detachment and increases the invasiveness of tumour cells. Finally, the level of VMP1 
mRNA was less in kidney metastases compared to primary tumours.  
Discussion 
 114
4 Discussion 
 
4.1 Establishment of high throughput apoptosis assay and screening 
The current emphasis of apoptosis in disease has led many researchers to look for the 
mechanisms mediating its effect. The identification of novel genetic regulators of 
programmed cell death would provide exciting insights into the pathogenesis of certain 
diseases, ultimately leading to the identification of novel therapeutic targets for curing 
specific diseases or limiting their progression. In an effort towards this, we have established a 
high throughput cell based apoptosis assay and screened for dominant apoptosis inducing 
proteins.  
 
4.1.1 Need for the identification of dominant apoptosis inducing genes 
Along with uncontrolled proliferation, the survival of tumour cells is also in part due 
to their inability to activate apoptosis [162]. The current approaches for cancer therapy 
include the induction of apoptosis by different external stimuli such as irradiation, death 
factors like Fas ligand, TNF α etc., and other chemical compounds [163]. Stimulation of cells 
with any of these activates well defined apoptotic pathways leading to changes in the 
expression levels of apoptosis modulating proteins. A large number of proteins that induce or 
inhibit apoptosis induced by these exogenous factors have been identified. However, proteins 
that are able to initiate apoptosis in a dominant fashion, e.g. by transient overexpression are 
rare and are mostly not identified yet. Identification of dominant apoptosis inducing proteins 
would be helpful in the development of novel therapeutic strategies to combat cancer. Such 
genes could be used to induce apoptosis of cancer cells, for example in gene therapy 
applications involving vector dependent overexpression of the protein and/or promoting the 
overexpression of the protein in vivo by stimulating the endogenous promoter. Modulating the 
expression of key components of the apoptotic machinery to tip the balance between pro- and 
anti-apoptotic signals in tumour cells is a rational approach in cancer therapy. 
 Protein-protein interactions are mostly responsible for the induction of apoptosis [26] 
[164]. Moreover, it is known that many apoptosis inducing proteins such as death domain 
containing proteins, p53, pro apoptotic Bcl-2 family proteins etc achieve their effect at 
elevated concentrations [165] [166] [167] [168]. So, one of the approaches to identify proteins 
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inducing apoptosis is to overexpress them in a cell system and generate these interactions 
artificially which would lead to the induction of apoptosis.  
 
4.1.2 Selection of the apoptosis assay amenable for high throughput screening 
The selection and establishment of a suitable assay was one of the most important 
parameters in the installation of the apoptosis screen. All the high throughput apoptosis 
screens reported by the time this project was initiated had been applied to test chemical 
compounds for their activity as inhibitors or activators of apoptosis [169] [170], but no high 
throughput screens to identify apoptosis activating/inhibiting proteins after transiently 
transfecting the cells with cDNAs were described. Since the drug screening assays do not 
depend on transient transfection of cDNAs, the results are typically detected from the whole 
population of cells using uniform well readout methods such as a plate reader. However, 
transient transfections introduce high cell-cell variations even within the same well due to 
differences in the protein expression levels within a population of cells. Moreover, some 
proteins exert their effect only once a certain expression level has reached. In such cases, only 
a method of detection that allows single cell resolution, can detect changes in signal obtained 
from a few cells within a well. Therefore, major efforts in the first part of the work were 
directed towards the selection of a suitable and sensitive method, and in the automation and 
optimization of the assay conditions.  
 
Technical considerations for assay selection 
We aimed at selecting an assay which is highly specific for apoptosis, sensitive 
enough to detect even minute changes in the parameter being assessed, and at the same time 
robust enough to be automated for high throughput screening. Although any assay, in theory, 
can be applied in high throughput screening, conversion to an automated format imposes 
certain constraints that affect the design of the assay in practice. Plate reader based assays, 
though do not allow resolution up to a single cell, offer the advantage that the data acquisition 
times are very short (approximately 2-3 minutes/96-well plate). Many high throughput 
applications use this method of detection mainly because of this reason.  
Methods based on flow cytometry (FACS) are most commonly used in apoptosis 
research because several parameters of individual cells can be measured simultaneously and it 
facilitates the measurement of adherent as well as floating (apoptotic) cells. Moreover, when 
cells are transfected with YFP tagged ORFs, the transfected cells can be distinguished from 
the untransfected cells by this method, thus allowing the analysis of protein effect in relation 
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to its expression level. Because of these advantages, I tried two different high throughput 
apoptosis assays – one based on plate reader and another based on FACS. More recently, 
automated microscopes are being used for high throughput applications to monitor changes at 
the level of individual cells within an assay well [3] [171]. However, microscopy based 
methods were not considered for high throughput detection of apoptosis because apoptotic 
cells lose their adherence and detach from the surface of the well easily. This might result in 
underestimation of the total number of apoptotic cells thus leading to misinterpretation of the 
assay outcome, and perhaps, missing the strongest apoptosis inducers.  
A diverse range of apoptosis assays are currently available, out of which TUNEL, annexin 
V binding assay, detection of cells with fractional DNA content (sub-G1 peak), and the 
activity of proteases are most widely used (refer section 1.4). However, some of these 
methods are not very specific for apoptosis, while some are not compatible with the cell 
system used here for the assay. 
1. Though extensively used, TUNEL assay detects both apoptotic and necrotic cells, and 
therefore can not be considered as a specific assay for apoptosis [172]. Moreover, this 
method is technically demanding and adapting it to a high throughput format is 
difficult. 
2.  FACS based Annexin V assay is suitable for use only with cell types that grow in 
suspension, because procedures applied to detach adherent cells from the surface leads 
to exposure of phosphatidylserine even in non-apoptotic cells [173]. But most of the 
suspension cell lines have a low transfection efficiency making them unsuitable for 
experiments based on transient transfections. 
3. Late apoptotic cells reveal themselves as a sub-G1 peak in a DNA histogram. 
However, cellular debris (perhaps due to necrosis) also accumulates in this sub-G1 
region, making this assay ambiguous.  
4. Activation of caspases is likely the most specific indicator of the apoptotic process. 
Apoptotic pathways originating from different cellular organelles converge on the 
activation of effector caspases, most importantly caspase-3. Several methods are 
currently available to detect the activation of caspase-3. 
 So, I tried to establish a high throughput apoptosis assay in which either the activity of 
caspase-3 can be determined as a function of FRET (plate reader assay), or the presence of 
activated caspase-3 can be detected by a specific antibody (FACS based assay).  
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4.1.3 Establishment of FRET based assay 
It has been demonstrated in several studies that it is feasible to use GFP based FRET 
method for detecting the activation of caspase-3 during apoptosis [140] [174]. A FRET based 
high throughput assay to identify novel apoptosis inhibiting drug compounds has been 
described by Tawa, P et al [169]. In this assay, HeLa cells stably expressing a FRET construct 
(fusion protein with the fluorophores W1B and Topaz linked together with a caspase-3 
substrate site) were treated with different drugs, and changes in the FRET signal was 
monitored using a plate reader. I tried to adapt this assay to screen for apoptosis activators in 
NIH3T3 cells. Therefore, a FRET probe was constructed with CFP and YFP, linked together 
with a special linker containing the caspase-3 cleavage site. The design and length of the 
linker region plays an important role in determining the strength of the FRET signal. One of 
the frequent problems encountered in such FRET constructs is that the caspase-3 substrate site 
is not always accessible for cleavage. So an optimized 16 amino acid linker region was used, 
which had been previously demonstrated by Luo KQ et al. to produce a strong FRET effect 
and also to be efficiently cleaved by caspase-3 due to the special design of the sequence 
flanking the DEVD substrate site [151]. 
Though treatment with staurosporine (1µM for 4 hours) was demonstrated by Tawa,P 
et al. to result in complete cleavage of the FRET probe, only a small amount of cleavage 
product was detected in our experiment (Figure 3.4B). This could be because of very high 
expression level of the FRET protein due to transient transfections, which might be beyond 
the cleavage capacity of the endogenous caspase-3. However, since the occurrence of FRET 
could be demonstrated by microscopy in cells transiently transfected with the FRET construct 
(Figure 3.5), I proceeded with the generation of stable cell line which would express less 
amount of protein compared to transiently transfected cells.  
Seven clones of the FRET protein (CFP-DEVD-YFP) and 2 clones of the control 
probe (CFP-YFP) were isolated and were found to constitutively express the fusion proteins. 
One clone stably expressing the FRET protein was used to detect the fluorescence using a 
plate reader. The fluorescence signal was observed only with a high cell number (18,000 
cells/well). But such a high cell number/well in a 96-well plate forms a very confluent 
monolayer, which is not suitable for transfections. Most of the plate reader based assays use 
cell lysates from which the fluorescence is detected. But the instrument needs to be very 
sensitive to detect signal from intact cells. Based on this experience, another assay was 
established where the signal from individual cells can be measured by a flow cytometer.  
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4.1.4 Establishment of assay to detect activated caspase-3 by flow cytometry 
 Detection of active caspase-3 provides a direct and specific way of identifying 
apoptosis. Antibodies detecting the cleaved or activated forms of caspase-3 have been 
developed and successfully applied in some studies to detect apoptosis [175] [141]. In spite of 
the specificity of detecting apoptosis, this method has not been used yet for any high 
throughput applications. Though flow cytometry is a common detection method in apoptosis 
research, to date, no flow cytometry based screens have been reported. Combining these two, 
a flow cytometry based high throughput assay was developed to screen for novel apoptosis 
activating proteins. Apart from the specificity of detecting apoptosis, this assay offers the 
advantage that the activation of caspase-3 and the expression level of the YFP tagged protein 
can be measured and correlated at the level of single cell. Moreover, the amount of 
information that can be extracted from the individual scatter plots gives a better picture about 
the protein compared to the plate reader based detection methods. For example, parameters 
such as the expression level of the protein that is required to induce apoptosis; proteins (such 
as death ligands, receptors, secreted proteins) that are able to induce apoptosis also in the 
untransfected cells of the same well can be easily identified from the scatter plots.  
 
Choice of cell line for the assay  
 The assay was initially tested with a subset of control proteins in NIH3T3 cell line. 
Though apoptosis activators could be identified in this cell line, the effects were statistically 
insignificant. Along with the poor quality of the mini-prep DNA (compared to maxi prep-
DNA), this is also in part due to the nature of this cell line resulting in low transfection 
efficiency. Moreover, this cell line seems to be more sensitive to stress conditions including 
transfection, which resulted in a significant population of untransfected cells undergoing 
apoptosis. This finally masked the specific signal obtained from the transfected population. 
Apoptosis is not always synchronous i.e. the cells within a population may begin apoptosis at 
different times, and the length of various stages of apoptosis varies from cell to cell. 
Therefore, to increase the possibility of detecting significant number of positive cells from a 
population of cells undergoing apoptosis in an asynchronous way, it is necessary to have a 
high number of transfected cells. So, the human epithelial cell line HEK293T, known for its 
high transfectability was used for screening. With this cell line, a transfection efficiency of 
more than 90% could be achieved even with miniprep DNA. Moreover, this cell line is not 
too sensitive to stress, which resulted in a very specific detection of the effect of 
overexpressed protein on apoptosis. 
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Assay Automation 
An ideal high throughput assay is one that can be performed in a single well with no 
other manipulation other than addition of the sample to be tested. Though it is very easy to 
automate such methods, the specificity and/or sensitivity of the assay will be compromised. 
Therefore, to develop a high throughput assay, it is necessary to maintain a balance between 
specificity/sensitivity of the method and the level of automation. Two high throughput screens 
to identify apoptosis activators (after transient transfections) have been described recently. In 
one of the screens, the activities of β-Galactosidase and reduction in the secretion of alkaline 
phosphatase from cells transfected with cDNAs were used as markers to detect apoptosis in a 
plate reader based assay [176]. Overexpressed proteins of the secretory pathway or proteins 
that are targeted to the plasmamembrane accumulate in the ER, preventing the normal protein 
transport mechanism of the cell. Therefore, utilizing the secretion level of a protein as a 
marker for apoptosis induction is not appropriate in such cases. Though it is easy to automate 
such a screen, the assay is not specific for apoptosis. Another screen for identifying apoptosis 
activators used the reverse transfection cell array technology, and the proapoptotic genes were 
identified by fluorescence microscopy based on the nuclear morphology (after staining with 
DAPI), and the formation of apoptotic bodies in transfected cells [177]. Analyzing the 
morphological changes of transfected cells as well as quantifying the amount of apoptosis by 
manual observation is very laborious, which makes this method not ideal for high throughput 
screening. Moreover, valid conclusions can not be drawn by analyzing less than 500 
transfected cells/spot.  
The caspase-3 apoptosis assay described here reached a reasonable compromise 
between specificity and level of automation. Detection of activated caspase-3 by flow 
cytometry is a very specific and sensitive assay for detecting apoptosis. The process of 
transfection is completely automated but the staining procedure involves some centrifugation 
steps which require manual intervention. Moreover, data from >10,000 cells/well could be 
analyzed, which resulted in statistically significant results.  
 
4.1.5 Screening for apoptosis inducing genes and candidate selection 
A total of 200 full length proteins have been screened in the assay. One frequent 
problem associated with the use of GFP tagged ORFs is that the localization of some proteins 
is affected based on the orientation of the tag [2] [4]. To circumvent this, both the tag 
orientations for each ORF have been screened, and each experiment was repeated 4 times. 
Initially a set of 12 candidate proteins which showed medium to strong activation of caspase-
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3 were selected, and were then screened in a nuclear fragmentation assay to confirm the 
specificity of the caspase-3 assay. Though all these proteins induced morphological changes 
of the nucleus, only 5 proteins that induced a very strong nuclear fragmentation were finally 
selected as candidates of the apoptosis assay. Thus, less than 2% of the screened genes 
induced activation of caspase-3. The high specificity of the caspase-3 assay was confirmed by 
the nuclear fragmentation assay- the proteins which produced a clear effect in the caspase-3 
assay also showed a strong nuclear fragmentation (Figure 3.14). The protein domain 
classifications from Source [178] and Interpro [179] provided the functional annotation of the 
candidates (Table 3.7). This screen has been done in a kidney cell system, and follow up 
experiments are necessary to validate these candidates in other cell types. In the following, the 
five candidates are described together with their association with apoptosis.     
 
4.1.6 Candidates of the apoptosis assay 
 
FUN14 domain containing 2 
The protein encoded by cDNA xq28i14160 is a mitochondrial protein and contains a 
Fungal ATP synthase domain [180]. The overexpressed protein is a strong activator of 
apoptosis. The protein had initially been identified in a yeast two hybrid screen to interact 
with Hepatitis C core protein [181]. Hepatitis C virus is a major causative agent of chronic 
hepatitis, cirrhosis, and hepatocellular carcinoma [182], and the core protein is a structural 
viral protein that packages the viral genomic RNA. Besides its essential role in viral 
replication, the core protein is involved in a variety of functions like signal transduction, cell 
cycle regulation, changes in gene transcription as well as apoptosis [183]. Previous studies 
regarding the role of this protein in apoptosis demonstrated controversial results. There are 
several studies indicating that the core protein suppresses apoptosis mediated by Fas, c-myc 
and TNF-α [184] [185] [186], while other studies showed that it promotes apoptosis by 
interacting with different proapoptotic pathways like TNFR I, Fas and the p53 pathways of 
apoptosis [187] [188] [189]. Though the differences in activity could be cell-type specific, it 
is clear that the core protein regulates apoptosis. But the precise mechanism by which this is 
done is not fully understood. The core protein was shown to suppress the activation of 
caspase-3 [190], while overexpression of the protein encoded by cDNA xq28i14160 leads to 
the activation of caspase-3. Therefore, it is possible that the core protein suppresses the 
apoptosis activating effect of the protein encoded by cDNA xq28i14160 by interacting with it. 
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Interferon alpha inducible protein 27 or ISG12(a) protein 
The protein encoded by the cDNA IRATp970A0419 is an interferon alpha inducible 
gene and belongs to the ISG12 gene family. Interferons are a family of cytokines which exert 
their biological function through the activation of interferon stimulated genes (ISGs). The 
ISGs participate in a variety of biological functions involving antiviral, apoptotic, 
antiproliferative, antitumor and immunomodulatory activities [191]. The protein sequence of 
ISG12 has 33% overall sequence identity to the product of the 6-16 gene (also an interferon 
stimulated gene), but the functions of 6-16 as well as ISG12 have not been identified yet. It 
has been demonstrated that a high degree of similarity exists between the induction pattern of 
6-16 and ISG12 in various cell lines [192] suggesting the possibility that these proteins might 
play related roles in the interferon system. Increased expression of 6-16 has been found during 
cell growth arrest and in senescent cells [193] [194] indicating that 6-16 is involved in growth 
inhibitory processes. Overexpression of ISG12(a) induced activation of caspase-3 and 
subsequently apoptosis, which is consistent with the growth inhibitory property of 6-16. 
However, 6-16 and ISG12 were shown to be upregulated in gastric cancers and, breast and 
epithelial cancers respectively [195] [196] [197] contradicting the growth inhibitory and/or 
apoptosis activating functions. A similar pattern has been observed for several well known 
oncogenes. Activation of oncogenes is observed in many cancers and it is well established 
that oncogenes promote cell proliferation and tumorigenesis. However, vector-dependent 
overexpression of oncogenes like c-myc, E1A, E2F-1 was shown to induce powerful 
apoptosis or growth arrest of cancer cells [198] [199] [200]. 
 
Solute carrier family 25, member 31 
The protein encoded by cDNA htes3_35n12 is a strong inducer of apoptosis and is a 
novel member of the mitochondrial solute carrier family 25. This family of proteins is 
involved in the exchange of cytosolic ADP for mitochondrial ATP [201]. Three isoforms of 
this protein family (Adenine nucleotide translocator (ANT) 1, 2 and 3) with tissue specific 
expression patterns have been described in humans [202]. The protein encoded by cDNA 
htes3_35n12 is the fourth isoform and shares 66-68% amino acid identity with the other three 
isoforms [203]. Overexpression of a well known member of this family, ANT1, has been 
demonstrated to induce apoptosis. Apoptosis induced by overexpressed ANT1 was shown not 
to be due to increased exchange of ADP/ADP by the formation of non-specific pore, but is 
through specific interactions with proteins of the mitochondrial permeability transition pore 
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and through regulation of NF-κB activity [204] [205]. The fourth isoform of this protein 
family might induce apoptosis in a mechanism similar to that of ANT1. 
 
Brain protein 44 
The protein encoded by cDNA hfbr2_7b16 is localized to the mitochondria and it 
belongs to a family of proteins of unknown function. No similarities to known proteins or 
domains have been found. However, genes similar to this have been found in dog, mouse, 
zebra fish, fruit fly and worm indicating that the function of the protein might be important in 
the cell (GeneCards) [206]. A similar protein called brain protein 44-like (from Rattus 
norvegicus) is predicted to be localized to the inner mitochondrial membrane and that it might 
be involved in the apoptosis of neuronal cells (SOURCE) [178]. This is consistent with the 
mitochondrial localization and the apoptosis inducing effect of brain protein 44 observed here. 
 
Vacuole membrane protein 1 
The protein encoded by cDNA hfkd2_3i13 is an apoptosis inducer and has no known 
domains or similarities to known proteins. Its homologue, rat Vmp1 was identified by Dusetti 
et al. in rat pancreas which is affected by pancreatitis [159]. Overexpressed rat Vmp1 was 
shown to localize to the endoplasmic reticulum (ER) and Golgi apparatus and that it promotes 
formation of intracellular vacuoles, with Vmp1 being integrated into the membranes of the 
vacuoles. Cells overexpressing Vmp1 died after 48 hours showing morphological features of 
apoptosis. The mRNA was shown to be absent in normal pancreas, but is strongly and rapidly 
activated after the induction of experimental pancreatitis. Therefore, Vmp1 was described as a 
stress induced gene that might be activated by pancreas as an emergency program against 
pancreatitis. Furthermore, rat Vmp1 mRNA was also found overexpressed during kidney 
ischemia. The expression of rat Vmp1 mRNA was also detected in several normal tissues like 
intestine, kidney, liver, lung, brain etc. suggesting that Vmp1 is essential for the normal 
growth and survival of cells. Moreover, VMP1 is evolutionarily conserved and its homologues 
are found also in lower organisms like Drosophila melanogaster, Caenorhabditis elegans and 
Arabidopsis thaliana, which further emphasizes that the function of Vmp1 protein might be 
very important.  
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4.2 Detailed analysis of Vacuole Membrane Protein 1 (Vmp1) 
The human VMP1 cDNA was isolated in our department from human fetal kidney, and 
the GFP tagged cDNA was used in various assays to determine the function of this protein. 
The overexpressed human Vmp1 was reported to localize in the endoplasmic reticulum (ER) 
and Golgi complex [5], and to have a repressing effect on secretory membrane transport in 
HeLa cells [171]. Slight overexpression in NIH3T3 cells resulted in repression of 
proliferation, and in human Caki-1 kidney cancer cells the overexpressed protein reduced 
anchorage independent growth [3]. Here overexpression of Vmp1 induced apoptosis in 
HEK293T cells. These results suggest a role of Vmp1 in tumour relevant cellular processes, 
which is further supported by expression profiling data [161] [143]. On this basis, we aimed 
to define the cellular processes Vmp1 is involved in, and how this protein is associated with 
tumorigenesis. Rat Vmp1 was shown to be overexpressed during pancreatitis and kidney 
ischemia, conditions in which cells die by apoptosis as well as necrosis. Since overexpression 
of Vmp1 was found to induce apoptosis, I first tried to determine why cells overexpressing 
Vmp1 undergo apoptosis.  
 
4.2.1 Vmp1 induces apoptosis through the ER stress pathway  
 Transient overexpression of GFP tagged Vmp1 induced apoptosis in HEK293T cells. 
Several criteria like the activation of caspase-3, morphology of the dying cells, and the 
fragmentation of nucleus (Figure 3.15) suggest that the Vmp1 induced cell death occurs by 
apoptosis rather than by necrosis. Vmp1 mRNA is expressed in many rat tissues [159]. 
Apparently, physiological levels of this protein are most probably essential for the cell. 
However, in HEK293T cells, elevated levels of this protein are not tolerated, with the 
consequence of cell death. One day after protein expression, vacuoles were seen in the cells, 
but the cells were not apoptotic as indicated by the absence of activated caspase-3 and the 
apoptotic morphology. Staining with marker proteins for ER and Golgi apparatus showed that 
the vacuoles were formed from the endoplasmic reticulum, suggesting that overexpression of 
Vmp1 induces morphological changes of the ER. However, by 2 days the vacuoles/ER 
collapsed, which was accompanied by induction of apoptosis. Along with the transfected 
cells, even the non-transfected bystander cells were found to undergo apoptosis. Though the 
exact mechanism of vacuole formation is not known, collapse of the ER might be due to 
protein overload leading to accumulation of unfolded proteins in the ER. This prevents the 
transport of essential membrane receptors and cell adhesion proteins (like Vmp1) to the 
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plasma membrane, resulting in failed cell junction formation and cell-cell signaling. Missing 
cell-cell contacts (between Vmp1 overexpressing cells and the neighbouring non-transfected 
cells) initiate a stress response in cultured cells which ultimately leads to apoptosis. This 
might explain the death of non-transfected cells co-cultured with Vmp1 overexpressing cells. 
This is also consistent with the results of Starkuviene et al, reporting that overexpression of 
Vmp1 inhibits the secretory pathway in HeLa cells. Thus, it is probable that apoptosis induced 
by overexpression of Vmp1 is through the ER-stress pathway.  
It is now well established that Endoplasmic Reticulum acts as a stress sensor and can 
initiate specific apoptosis pathways as a result of protein accumulation and/or depletion of 
calcium stores [62]. Vmp1 was found to be overexpressed during pancreatitis and kidney 
ischemia, and it has been reported that increase in the cytosolic calcium (or decrease in the ER 
calcium stores) has been observed in these two conditions [207] [208]. This might be a result 
of accumulation of Vmp1 in the ER, resulting in collapse of the ER, thus releasing the 
calcium into the cytosol. Similar effect has been observed in Alzheimer’s disease in which 
mutations in the presenilin genes was responsible for the accumulation of unfolded proteins in 
the ER causing apoptosis of the neuronal cells [125]. 
 
4.2.2 Vmp1 is a plasmamembrane protein 
Localization studies with overexpressed GFP-tagged Vmp1 revealed two different 
localizations- Endoplasmic Reticulum and the Plasma membrane (Figure 3.16). Vmp1 was 
predicted by SOSUI [160] to be an integral membrane protein containing 7 transmembrane 
domains, an extracellular N-terminal and a cytoplasmic C-terminal end, two large and one 
small extracellular domains, and only short intracellular domains (Figure 3.20A). However, 
analysis of the protein sequence did not reveal specific ER retention signal. Moreover, to date 
no ER-located seven transmembrane domains containing protein has been described. 
Therefore, it was hypothesised that Vmp1 is a plasma membrane protein and the localization 
of Vmp1 in the ER might be only due to accumulation of the protein as a result of high 
expression level. To confirm this, HEK293T cells were stained without prior 
permeabilisation, with a Vmp1 antibody directed against a predicted extracellular domain. 
Confocal microscopy indeed revealed that endogenous Vmp1 is present at the plasma 
membrane, where it is distributed in a punctuate pattern all over the cell (Figure 3.20B). In 
subconfluent colonies of cultured HEK293T cells Vmp1 was also detected in sites of initial 
cell-cell contacts, suggesting that Vmp1 might be involved in the formation of junctions 
between cells.  
Discussion 
 125
4.2.3 Vmp1 is an essential cell-cell contact protein 
 The first step towards understanding the function of a protein is to find the interacting 
partners of the protein of interest. But no predicted protein interaction domains or similarities 
to known proteins were identified in the protein sequence of Vmp1. Since Vmp1 also 
localizes to areas of cell-cell contact, another possibility was to perform colocalization studies 
with cell junction marker proteins. Based on these experiments, I could exclude that Vmp1 is 
a structural component of any of the cell junctions. However, Vmp1 was found to colocalize 
with ZO-1, a tight junction protein, but the colocalization was limited to spot-like areas 
between cells where ZO-1 had not yet incorporated into the tight junctions (Figure 3.21C). 
This suggested that the interaction of Vmp1 and ZO-1 is transient and might occur before the 
formation of tight junctions. Coimmunoprecipitation experiments proved that Vmp1 indeed 
interacts with ZO-1 (Figure 3.22).  
In epithelial cells, the initial cell-cell contact is established by Cadherins, which form 
homodimers in the intercellular space in a calcium-dependent manner [209]. Cell junction 
formation and polarization of epithelial cells then initiates by the formation of primordial 
adherens junctions at the sites of cell-cell contact [210]. The primordial junctions are spot-like 
structures and consist of both adherens and tight junction proteins [211] [212] [213]. When 
the cells start to polarize, tight junctions are formed, and the proteins specifically enriched at 
adherens junctions and tight junctions start to segregate. Though ZO-1 is traditionally 
considered as a marker for tight junctions, it was found also at the primordial junctions 
together with E-cadherin [211]. Since the colocalization of Vmp1 and ZO-1 was seen outside 
the tight junctions, I postulated that Vmp1 colocalized with ZO-1 in primordial junctions and 
thus might play a role in maturation of cell junctions and/or polarization of epithelial cells.  
This idea was further strengthened by the finding that the staining patterns of Vmp1 
and the gap junction protein Connexin-43 were similar in some cells though exact 
colocalization was not found. This indicates that the initial cell-cell contacts established by 
Vmp1 might trigger the formation of gap junctions between these cells. A similar 
phenomenon was observed in case of regenerating hepatocytes where E-cadherin mediated 
cell-cell contacts sites acted as foci for gap junction formation [214]. I thus hypothesize that, 
similar to E-cadherin, the initial cell-cell contacts established by Vmp1 between adjacent cells 
might occur by homo-or heteromerization of the large extracellular domains of Vmp1. 
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4.2.4 Loss of Vmp1 induces cell detachment and invasion  
 Down regulation of VMP1 mRNA in HEK293T cells resulted in a reduction of cell 
adhesion (Figure 3.23). This is possibly due to the failed formation of cell junctions and 
caused by the absence of Vmp1 which is essential in the initial stages of cell junction 
formation. Tumour progression is frequently accompanied by decreased cell-cell and cell-
matrix adhesion [215]. Reduced levels of cell-cell adhesion proteins often correlate with 
tumour invasion and metastasis [216] [217] [218]. To check if this holds true for Vmp1, the 
invasion potential of CaKi-2 cells (non-invasive kidney cancer cell line) in which VMP1 
mRNA is down regulated by transfections with siRNA was determined. Loss of Vmp1 
resulted in an increase in the invasion potential of the cells, which might be due to decreased 
formation of cell junctions. These results are consistent with previous studies in our 
department showing that VMP1 expression is lower in invasive Caki-1 cells compared to the 
non-invasive Caki-2 kidney cancer cells [3]. This further suggests that the expression level of 
Vmp1 determines the invasion capacity of cancer cells. 
Disruption of cell junctions is commonly associated with metastasis of epithelial 
cancer cells. For example, elimination of Adherens Junction formation due to loss of E-
cadherin expression has been described to correlate with the acquisition of metastatic capacity 
in tumour cells [216]. Kim et al. recently reported tight junctions to be significantly reduced 
in renal clear-cell carcinoma when compared to normal tissue [219]. In pancreatic cancer 
cells, the expression of the tight junction protein claudin-4 is associated with reduced invasive 
and metastatic potential [218]. It was shown that the tight junction plaque proteins ZO-1 and 
MUPP-1 were significantly lower expressed in patients with metastatic breast cancer 
compared to patients remaining disease-free after primary tumour excision[217]. This 
encouraged me to check for the expression level of VMP1 mRNA in tumour samples. 
Expression profiling studies showed that VMP1 is up regulated in kidney tumours compared 
to normal kidney [220] [161]. Since loss of Vmp1 in cancer cells might initiate invasion of 
cancer cells leading to metastases, the mRNA level of VMP1 in primary tumours was 
compared with that of metastases (in collaboration with Dr. Holger Sültmann). As expected, 
VMP1 mRNA was less in metastases compared to the primary tumours. This suggests that 
downregulation of Vmp1 is associated with the transition from primary to secondary tumours 
at least in kidney cancer, and that the protein is a critical determinant of cell invasiveness. 
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4.2.5 Role of Vmp1 in disease 
Vmp1 mRNA was previously shown to be overexpressed during kidney ischemia and 
acute pancreatitis in rat tissues [159]. In the present work, I have shown that human Vmp1 is 
associated with metastasis of cancer cells. Based on the findings that Vmp1 is a cell-cell 
contact protein involved in the initiation of cell junction formation, and that overexpression of 
Vmp1 induces apoptosis in cultured cells, I propose the following models for its role in 
tumour invasion, kidney ischemia and pancreatitis. 
 
4.2.5.1 Proposed role of Vmp1 in tumour invasion 
The first step in the generation of intercellular adhesion is the formation of primordial 
junctions involving proteins of AJ and TJ. Formation of cell-cell contacts and the subsequent 
maturation of the components into distinct AJ and TJ take place properly only in the presence 
of Vmp1 (Figure 4.1.A). Consequently, downregulation of Vmp1 leads to failure in the 
formation of both junctions and results in non-polarised, migrating cells. In tumour cells, 
these events could initiate invasiveness through cytoskeletal changes, perturbed signaling 
pathways and transcriptional dysregulation. 
On the molecular level, a comparable mechanism has been described for the 
primordial and AJ protein E-cadherin, which also functions as an invasion suppressor [221]. 
The cytoplasmic domain of E-cadherin recruits β-catenin to adherens junctions and connects 
the adherens junctions with the actin cytoskeleton [222] (Figure 4.1.B). Free β-catenin is 
normally phosphorylated by glycogen synthetase kinase 3β (GSK-3β) in the absence of E-
cadherin [223], and is subsequently degraded. If this mechanism is blocked, β-catenin first 
accumulates in the cytoplasm and is then translocated into the nucleus [224]. There it binds to 
member of TCF/LEF-1 family transcription factors which activate the expression of important 
growth regulatory genes like cyclin-D1 and c-myc [225]. In addition, loss of functional AJ 
would further result in changes of cytoskeletal organization, which in turn might lead to a 
higher invasive potential of the tumour cells. 
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Figure 4.1. Model for the involvement of Vmp1 in tumor invasion (modified model of Ebnet et al [213]. 
(A) Initial contacts between epithelial cells appear as primordial, spot-like junctions, containing proteins of adherens 
junctions and tight junctions. Vmp1 initiates the formation of such structures, which later mature into TJs and AJs (blue and 
yellow bars respectively, in the Z-sectional view). Loss of Vmp1 inhibits TJ and AJ establishment, supporting cell migration 
and metastasis. (B) Presence of intact TJs and AJs recruits the cell adhesion molecules to the junctions. Failed formation of 
the junctions results in the translocation of some of these proteins to the nucleus where they activate genes resulting cell 
growth and proliferation. These events might initiate tumour growth and invasion.    
 
The loss of functional tight junctions has also been reported to have similar effects on 
cell proliferation and invasion. Tight junctions act as a barrier permitting the selective passage 
of ions and solutes through the paracellular pathway [226]. On one hand they work as a fence 
separating plasma membrane into apical and basolateral areas, while on the other, they act as 
multifunctional complexes recruiting signaling proteins that regulate cell polarity, gene 
expression, and proliferation [227] [228]. In tight junctions, the peripheral membrane protein 
ZO-1 binds to integral membrane proteins thereby serving as an adaptor e.g. for actin and the 
transcription factor ZONAB (Figure 4.1.B). However, in subconfluent cells with no junction 
formation, and during the remodeling of cell contacts [229], ZO-1 localises to the nucleus 
where it interacts again with the transcription factor ZONAB. ZO-1 and ZONAB have been 
shown to control ErbB2 expression in MDCK cells [230]. If ZO-1 and ZONAB are not 
A B 
a 
b 
Actin 
Actin 
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sequestered to tight junctions as a consequence of missing tight junctions, they might act 
permanently as transcriptional modulators, promoting proliferation and invasiveness. Failed 
formation of adherens and tight junctions due to downregulation of Vmp1 could induce 
similar effects on cell adherence and invasion.  
 
4.2.5.2 Proposed role of Vmp1 in Kidney Ischemia 
Ischemic renal failure is characterized by loss of ability of the kidneys to excrete 
wastes, to concentrate urine and maintain fluid balance. This is a result of dysfunction of 
kidney tubules, and is associated with the shedding of viable and nonviable epithelial cells 
into the lumen, thus causing tubular obstruction [128, 231] (Figure 4.2.A). The major cellular 
and molecular changes occurring during kidney ischemia include loss of epithelial cell 
polarity [232], misfolding and/or aggregation of membrane and secreted proteins [233], 
mislocalization and degradation of proteins forming intercellular junctions [234], perturbation 
of integrin mediated adhesion [235] [236], and induction of apoptotic or non apoptotic cell 
death [237]. Kidneys damaged by ischemia have the ability to recover their structure and 
function completely. However, the recovery is dependent on the magnitude and duration of 
the ischemic insult. Sub-lethal ischemic insult results in complete recovery of the renal 
tubules, while prolonged ischemia leads to cell death by apoptosis and necrosis [238].  
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Figure 4.2 Model for the involvement of Vmp1 in Kidney ischemia (Modified models from (A) Schrier et al [128] and (B) 
Bush etal [238].  
(A) Obstruction of the tubule during ischemia is caused by the shedding of viable cells (as a result of lost cell junctions) and 
nonviable cells (apoptotic and necrotic cells) into the lumen. (B) Cells subjected to mild ischemia mostly reuse the existing 
Vmp1 to assemble new junctions. With increase in the severity of ischemia, cells synthesize new Vmp1 which might 
accumulate in the ER causing apoptosis. 
 
 
Vmp1 was shown to be overexpressed in kidney subjected to ischemic injury [159], 
but the role of Vmp1 in kidney ischemia is not known yet. Based on the experimental 
evidence that Vmp1 is a cell adhesion protein involved in the formation of initial cell-cell 
contacts, I hypothesise that Vmp1 might be involved in the recovery phase leading to the 
regeneration of epithelial cell junctions. Loss of intercellular cell junctions is a major event in 
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ischemic renal failure. During ischemia, cell adhesion molecules like E-Cadherin are either 
redistributed at the plasma membrane, internalized or degraded leading to the disruption of 
cell junctions [234] [239]. However, in the recovery phase following mild ischemia, the cell 
junctional complexes are reassembled mostly by reusing the already existing (internalized or 
redistributed) proteins and, to a lesser extent, by synthesis of new key adhesion molecules like 
E-cadherin [238] (Figure 4.2.B). During intermediate and severe ischemia, the proteins in the 
cell are degraded very rapidly. In an attempt to repair this, the cells synthesize large amounts 
of essential membrane and secreted proteins (growth factors, cytokines, adhesion molecules 
etc) which must pass through the secretory pathway. But under conditions of ischemia, the 
capacity of the endoplasmic reticulum to fold these proteins is compromised [233]. This leads 
to accumulation of newly synthesized proteins in the ER which in turn results in ER stress and 
cell death.  
Since Vmp1 is involved in the initial stages of cell junction formation, it is well 
possible that cells synthesize Vmp1 during the recovery phase of ischemic injury to facilitate 
the formation of new junctions (Figure 4.2.B). This explains the observation of Dusetti et al. 
that Vmp1 is overexpressed in kidney subjected to ischemia. In such cases when the ischemic 
insult still continues, the newly synthesized Vmp1, a protein with 6-7 transmembrane 
domains, might also accumulate in the ER and thus contribute to the ER stress and apoptosis 
through the activation of caspase-3. The dead (both apoptotic and necrotic cells) and the 
viable cells (due to loss of cell junctions) are shed into the lumen resulting in tubular 
obstruction and other symptoms of ischemic kidney failure.  
 
4.2.5.3 Proposed role of VMP1 in Pancreatitis  
Pancreatitis is characterized by the premature intracellular activation of digestive 
enzymes accompanied by appearance of cytosolic vacuoles within the pancreatic acinar cells. 
The exact mechanism responsible for enzyme activation remains unknown, but it is clear that 
these changes are triggered by an abnormal increase in the cytosolic calcium which is itself 
dependent on the release of calcium from the ER [240]. It has been reported that acinar cells 
die through both necrosis and apoptosis [241], and the severity of pancreatitis directly 
correlates with necrosis and inversely with apoptosis. However, acinar cells packed with 
activated enzymes prefer to die by apoptosis (rather than necrosis) to prevent release of 
harmful enzymes into the surrounding tissue causing inflammation. Therefore, strategies to 
either decrease both types of cell death or ´switch` cell death from necrosis to apoptosis will 
decrease the severity of the disease and improve the outcome. 
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Vmp1 was shown to be overexpressed during acute pancreatitis and that cells 
overexpressing Vmp1 die through apoptosis [159]. The present study showed that apoptosis 
induced by Vmp1 involves the activation of caspase-3 and that the cells die as a result of 
vacuolization and collapse of the ER. Accumulation of Vmp1 in the ER might lead to the 
depletion of calcium stores of the ER, suggesting the possibility that Vmp1 is responsible for 
the pathogenesis of pancreatitis. However, overexpression of Vmp1 induces apoptosis, which 
could as well be a part of the defence mechanism of acinar cells allowing recovery after the 
acute attack. The role of cell adhesion proteins in pancreatitis and the reasons for 
overexpression of Vmp1 during pancreatitis however remain unclear.  
 
In summary, I have established a high throughput apoptosis assay and screened for 
previously non-characterized human proteins, that induce apoptosis upon overexpression. 
This screen led to the identification of five cancer/disease relevant proteins. Functional 
analysis of Vmp1, one of the candidates of the assay, revealed that Vmp1 is a cell adhesion 
protein involved in the formation of initial cell-cell-contacts. Further, downregulation of 
VMP1 is associated with the transition from primary to secondary tumors at least in kidney 
cancer and the Vmp1 expression level is a critical determinant of cell invasiveness. Based on 
the functional data available till now, I have predicted and/or refined models for the 
involvement of Vmp1 in tumour metastasis, kidney ischemia and pancreatitis. The exact 
mechanism by which Vmp1 reduction induces a metastatic phenotype and overexpression 
affects kidney ischemia and pancreatitis remains to be elucidated.  
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5 Abbreviations 
 
°C     degrees centigrade 
µg     micro grams  
µl     micro litre 
µM     micro molar 
µm     micro meter 
a.a.     amino acids  
Amp     ampicillin 
APC     allophycocyanin 
APS     ammonium per sulfate 
ATP     adenosine triphosphate 
BCA     bicinchonic acid 
bp     base pairs 
BrdU     bromo-deoxy uridine 
BSA     bovine serum albumin 
cDNA     complementary deoxyribonucleic acid 
CFP     cyan fluorescent protein 
Co-IP     co-immunoprecipitation 
DAPI     4', 6-Diamidino-2-phenylindole 
ddH2O     double distilled water 
dNTP     deoxynucleotide triphosphate 
DMEM    dulbecco´s modified Eagle’s medium 
DMSO     dimethyl sulphoxide 
DNA     deoxyribonucleic acid 
E.coli     Escherichia coli 
EDC     1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
EDTA     ethylene diamine tetra acetic acid 
ELISA     enzyme linked immunosorbant assay 
FACS     fluorescence actovated cell sorter 
FBS     fetal bovine serum 
Fw     forward 
gm     grams  
GFP     green fluorescent protein 
GTP     guanosine triphosphate 
HRP     horse radish peroxide 
IP     immunoprecipitation 
Kan     kanamycin  
kb      kilo bases 
kDa     kilodalton 
kV     kilovolts 
LB     Luria Bertani 
M     molar 
mg     milligrams 
min     minute(s) 
ml     milliliter 
mM     millimolar 
ng     nanograms 
nm     nanometer 
O.D     optical density 
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ORF     open reading frame 
PAGE     polyacrylamide gel electrophoresis 
PBS     phosphate buffered saline 
PCR     polymerase chain reaction 
PFA     paraformaldehyde 
pM     pico molar 
PMSF     phenylmethylsulfonyl fluoride 
PS     penicillin / streptomycin  
PVDF     polyvinylidene fluoride 
RFU     relative fluorescence units 
RNA     ribonucleic acid  
rpm     revolutions per minute 
Rv     reverse 
SDS     sodium dodecyl sulfate 
SDS-PAGE    SDS-polyacrylamide gel electrophoresis 
siRNA     small interfering ribo nucleic acid  
TAE     tris/Acetate/EDTA-buffer 
TEMED    N, N, N´, N´-Tetramethylethylenediamide  
v     volt 
YFP     yellow fluorescent protein 
Supplements 
 135
6 Supplements 
 
Table 6.1. Proteins screened in the caspase-3 assay 
 
CloneID AccNO RZPDID Symbol GeneName 
akxq28A228 BC006540 IMAGp958A228 BRCC3 
BRCA1/BRCA2-containing 
complex, subunit 3 
akxq28ak055600 AK055600 NULL NULL NULL 
akxq28c1710741 BC022064 IMAGp998C1710741 FATE1 fetal and adult testis expressed 1 
akxq28c171466 BC022305 IMAGp958C171466 CLIC2 chloride intracellular channel 2 
akxq28D0812213 BM541828 IMAGp998D0812213 LOC203547 hypothetical protein LOC203547 
akxq28d201286 BC032121 IMAGp958D201286 FAM58A 
family with sequence similarity 58, 
member A 
akxq28D211790 BC015744 IMAGp958D211790 XX-FW81657 
DNA segment on chromosome X 
(unique) 9879 expressed sequence 
akxq28e054515 AI218223 IMAGp998E054515 CTAG1B cancer/testis antigen 1B 
akxq28e16117 BC002606 IMAGp998E16117 PDZD4 PDZ domain containing 4 
akxq28f031904 AA425725 IMAGp998F031904 STK23 serine/threonine kinase 23 
akxq28f10122 BC002416 IMAGp958F10122 BGN biglycan 
akxq28G021845 BC025298 IMAGp958G021845 IL9R interleukin 9 receptor 
akxq28g159617 BC008203 IMAGp998G159617 CXorf12 
chromosome X open reading frame 
12 
akxq28g17175 R59087 IMAGp998G17175 NULL NULL 
akxq28g228444 BC001561 IMAGp998G228444 DNASE1L1 deoxyribonuclease I-like 1 
akxq28i0610741 BC040301 IMAGp998I0610741 PASD1 PAS domain containing 1 
akxq28i1411448 BI824481 IMAGp998I1411448 AVPR2 
arginine vasopressin receptor 2 
(nephrogenic diabetes insipidus) 
akxq28i14160 BC000255 IMAGp958I14160 FUNDC2 FUN14 domain containing 2 
akxq28i19182 BC000738 IMAGp958I19182 EMD 
emerin (Emery-Dreifuss muscular 
dystrophy) 
akxq28i205 BC000308 IMAGp958I205 ARD1A 
ARD1 homolog A, N-
acetyltransferase (S. cerevisiae) 
akxq28i231435 BC012114 IMAGp958I231435 IKBKG 
inhibitor of kappa light polypeptide 
gene enhancer in B-cells, kinase 
gamma 
akxq28j056793 AW517432 IMAGp998J056793 NULL NULL 
akxq28j1311548 BC032351 IMAGp998J1311548 SSR4 
signal sequence receptor, delta 
(translocon-associated protein delta) 
akxq28j234 BC002392 IMAGp958J234 MPP1 
membrane protein, palmitoylated 1, 
55kDa 
akxq28k05855 BC006170 IMAGp958K05855 IDS 
iduronate 2-sulfatase (Hunter 
syndrome) 
akxq28l16384 BC025269 IMAGp958L16384 TMLHE trimethyllysine hydroxylase, epsilon 
akxq28L23832 BC011612 IMAGp958L23832 MECP2 
methyl CpG binding protein 2 (Rett 
syndrome) 
akxq28m09186 BC007631 IMAGp958M09186 PNMA6A paraneoplastic antigen like 6A 
akxq28n1210739 BC025382 IMAGp998N1210739 TKTL1 transketolase-like 1 
akxq28n167159 BC003358 IMAGp998N167159 RPL10 ribosomal protein L10 
akxq28o048419 BC000933 IMAGp998O048419 IDH3G 
isocitrate dehydrogenase 3 (NAD+) 
gamma 
akxq28o05362 H40393 IMAGp998O05362 CXorf52 
chromosome X open reading frame 
52 
akxq28o054208 AI038709 IMAGp998O054208 SPRY3 sprouty homolog 3 (Drosophila) 
akxq28o22185 BC000724 IMAGp958O22185 ATP6AP1 
ATPase, H+ transporting, lysosomal 
accessory protein 1 
akxq28u66048 BG430930 IMAGp958J081364 NULL NULL 
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hamy2_11n4 AL136544 DKFZp761N0411 SMC6L1 
SMC6 structural maintenance of 
chromosomes 6-like 1 (yeast) 
hamy2_16n19 NULL DKFZp761N1916 NULL NULL 
hamy2_1f24 AL136562 DKFZp761F241 CCDC3 coiled-coil domain containing 3 
hamy2_1h17 AL137502 DKFZp761H171 RRAGD Ras-related GTP binding D 
hamy2_24k15 AL136581 DKFZp761K1524 C14orf135 
chromosome 14 open reading frame 
135 
hamy2_2h17 AL157429 DKFZp761H172 BANP BTG3 associated nuclear protein 
hamy2_7j19 AL583909 DKFZp761J197 KIAA1539 KIAA1539 
hfbr1_10j21 AL834397 DKFZp547J2110 TRNT1 
tRNA nucleotidyl transferase, CCA-
adding, 1 
hfbr1_15b14 AL834131 DKFZp547B1415 FLJ36888 hypothetical protein FLJ36888 
hfbr1_15f6 AL834132 DKFZp547F0615 C10orf83 
chromosome 10 open reading frame 
83 
hfbr1_3f21 AL512743 DKFZp547F213 SYT13 synaptotagmin XIII 
hfbr1_4l13 AL162061 DKFZp547L134 NUP62 nucleoporin 62kDa 
hfbr1_5c24 AL834449 DKFZp547C245 RTN4R reticulon 4 receptor 
hfbr1_6j22 AL834457 DKFZp547J226 SYNPR synaptoporin 
hfbr1_6l10 AL512715 DKFZp547L106 ARHGEF2 
rho/rac guanine nucleotide exchange 
factor (GEF) 2 
hfbr2_16p15 AL110128 DKFZp564P1516 PPT2 palmitoyl-protein thioesterase 2 
hfbr2_2h1 AL136633 DKFZp564H012 MRPL18 mitochondrial ribosomal protein L18 
hfbr2_2h10 AL136634 DKFZp564H102 SUHW4 
suppressor of hairy wing homolog 4 
(Drosophila) 
hfbr2_3b16 AL050268 DKFZp564B163 RAB1A 
RAB1A, member RAS oncogene 
family 
hfbr2_3c10 AL050269 DKFZp564C103 NAT9 N-acetyltransferase 9 
hfbr2_3m17 AL136644 DKFZp564M173 PHPT1 phosphohistidine phosphatase 1 
hfbr2_62f10 AL713790 DKFZp564F1062 SLC30A8 
solute carrier family 30 (zinc 
transporter), member 8 
hfbr2_6i20 AL136665 DKFZp564I206 MRPL15 mitochondrial ribosomal protein L15 
hfbr2_72b11 AL136669 DKFZp564B1172 ICF45 
interphase cyctoplasmic foci protein 
45 
hfbr2_72b18 AL136670 DKFZp564B1872 POLI polymerase (DNA directed) iota 
hfbr2_72n12 AL136676 DKFZp564N1272 GABARAPL1 
GABA(A) receptor-associated 
protein like 1 
hfbr2_78c24 AL136680 DKFZp564C2478 GBP3 guanylate binding protein 3 
hfbr2_78k24 AL136690 DKFZp564K2478 USP18 ubiquitin specific peptidase 18 
hfbr2_7a24 AL713701 DKFZp564A247 C21orf7 
chromosome 21 open reading frame 
7 
hfbr2_7b16 AL110297 DKFZp564B167 BRP44 brain protein 44 
hfbr2_7c4 AL133600 DKFZp564C047 STAM2 
signal transducing adaptor molecule 
(SH3 domain and ITAM motif) 2 
hfbr2_7j4 AL136694 DKFZp564J047 C1orf49 
chromosome 1 open reading frame 
49 
hfbr2_7k24 AL110233 DKFZp564K247 HIGD1A HIG1 domain family, member 1A 
hfkd2_24a15 AL136704 DKFZp566A1524 FAM49A 
family with sequence similarity 49, 
member A 
hfkd2_24e23 AL136708 DKFZp566E2324 C6orf59 
chromosome 6 open reading frame 
59 
hfkd2_24n20 AL136709 DKFZp566N2024 ABI3 ABI gene family, member 3 
hfkd2_3i13 AL136711 DKFZp566I133 VMP1 transmembrane protein 49 
hfkd2_46k19 AL136721 DKFZp566K1946 PCBD2 
pterin-4 alpha-carbinolamine 
dehydratase/dimerization cofactor of 
hepatocyte nuclear factor 1 alpha 
(TCF1) 2 
hfkd2_46m10 AL136723 DKFZp566M1046 C11orf56 
chromosome 11 open reading frame 
56 
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hfkd2_4j16 AL117566 DKFZp566J164 UBE1C 
ubiquitin-activating enzyme E1C 
(UBA3 homolog, yeast) 
hlcc1_18i9 AL832636 DKFZp451I0918 TXLNA taxilin alpha 
hlcc1_1m20 NULL DKFZp451M201 NULL NULL 
hlcc1_3e22 AL831980 DKFZp451E223 NRAP nebulin-related anchoring protein 
hlcc2_1m1 NULL DKFZp313M011 NULL NULL 
hlcc3_116l20 BX538218 DKFZp686L20116 RP11-308B5 
similar to hypothetical protein 
MGC17347 
hlcc3_148h13 NULL DKFZp686H13148 NULL NULL 
hlcc3_159g12r1s1 NULL NULL NULL NULL 
hlcc3_171f5 BX647330 DKFZp686F05171 IFI27 interferon, alpha-inducible protein 27 
hlcc3_223m12 NULL DKFZp686M12223 NULL NULL 
hlcc3_261i1r1s1 NULL NULL NULL NULL 
hlcc3_51c2 NULL DKFZp686C0251 NULL NULL 
hlcc3_52b8 BX537406 DKFZp686B0852 TRIAD3 TRIAD3 protein 
hlcc3_52f6 BX537408 DKFZp686F0652 RAB5B 
RAB5B, member RAS oncogene 
family 
hlcc3_52k13 BX537967 DKFZp686K1352 TCF12 
transcription factor 12 (HTF4, helix-
loop-helix transcription factors 4) 
hlcc3_59e24 BX537969 DKFZp686E2459 RBM10 RNA binding motif protein 10 
hlcc3_59o14 BX537412 DKFZp686O1459 DYNC1I2 
dynein, cytoplasmic 1, intermediate 
chain 2 
hlcc3_59p19 BX537413 DKFZp686P1959 STRA6 
stimulated by retinoic acid gene 6 
homolog (mouse) 
hlcc3_74g21 NULL DKFZp686G2174 NULL NULL 
hlcc3_82o22 BX537382 DKFZp686O2282 SLC38A3 solute carrier family 38, member 3 
hlcc3_86a15 BX537971 DKFZp686A1586 LOC493856 
similar to RIKEN cDNA 
1500009M05 gene 
hlcc3_86f23 BX537972 DKFZp686F2386 LYSMD3 
LysM, putative peptidoglycan-
binding, domain containing 3 
hlcc3_98b23 NULL DKFZp686B2398 NULL NULL 
hlcc4_5d1r1s1 NULL NULL NULL NULL 
hmel2_11h17 AL359618 DKFZp762H1711 CHCHD8 
coiled-coil-helix-coiled-coil-helix 
domain containing 8 
hmel2_12e11 AL162047 DKFZp762E1112 NCOA4 nuclear receptor coactivator 4 
hmel2_12j1 AL713689 DKFZp762J0112 KIAA1524 KIAA1524 
hncc1_42m18 BX648228 NULL MIA2 melanoma inhibitory activity 2 
htes3_10n10 AL136733 DKFZp434N1010 UBAP1 ubiquitin associated protein 1 
htes3_10n4 AL136734 DKFZp434N0410 RAB18 
RAB18, member RAS oncogene 
family 
htes3_13c10 AL136747 DKFZp434C1013 CSTF2T 
cleavage stimulation factor, 3' pre-
RNA, subunit 2, 64kDa, tau variant 
htes3_14g5 AL136750 DKFZp434G0514 LYAR hypothetical protein FLJ20425 
htes3_15c5 AL133046 DKFZp434C0515 SSX2IP 
synovial sarcoma, X breakpoint 2 
interacting protein 
htes3_15h1 AL136760 DKFZp434H0115 TTC25 tetratricopeptide repeat domain 25 
htes3_15i5 AL136761 DKFZp434I0515 RSHL-1 Radial spokehead-like 1 
htes3_17b4 AL133067 DKFZp434B0417 PDZRN4 
PDZ domain containing RING finger 
4 
htes3_17i21 AL136777 DKFZp434I2117 FAM57B 
family with sequence similarity 57, 
member B 
htes3_17j6 AL136778 DKFZp434J0617 RKHD3 
ring finger and KH domain 
containing 3 
htes3_17n18 AL136781 DKFZp434N1817 C3orf20 
chromosome 3 open reading frame 
20 
htes3_19a13 AL136786 DKFZp434A1319 C16orf48 
chromosome 16 open reading frame 
48 
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htes3_1c15 AL080168 DKFZp434C151 ATG4B 
ATG4 autophagy related 4 homolog 
B (S. cerevisiae) 
htes3_1k11 AL136796 DKFZp434K111 KLHL25 kelch-like 25 (Drosophila) 
htes3_1k15 AL080177 DKFZp434K151 UBL3 ubiquitin-like 3 
htes3_1l15 AL117487 DKFZp434L151 TADA3L 
transcriptional adaptor 3 (NGG1 
homolog, yeast)-like 
htes3_20k2 AL136801 DKFZp434K0220 TRPV1 
transient receptor potential cation 
channel, subfamily V, member 1 
htes3_22n13 AL713710 DKFZp434N1322 MKL1 
megakaryoblastic leukemia 
(translocation) 1 
htes3_23a19 AL136813 DKFZp434A1923 CPSF3L 
cleavage and polyadenylation 
specific factor 3-like 
htes3_26g22 AL136819 DKFZp434G2226 KIF18A kinesin family member 18A 
htes3_29f24 AL136832 DKFZp434F2429 ARHGEF3 
Rho guanine nucleotide exchange 
factor (GEF) 3 
htes3_2d11 AL080197 DKFZp434D112 LOC51233 hypothetical protein LOC51233 
htes3_2d15 AL136835 DKFZp434D152 TOLLIP toll interacting protein 
htes3_2i17 AL834386 DKFZp434I172 C3orf20 
chromosome 3 open reading frame 
20 
htes3_30a5 AL136842 DKFZp434A0530 CDC42EP3 
CDC42 effector protein (Rho 
GTPase binding) 3 
htes3_35a11 AL122068 DKFZp434A1135 RAD17 RAD17 homolog (S. pombe) 
htes3_35g6 AL136853 DKFZp434G0635 BTBD1 BTB (POZ) domain containing 1 
htes3_35n12 AL136857 DKFZp434N1235 SLC25A31 
solute carrier family 25 
(mitochondrial carrier; adenine 
nucleotide translocator), member 31 
htes3_35n9 AL713761 DKFZp434N0935 CES2 carboxylesterase 2 (intestine, liver) 
htes3_35p17 AL136859 DKFZp434P1735 ARMC4 armadillo repeat containing 4 
htes3_3a7 AL080126 DKFZp434A073 KIAA0683 KIAA0683 gene product 
htes3_4d6 AL110225 DKFZp434D064 DBN1 drebrin 1 
htes3_4f5 AL136863 DKFZp434F054 WDR24 WD repeat domain 24 
htes3_4h6 AL136864 DKFZp434H064 KLC2 kinesin light chain 2 
htes3_4i11 AL080154 DKFZp434I114 C20orf28 
chromosome 20 open reading frame 
28 
htes3_50n23 AL713673 DKFZp434N2350 C12orf25 
chromosome 12 open reading frame 
25 
htes3_5c13 AL136874 DKFZp434C135 RNF32 ring finger protein 32 
htes3_7j3 AL136891 DKFZp434J037 NUAK2 NUAK family, SNF1-like kinase, 2 
htes3_7j8 AL136892 DKFZp434J087 FLJ20323 hypothetical protein FLJ20323 
htes3_8g5 AL136899 DKFZp434G058 FBXO21 F-box protein 21 
hute1_17k7 AL136910 DKFZp586K0717 FIP1L1 FIP1 like 1 (S. cerevisiae) 
hute1_18i19 AL136911 DKFZp586I1918 LIMA1 LIM domain and actin binding 1 
hute1_18i4 AL136912 DKFZp586I0418 ATG10 
ATG10 autophagy related 10 
homolog (S. cerevisiae) 
hute1_19k9 AL050283 DKFZp586K0919 SENP3 
SUMO1/sentrin/SMT3 specific 
peptidase 3 
hute1_21p24 AL110267 DKFZp586P2421 OGN 
osteoglycin (osteoinductive factor, 
mimecan) 
hute1_23e13 AL136936 DKFZp586E1323 HSPB8 heat shock 22kDa protein 8 
hute1_23h7 AL080212 DKFZp586H0723 RAP1B 
RAP1B, member of RAS oncogene 
family 
hute1_24b4 AL136940 DKFZp586B0424 HSPC049 HSPC049 protein 
hute1_24j6 AL136944 DKFZp586J0624 SLC40A1 
solute carrier family 40 (iron-
regulated transporter), member 1 
IMAGp958C20216 BC004352 IMAGp958C20216 KIF22 kinesin family member 22 
IMAGp958D0156 BC015149 IMAGp958D0156 MAP4 microtubule-associated protein 4 
IMAGp958D231833 BC042168 IMAGp958D231833 CTSZ cathepsin Z 
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IMAGp958E161161 BC011656 IMAGp958E161161 CDC27 cell division cycle 27 
IMAGp958G021430 BC018739 IMAGp958G021430 BUB1B 
BUB1 budding uninhibited by 
benzimidazoles 1 homolog beta 
(yeast) 
IMAGp958I1955 BC008718 IMAGp958I1955 BIRC5 
baculoviral IAP repeat-containing 5 
(survivin) 
IMAGp958O04299 BC018634 IMAGp958O04299 MAP1LC3B 
microtubule-associated protein 1 
light chain 3 beta 
IMAGp958O182624 BC062691 IMAGp958O182624 HSPC159 HSPC159 protein 
IMAGp998A1112724 BC036801 IMAGp998A1112724 LOC387856 
similar to expressed sequence 
AI836003 
IMAGp998D0110102 BC017713 IMAGp998D0110102 CDC23 
CDC23 (cell division cycle 23, yeast, 
homolog) 
IMAGp998d2012760 BM554036 IMAGp998D2012760 NUP62 nucleoporin 62kDa 
IMAGp998E1010430 BC013757 IMAGp998E1010430 LRRC58 leucine rich repeat containing 58 
IMAGp998H159957 BC021901 IMAGp998H159957 RAB21 
RAB21, member RAS oncogene 
family 
IMAGp998J0312216 BC035925 IMAGp998J0312216 C1orf31 
chromosome 1 open reading frame 
31 
IMAGp998K0111687 BC057767 IMAGp998K0111687 C20orf132 
chromosome 20 open reading frame 
132 
IRALp962A2027 BC010090 IRALp962A2027 ACTR1B 
ARP1 actin-related protein 1 
homolog B, centractin beta (yeast) 
IRALp962G143 BC007318 IRALp962G143 MAPRE2 
microtubule-associated protein, 
RP/EB family, member 2 
IRATp970A0419 BC015492 IRATp970A0419 IFI27 interferon, alpha-inducible protein 27 
IRATp970A0916 BC018190 IRATp970A0916 MT1X metallothionein 1X 
IRATp970B025 BC000870 IRATp970B025 FLJ20516 timeless-interacting protein 
IRATp970C094 BC006794 IRATp970C094 IFITM3 
interferon induced transmembrane 
protein 3 (1-8U) 
IRATp970D076 BC008640 IRATp970D076 ICA1 islet cell autoantigen 1, 69kDa 
IRATp970E119 BC009685 IRATp970E119 CAV1 caveolin 1, caveolae protein, 22kDa 
IRATp970E1212 BC015044 IRATp970E1212 MOAP1 modulator of apoptosis 1 
IRATp970E129 BC009698 IRATp970E129 APOC1 apolipoprotein C-I 
IRATp970F0215 BC012841 IRATp970F0215 XBP1 X-box binding protein 1 
IRAUp969A115 BC001105 IRAUp969A115 DBNDD2 
dysbindin (dystrobrevin binding 
protein 1) domain containing 2 
IRAUp969B0615 BC000785 IRAUp969B0615 SCAND1 SCAN domain containing 1 
IRAUp969B0732 BC006245 IRAUp969B0732 FGF18 fibroblast growth factor 18 
IRAUp969B1123 BC003513 IRAUp969B1123 CXCL14 chemokine (C-X-C motif) ligand 14 
IRAUp969B1159 BC009830 IRAUp969B1159 RDH14 
retinol dehydrogenase 14 (all-
trans/9-cis/11-cis) 
IRAUp969C0366 BC011551 IRAUp969C0366 ZC3HC1 zinc finger, C3HC-type containing 1 
IRAUp969C1021 BC002778 IRAUp969C1021 MYLC2PL 
myosin light chain 2, precursor 
lymphocyte-specific 
IRAUp969C1049 BC013401 IRAUp969C1049 PHB prohibitin 
IRAUp969D0269 BC014310 IRAUp969D0269 RPL10L ribosomal protein L10-like 
IRAUp969D0336 BC007936 IRAUp969D0336 GAP43 growth associated protein 43 
IRAUp969E0545 BC005916 IRAUp969E0545 PTN 
pleiotrophin (heparin binding growth 
factor 8, neurite growth-promoting 
factor 1) 
IRAUp969F0711 BC000198 IRAUp969F0711 SF3B5 splicing factor 3b, subunit 5, 10kDa 
IRAUp969G0266 BC012340 IRAUp969G0266 C12orf5 
chromosome 12 open reading frame 
5 
IRAUp969G0523 BC004309 IRAUp969G0523 RAB4A 
RAB4A, member RAS oncogene 
family 
IRAUp969G0648 BC009471 IRAUp969G0648 AMACR alpha-methylacyl-CoA racemase 
IRAUp969G065 BC001693 IRAUp969G065 LGALS1 lectin, galactoside-binding, soluble, 1 
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(galectin 1) 
IRAUp969G086 BC002503 IRAUp969G086 SAT 
spermidine/spermine N1-
acetyltransferase 
IRAUp969G0861 BC011757 IRAUp969G0861 GADD45A 
growth arrest and DNA-damage-
inducible, alpha 
IRAUp969G0939 BC008361 IRAUp969G0939 FBXO7 F-box protein 7 
IRAUp969H0369 BC019230 IRAUp969H0369 AKR1C3 
aldo-keto reductase family 1, 
member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II) 
IRAUp969H1045 BC005919 IRAUp969H1045 PLA2G2A 
phospholipase A2, group IIA 
(platelets, synovial fluid) 
IRAUp969H1218 BC004993 IRAUp969H1218 ANXA5 annexin A5 
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